reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason
CD005139-bib-0001,"Keane PA, Heussen FM, Ouyang Y, Mokwa N, Walsh AC, Tufail A, et al. ",Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration, Investigative Ophthalmology and Visual Science ,2012,53,    ,['citation-journal']," Keane PA, Heussen FM, Ouyang Y, Mokwa N, Walsh AC, Tufail A, et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2012;53(3):1152‐61. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1167/iovs.11-8130', 'https://www.ncbi.nlm.nih.gov/pubmed/22281826', 'https://scholar.google.com/scholar_lookup?title=Assessment+of+differential+pharmacodynamic+effects+using+optical+coherence+tomography+in+neovascular+age‐related+macular+degeneration+&author=PA+Keane&author=FM+Heussen&author=Y+Ouyang&author=N+Mokwa&author=AC+Walsh&author=A+Tufail&publication_year=2012&hl=en']",22281826,https://doi.org/10.1167/iovs.11-8130, ABC 2010 {published and unpublished data}  ,included,CD005139-bbs2-0001,
CD005139-bib-0002,"Patel PJ, Chen FK, Cruz L, Rubin GS, Tufail A. ",Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration, Investigative Ophthalmology and Visual Science ,2011,52,    ,['citation-journal']," Patel PJ, Chen FK, Cruz L, Rubin GS, Tufail A. Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2011;52(6):3089‐93. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1167/iovs.10-6208', 'https://www.ncbi.nlm.nih.gov/pubmed/21310910', 'https://scholar.google.com/scholar_lookup?title=Contrast+sensitivity+outcomes+in+the+ABC+Trial:+a+randomized+trial+of+bevacizumab+for+neovascular+age‐related+macular+degeneration+&author=PJ+Patel&author=FK+Chen&author=L+Cruz&author=GS+Rubin&author=A+Tufail&publication_year=2011&hl=en']",21310910,https://doi.org/10.1167/iovs.10-6208, ABC 2010 {published and unpublished data}  ,included,CD005139-bbs2-0001,
CD005139-bib-0003,"Patel PJ, Henderson L, Sivaprasad S, Bunce C, Wormald R, Tufail A. ",The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Patel PJ, Henderson L, Sivaprasad S, Bunce C, Wormald R, Tufail A. The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 4536. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+ABC+trial+‐+a+randomized+double‐masked+phase+III+study+of+the+efficacy+and+safety+of+Avastin®+(Bevacizumab)+intravitreal+injections+compared+to+standard+therapy+in+subjects+with+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration+(AMD)+&author=PJ+Patel&author=L+Henderson&author=S+Sivaprasad&author=C+Bunce&author=R+Wormald&author=A+Tufail&publication_year=2007&hl=en']",,, ABC 2010 {published and unpublished data}  ,included,CD005139-bbs2-0001,
CD005139-bib-0004,"Patel PJ, Rubin GS, Chen FK, Da‐Cruz L, Tufail A. ",Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial, Investigative Ophthalmology and Visual Science ,2015,56(7),    ,['citation-journal']," Patel PJ, Rubin GS, Chen FK, Da‐Cruz L, Tufail A. Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial.  Investigative Ophthalmology and Visual Science 2015;56(7):4794. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Impact+of+anti‐vascular+endothelial+growth+factor+therapy+on+reading+performance+in+age‐related+macular+degeneration:+a+randomized+controlled+trial+&author=PJ+Patel&author=GS+Rubin&author=FK+Chen&author=L+Da‐Cruz&author=A+Tufail&publication_year=2015&hl=en']",,, ABC 2010 {published and unpublished data}  ,included,CD005139-bbs2-0001,
CD005139-bib-0005,"Patel PJ, Tufail A, Bunce C, da Cruz L, Dowler J, Egan C, et al. ","A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design", Trials ,2008,9,    ,['citation-journal']," Patel PJ, Tufail A, Bunce C, da Cruz L, Dowler J, Egan C, et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design.  Trials 2008;9:56. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1745-6215-9-56', 'https://www.ncbi.nlm.nih.gov/pubmed/18854025', 'https://scholar.google.com/scholar_lookup?title=A+randomised,+double‐masked+phase+III/IV+study+of+the+efficacy+and+safety+of+Avastin®+(Bevacizumab)+intravitreal+injections+compared+to+standard+therapy+in+subjects+with+choroidal+neovascularisation+secondary+to+age‐related+macular+degeneration:+clinical+trial+design+&author=PJ+Patel&author=A+Tufail&author=C+Bunce&author=L+Cruz&author=J+Dowler&author=C+Egan&publication_year=2008&hl=en']",18854025,https://doi.org/10.1186/1745-6215-9-56, ABC 2010 {published and unpublished data}  ,included,CD005139-bbs2-0001,
CD005139-bib-0006,"Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al. ",Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study, BMJ ,2010,340,    ,['citation-journal']," Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.  BMJ 2010;340:c2459. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/bmj.c2459', 'https://www.ncbi.nlm.nih.gov/pubmed/20538634', 'https://scholar.google.com/scholar_lookup?title=Bevacizumab+for+neovascular+age+related+macular+degeneration+(ABC+Trial):+multicentre+randomised+double+masked+study+&author=A+Tufail&author=PJ+Patel&author=C+Egan&author=P+Hykin&author=L+Cruz&author=Z+Gregor&publication_year=2010&hl=en']",20538634,https://doi.org/10.1136/bmj.c2459, ABC 2010 {published and unpublished data}  ,included,CD005139-bbs2-0001,
CD005139-bib-0007,"Alexander SG, Blodi BA, Webster MKW, Elledge JA, Hiner CJ, Armstrong J, et al. ",Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data, Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Alexander SG, Blodi BA, Webster MKW, Elledge JA, Hiner CJ, Armstrong J, et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data.  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 2207. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+in+subjects+with+predominantly+classic+CNV:+reading+center+evaluation+of+angiographic+eligibility+characteristics+and+baseline+fluorescein+angiographic+data+&author=SG+Alexander&author=BA+Blodi&author=MKW+Webster&author=JA+Elledge&author=CJ+Hiner&author=J+Armstrong&publication_year=2006&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0008,"Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. ",Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab, Retina ,2010,30,    ,['citation-journal']," Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab.  Retina 2010;30(9):1376‐85. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3181dcfb0b', 'https://www.ncbi.nlm.nih.gov/pubmed/20683380', 'https://scholar.google.com/scholar_lookup?title=Dosing+regimen+and+the+frequency+of+macular+hemorrhages+in+neovascular+age‐related+macular+degeneration+treated+with+ranibizumab+&author=I+Barbazetto&author=N+Saroj&author=H+Shapiro&author=P+Wong&author=KB+Freund&publication_year=2010&hl=en']",20683380,https://doi.org/10.1097/IAE.0b013e3181dcfb0b, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0009,"Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. ",Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials, American Journal of Ophthalmology ,2010,149,    ,['citation-journal']," Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.  American Journal of Ophthalmology 2010;149(6):939‐46. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2010.01.007', 'https://www.ncbi.nlm.nih.gov/pubmed/20378094', 'https://scholar.google.com/scholar_lookup?title=Incidence+of+new+choroidal+neovascularization+in+fellow+eyes+of+patients+treated+in+the+MARINA+and+ANCHOR+trials+&author=IA+Barbazetto&author=N+Saroj&author=H+Shapiro&author=P+Wong&author=AC+Ho&author=KB+Freund&publication_year=2010&hl=en']",20378094,https://doi.org/10.1016/j.ajo.2010.01.007, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0010,"Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al. ",Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials, Retina ,2012,32,    ,['citation-journal']," Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.  Retina 2012;32(9):1821‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e31825db6ba', 'https://www.ncbi.nlm.nih.gov/pubmed/23011184', 'https://scholar.google.com/scholar_lookup?title=Cerebrovascular+accidents+in+patients+treated+for+choroidal+neovascularization+with+ranibizumab+in+randomized+controlled+trials+&author=NM+Bressler&author=DS+Boyer&author=DF+Williams&author=S+Butler&author=SF+Francom&author=B+Brown&publication_year=2012&hl=en']",23011184,https://doi.org/10.1097/IAE.0b013e31825db6ba, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0011,"Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. ",Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial, Archives of Ophthalmology ,2009,127,    ,['citation-journal']," Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.  Archives of Ophthalmology 2009;127(1):13‐21. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archophthalmol.2008.562', 'https://www.ncbi.nlm.nih.gov/pubmed/19139332', 'https://scholar.google.com/scholar_lookup?title=Improved+vision‐related+function+after+ranibizumab+vs+photodynamic+therapy:+a+randomized+clinical+trial+&author=NM+Bressler&author=TS+Chang&author=JT+Fine&author=CM+Dolan&author=J+Ward&publication_year=2009&hl=en']",19139332,https://doi.org/10.1001/archophthalmol.2008.562, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0012,"Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al. ",Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR, Ophthalmology ,2010,117,    ,['citation-journal']," Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR.  Ophthalmology 2010;117(4):747‐56. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2009.09.002', 'https://www.ncbi.nlm.nih.gov/pubmed/20189654', 'https://scholar.google.com/scholar_lookup?title=Vision‐related+function+after+ranibizumab+treatment+by+better‐+or+worse‐seeing+eye:+clinical+trial+results+from+MARINA+and+ANCHOR+&author=NM+Bressler&author=TS+Chang&author=IJ+Suñer&author=JT+Fine&author=CM+Dolan&author=J+Ward&publication_year=2010&hl=en']",20189654,https://doi.org/10.1016/j.ophtha.2009.09.002, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0013,"Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, et al. ",Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab, Ophthalmology ,2013,120,    ,['citation-journal']," Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab.  Ophthalmology 2013;120(1):160‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.07.027', 'https://www.ncbi.nlm.nih.gov/pubmed/23009891', 'https://scholar.google.com/scholar_lookup?title=Driving+ability+reported+by+neovascular+age‐related+macular+degeneration+patients+after+treatment+with+ranibizumab+&author=NM+Bressler&author=TS+Chang&author=R+Varma&author=I+Suner&author=P+Lee&author=CM+Dolan&publication_year=2013&hl=en']",23009891,https://doi.org/10.1016/j.ophtha.2012.07.027, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0014,"Bressler NM, Dolan CM, Fine J, Marceau C, Chang TS. ",Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT,,,,   ,['citation-other']," Bressler NM, Dolan CM, Fine J, Marceau C, Chang TS. Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0015,"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim R, et al. ",Ranibizumab versus verteporfin for neovascular age‐related macular degeneration, New England Journal of Medicine ,2006,355,    ,['citation-journal']," Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim R, et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration.  New England Journal of Medicine 2006;355(14):1432‐44. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa062655', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+versus+verteporfin+for+neovascular+age‐related+macular+degeneration&author=DM+Brown&author=PK+Kaiser&author=M+Michels&author=G+Soubrane&author=JS+Heier&author=R+Kim&publication_year=2006&hl=en']",,https://doi.org/10.1056/NEJMoa062655, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0016,"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. ",Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study, Ophthalmology ,2009,116,    ,['citation-journal']," Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study.  Ophthalmology 2009;116(1):57‐65. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2008.10.018', 'https://www.ncbi.nlm.nih.gov/pubmed/19118696', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+versus+verteporfin+photodynamic+therapy+for+neovascular+age‐related+macular+degeneration:+two‐year+results+of+the+ANCHOR+study+&author=DM+Brown&author=M+Michels&author=PK+Kaiser&author=JS+Heier&author=JP+Sy&author=T+Ianchulev&publication_year=2009&hl=en']",19118696,https://doi.org/10.1016/j.ophtha.2008.10.018, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0017,"Brown DM, Shapiro H, Schneider S. ","Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration", Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Brown DM, Shapiro H, Schneider S. Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 2963. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Subgroup+analysis+of+first‐year+results+of+ANCHOR:+a+phase+III,+double‐masked,+randomized+comparison+of+ranibizumab+and+verteporfin+photodynamic+therapy+for+predominantly+classic+choroidal+neovascularization+related+to+age‐related+macular+degeneration+&author=DM+Brown&author=H+Shapiro&author=S+Schneider&publication_year=2006&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0018,"Chang TS, Fine JT, Bressler N. ",Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®), Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Chang TS, Fine JT, Bressler N. Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®).  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 5252. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Self‐reported+vision‐specific+quality+of+life+at+1+year+in+patients+with+neovascular+age‐related+macular+degeneration+in+2+phase+III+randomized+clinical+trials+of+ranibizumab+(Lucentis®)+&author=TS+Chang&author=JT+Fine&author=N+Bressler&publication_year=2006&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0019,"Ciulla TA, Shapiro H, Schneider S. ",Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Ciulla TA, Shapiro H, Schneider S. Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 4573. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+for+neovascular+age‐related+macular+degeneration+(AMD):+1‐year+visual+acuity+(VA)+results+for+fellow+eyes+with+neovascular+AMD+in+MARINA+and+ANCHOR+&author=TA+Ciulla&author=H+Shapiro&author=S+Schneider&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0020,"Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. ",Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration, Ophthalmology ,2011,118,    ,['citation-journal']," Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration.  Ophthalmology 2011;118(12):2447‐52. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2011.05.026', 'https://www.ncbi.nlm.nih.gov/pubmed/21872935', 'https://scholar.google.com/scholar_lookup?title=Incidence+of+retinal+pigment+epithelial+tears+after+intravitreal+ranibizumab+injection+for+neovascular+age‐related+macular+degeneration+&author=ET+Cunningham&author=L+Feiner&author=C+Chung&author=L+Tuomi&author=JS+Ehrlich&publication_year=2011&hl=en']",21872935,https://doi.org/10.1016/j.ophtha.2011.05.026, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0021,"Heier JS, Chung C, Schneider S. ",Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Heier JS, Chung C, Schneider S. Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 2872. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Time+course+of+visual+acuity+changes+with+ranibizumab+(Lucentis®)+in+the+2‐year+ANCHOR+study+of+patients+with+neovascular+age‐related+macular+degeneration+(AMD)+&author=JS+Heier&author=C+Chung&author=S+Schneider&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0022,"Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. ",Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results, American Journal of Ophthalmology ,2007,144,    ,['citation-journal']," Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results.  American Journal of Ophthalmology 2007;144(6):850‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2007.08.012', 'https://www.ncbi.nlm.nih.gov/pubmed/17949673', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+predominantly+classic+neovascular+age‐related+macular+degeneration:+subgroup+analysis+of+first‐year+ANCHOR+results+&author=PK+Kaiser&author=DM+Brown&author=K+Zhang&author=HL+Hudson&author=FG+Holz&author=H+Shapiro&publication_year=2007&hl=en']",17949673,https://doi.org/10.1016/j.ajo.2007.08.012, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0023,Korobelnik JF. ,Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD,,,,   ,['citation-other'], Korobelnik JF. Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ,[''],,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0024,Lanzetta P. ,Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal'], Lanzetta P. Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 5571. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+and+patient‐reported+outcomes:+VFQ‐25+data+from+the+ANCHOR+and+PIER+trials+in+patients+with+neovascular+AMD+&author=P+Lanzetta&publication_year=2008&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0025,"Lanzetta P, MARINA and ANCHOR Study Groups. ",Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD,,,,   ,['citation-other']," Lanzetta P, MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0026,"Loewenstein A, MARINA and ANCHOR Study Groups. ",Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration,,,,   ,['citation-other']," Loewenstein A, MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0027,"McDonald HR, Schneider S, Sy JP. ","One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration",,2006,,    ,['citation-other']," McDonald HR, Schneider S, Sy JP. One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=One‐year+results+of+ANCHOR:+a+phase+III,+multicenter,+randomized,+double‐masked+comparison+of+ranibizumab+and+verteporfin+photodynamic+therapy+in+treatment+of+predominantly+classic+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration+&author=HR+McDonald&author=S+Schneider&author=JP+Sy&publication_year=2006&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0028,"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. ","Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP)", Ophthalmology ,2013,120,    ,['citation-journal']," Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP).  Ophthalmology 2013;120(11):2292‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.03.046', 'https://www.ncbi.nlm.nih.gov/pubmed/23642856', 'https://scholar.google.com/scholar_lookup?title=Seven‐year+outcomes+in+ranibizumab‐treated+patients+in+ANCHOR,+MARINA,+and+HORIZON:+a+multicenter+cohort+study+(SEVEN‐UP)+&author=S+Rofagha&author=RB+Bhisitkul&author=DS+Boyer&author=SR+Sadda&author=K+Zhang&publication_year=2013&hl=en']",23642856,https://doi.org/10.1016/j.ophtha.2013.03.046, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0029,"Rosenfeld PJ, Shapiro H, Shams N, Schneider S, Depperschmidt EE, MARINA and ANCHOR Study Groups. ",Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Rosenfeld PJ, Shapiro H, Shams N, Schneider S, Depperschmidt EE, MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 4576. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Baseline+and+treatment+characteristics+of+patients+losing+vision+at+year+1+of+the+MARINA+and+ANCHOR+trials+&author=PJ+Rosenfeld&author=H+Shapiro&author=N+Shams&author=S+Schneider&author=EE+Depperschmidt&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0030,"Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. ",Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials, Ophthalmology ,2011,118,    ,['citation-journal']," Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.  Ophthalmology 2011;118(3):523‐30. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2010.07.011', 'https://www.ncbi.nlm.nih.gov/pubmed/20920825', 'https://scholar.google.com/scholar_lookup?title=Characteristics+of+patients+losing+vision+after+2+years+of+monthly+dosing+in+the+phase+III+ranibizumab+clinical+trials+&author=PJ+Rosenfeld&author=H+Shapiro&author=L+Tuomi&author=M+Webster&author=J+Elledge&author=B+Blodi&publication_year=2011&hl=en']",20920825,https://doi.org/10.1016/j.ophtha.2010.07.011, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0031,"Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. ",Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 329. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lesion+characteristics+in+ranibizumab+(Lucentis®)+treated+patients+with+a+visual+acuity+(VA)+gain+or+loss+in+the+MARINA+and+ANCHOR+trials+for+wet+age‐related+macular+degeneration+(AMD)+&author=PJ+Rosenfeld&author=H+Shapiro&author=L+Tuomi&author=M+Webster&author=J+Elledge&author=B+Blodi&publication_year=2008&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0032,"Sadda SR, Shapiro H, Schneider S. ",Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Sadda SR, Shapiro H, Schneider S. Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 4561. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Anatomic+outcomes+at+2+years+in+the+ANCHOR+study+comparing+ranibizumab+(Lucentis®)+and+verteporfin+photodynamic+therapy+(PDT)+in+predominantly+classic+neovascular+age‐related+macular+degeneration+(AMD)+&author=SR+Sadda&author=H+Shapiro&author=S+Schneider&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0033,"Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. ",Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study, Retina ,2010,30,    ,['citation-journal']," Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study.  Retina 2010;30(9):1390‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3181e44599', 'https://www.ncbi.nlm.nih.gov/pubmed/20924261', 'https://scholar.google.com/scholar_lookup?title=Anatomical+benefit+from+ranibizumab+treatment+of+predominantly+classic+neovascular+age‐related+macular+degeneration+in+the+2‐year+anchor+study+&author=SR+Sadda&author=G+Stoller&author=DS+Boyer&author=BA+Blodi&author=H+Shapiro&author=T+Ianchulev&publication_year=2010&hl=en']",20924261,https://doi.org/10.1097/IAE.0b013e3181e44599, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0034,"Schwartz SG, Bressler N, Fine JT, Dolan CM, Yu EM, Ward JF, et al. ","Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT", Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Schwartz SG, Bressler N, Fine JT, Dolan CM, Yu EM, Ward JF, et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 1822. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Patient‐reported+visual+function+over+24+months+in+predominantly+classic+neovascular+AMD:+results+from+ANCHOR,+a+phase+III+trial+of+ranibizumab+and+verteporfin+PDT+&author=SG+Schwartz&author=N+Bressler&author=JT+Fine&author=CM+Dolan&author=EM+Yu&author=JF+Ward&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0035,"Sutter FK, Kurz‐Levin MM. ",Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Sutter FK, Kurz‐Levin MM. Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 2884. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Towards+an+optimized+treatment+scheme+of+ranibizumab+in+patients+with+subfoveal+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration:+subanalysis+of+clinical+trial+data+and+clinical+routine+use+&author=FK+Sutter&author=MM+Kurz‐Levin&publication_year=2008&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0036,"Webster MK, Blodi BA, Elledge JA, Danis RP. ",Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data,,2007,,    ,['citation-other']," Webster MK, Blodi BA, Elledge JA, Danis RP. Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Angiographic+results+of+the+ANCHOR+study+of+ranibizumab+in+neovascular+age‐related+macular+degeneration:+reading+center+evaluation+of+angiographic+data+&author=MK+Webster&author=BA+Blodi&author=JA+Elledge&author=RP+Danis&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0037,"Weinberg DV, Shapiro H, Ehrlich JS. ",Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials, Ophthalmology ,2013,120,    ,['citation-journal']," Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.  Ophthalmology 2013;120(6):1278‐82. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.11.042', 'https://www.ncbi.nlm.nih.gov/pubmed/23453513', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+treatment+outcomes+in+phakic+versus+pseudophakic+eyes:+an+individual+patient+data+analysis+of+2+phase+3+trials+&author=DV+Weinberg&author=H+Shapiro&author=JS+Ehrlich&publication_year=2013&hl=en']",23453513,https://doi.org/10.1016/j.ophtha.2012.11.042, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0038,"Win PH, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. ",Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Win PH, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 5578. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Self‐reported+perception+of+driving+function+after+ranibizumab+therapy+in+patients+with+neovascular+age‐related+macular+degeneration+(AMD)+&author=PH+Win&author=NM+Bressler&author=TS+Chang&author=JT+Fine&author=CM+Dolan&author=J+Ward&publication_year=2008&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0040,Wolf S. ,"Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD", Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Wolf S. Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 2883. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Visual+acuity+gain+with+ranibizumab+therapy:+two‐year+data+from+the+MARINA,+ANCHOR,+and+PIER+trials+in+patients+with+neovascular+AMD+&author=S+Wolf&publication_year=2008&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0039,"Wolf S, Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Prünte C, et al. ",Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR, British Journal of Ophthalmology ,2011,95,    ,['citation-journal']," Wolf S, Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Prünte C, et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR.  British Journal of Ophthalmology 2011;95(12):1713‐8. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjophthalmol-2011-300471', 'https://scholar.google.com/scholar_lookup?title=Outcomes+following+three‐line+vision+loss+during+treatment+of+neovascular+age‐related+macular+degeneration:+subgroup+analyses+from+MARINA+and+ANCHOR+&author=S+Wolf&author=FG+Holz&author=JF+Korobelnik&author=P+Lanzetta&author=P+Mitchell&author=C+Prünte&publication_year=2011&hl=en']",,https://doi.org/10.1136/bjophthalmol-2011-300471, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0041,Yang YC. ,Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal'], Yang YC. Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 4545. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Two+year+contrast+sensitivity+results+from+the+ANCHOR+study+comparing+intravitreal+ranibizumab+0.3mg+and+0.5mg+with+verteporfin+PDT+for+predominantly+classic+CNV+lesions+secondary+to+age‐related+macular+degeneration+&author=YC+Yang&publication_year=2007&hl=en']",,, ANCHOR 2006 {published and unpublished data}  ,included,CD005139-bbs2-0002,
CD005139-bib-0042,"Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. ",Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration, Indian Journal of Ophthalmology ,2011,59,    ,['citation-journal']," Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration.  Indian Journal of Ophthalmology 2011;59(3):191‐6. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4103/0301-4738.81023', 'https://www.ncbi.nlm.nih.gov/pubmed/21586838', 'https://scholar.google.com/scholar_lookup?title=Comparative+role+of+intravitreal+ranibizumab+versus+bevacizumab+in+choroidal+neovascular+membrane+in+age‐related+macular+degeneration+&author=P+Biswas&author=S+Sengupta&author=R+Choudhary&author=S+Home&author=A+Paul&author=S+Sinha&publication_year=2011&hl=en']",21586838,https://doi.org/10.4103/0301-4738.81023, Biswas 2011 {published data only}  ,included,CD005139-bbs2-0003,
CD005139-bib-0043,"Schauwvlieghe AME, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MGW, et al. ",Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study, PLOS ONE ,2016,11,    ,['citation-journal']," Schauwvlieghe AME, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MGW, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study.  PLOS ONE 2016;11(5):e0153052. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1371/journal.pone.0153052', 'https://www.ncbi.nlm.nih.gov/pubmed/27203434', 'https://scholar.google.com/scholar_lookup?title=Comparing+the+effectiveness+of+bevacizumab+to+ranibizumab+in+patients+with+exudative+age‐related+macular+degeneration.+The+BRAMD+study+&author=AME+Schauwvlieghe&author=G+Dijkman&author=JM+Hooymans&author=FD+Verbraak&author=CB+Hoyng&author=MGW+Dijkgraaf&publication_year=2016&hl=en']",27203434,https://doi.org/10.1371/journal.pone.0153052, BRAMD 2016 {published data only}  ,included,CD005139-bbs2-0004,
CD005139-bib-0044,"Schauwvlieghe ASME, Dijkman G, Hooymans JMM, Verbraak FD, Dijkgraaf MG, Peto T, et al. ",Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration, Investigative Ophthalmology and Visual Science ,2014,55(13),    ,['citation-journal']," Schauwvlieghe ASME, Dijkman G, Hooymans JMM, Verbraak FD, Dijkgraaf MG, Peto T, et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2014;55(13):870. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparing+the+effectiveness+of+bevacizumab+to+ranibizumab+in+patients+with+exudative+age‐related+macular+degeneration+&author=ASME+Schauwvlieghe&author=G+Dijkman&author=JMM+Hooymans&author=FD+Verbraak&author=MG+Dijkgraaf&author=T+Peto&publication_year=2014&hl=en']",,, BRAMD 2016 {published data only}  ,included,CD005139-bbs2-0004,
CD005139-bib-0049,,Comparison of Age‐Related Macular Degeneration Treatment Trials,,,,   ,['citation-other'], Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). CENTRAL    ,[''],,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0045,"Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, et al. ",Outcomes of eyes with lesions composed of >50% blood in the comparison of age‐related macular degeneration treatments trials (CATT), Ophthalmology ,2015,122,    ,['citation-journal']," Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, et al. Outcomes of eyes with lesions composed of >50% blood in the comparison of age‐related macular degeneration treatments trials (CATT).  Ophthalmology 2015;122(2):391‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2014.08.020', 'https://www.ncbi.nlm.nih.gov/pubmed/25307130', 'https://scholar.google.com/scholar_lookup?title=Outcomes+of+eyes+with+lesions+composed+of+>50%+blood+in+the+comparison+of+age‐related+macular+degeneration+treatments+trials+(CATT)+&author=MM+Altaweel&author=E+Daniel&author=DF+Martin&author=RA+Mittra&author=JE+Grunwald&author=MM+Lai&publication_year=2015&hl=en']",25307130,https://doi.org/10.1016/j.ophtha.2014.08.020, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0046,"CATT Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE. ",Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2016,123,    ,['citation-journal']," CATT Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE. Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2016;123(8):1751‐61. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2016.03.045', 'https://www.ncbi.nlm.nih.gov/pubmed/27156698', 'https://scholar.google.com/scholar_lookup?title=Five‐year+outcomes+with+anti‐vascular+endothelial+growth+factor+treatment+of+neovascular+age‐related+macular+degeneration:+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=MG+Maguire&author=DF+Martin&author=GS+Ying&author=GJ+Jaffe&author=E+Daniel&author=JE+Grunwald&publication_year=2016&hl=en']",27156698,https://doi.org/10.1016/j.ophtha.2016.03.045, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0047,"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. ",Ranibizumab and bevacizumab for neovascular age‐related macular degeneration, New England Journal of Medicine ,2011,364,    ,['citation-journal']," CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age‐related macular degeneration.  New England Journal of Medicine 2011;364(20):1897‐908. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+and+bevacizumab+for+neovascular+age‐related+macular+degeneration&author=DF+Martin&author=MG+Maguire&author=GS+Ying&author=JE+Grunwald&author=SL+Fine&author=GJ+Jaffe&publication_year=2011&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0048,"Ciulla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, et al. ",Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2015,122,    ,['citation-journal']," Ciulla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2015;122(6):1203‐11. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/25824327', 'https://scholar.google.com/scholar_lookup?title=Influence+of+the+vitreomacular+interface+on+treatment+outcomes+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=TA+Ciulla&author=GS+Ying&author=MG+Maguire&author=DF+Martin&author=GJ+Jaffe&author=JE+Grunwald&publication_year=2015&hl=en']",25824327,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0050,"Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, et al. ",Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT), Ophthalmology ,2016,123,    ,['citation-journal']," Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT).  Ophthalmology 2016;123(3):609‐16. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.10.034', 'https://www.ncbi.nlm.nih.gov/pubmed/26681392', 'https://scholar.google.com/scholar_lookup?title=Outcomes+in+eyes+with+retinal+angiomatous+proliferation+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+(CATT)+&author=E+Daniel&author=J+Shaffer&author=GS+Ying&author=JE+Grunwald&author=DF+Martin&author=GJ+Jaffe&publication_year=2016&hl=en']",26681392,https://doi.org/10.1016/j.ophtha.2015.10.034, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0051,"Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al. ",Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials,,2014,,    ,['citation-other']," Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Risk+of+scar+in+the+Comparison+of+Age‐related+Macular+Degeneration+Treatments+Trials&author=E+Daniel&author=CA+Toth&author=JE+Grunwald&author=GJ+Jaffe&author=DF+Martin&author=SL+Fine&publication_year=2014&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0052,"Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, et al. ",Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2014,121,    ,['citation-journal']," Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2014;121(1):150‐61. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.08.015', 'https://www.ncbi.nlm.nih.gov/pubmed/24084496', 'https://scholar.google.com/scholar_lookup?title=Risk+of+geographic+atrophy+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=JE+Grunwald&author=E+Daniel&author=J+Huang&author=GS+Ying&author=MG+Maguire&author=CA+Toth&publication_year=2014&hl=en']",24084496,https://doi.org/10.1016/j.ophtha.2013.08.015, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0053,"Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, et al. ",Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2012,119,    ,['citation-journal']," Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2012;119(8):1634‐41. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.02.013', 'https://www.ncbi.nlm.nih.gov/pubmed/22512984', 'https://scholar.google.com/scholar_lookup?title=Photographic+assessment+of+baseline+fundus+morphologic+features+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=JE+Grunwald&author=E+Daniel&author=GS+Ying&author=M+Pistilli&author=MG+Maguire&author=J+Alexander&publication_year=2012&hl=en']",22512984,https://doi.org/10.1016/j.ophtha.2012.02.013, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0054,"Grunwald JE, Pistilli M, Daniel E, Ying GS, Fine SL, Martin DF, Maguire MG. ",Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT), Investigative Ophthalmology and Visual Science ,2014,55(13),    ,['citation-journal']," Grunwald JE, Pistilli M, Daniel E, Ying GS, Fine SL, Martin DF, Maguire MG. Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT).  Investigative Ophthalmology and Visual Science 2014;55(13):1649. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Size+and+growth+of+geographic+atrophy+in+the+Comparison+of+Age‐related+Macular+Degeneration+Treatments+Trials+(CATT)+&author=JE+Grunwald&author=M+Pistilli&author=E+Daniel&author=GS+Ying&author=SL+Fine&author=DF+Martin&author=MG+Maguire&publication_year=2014&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0055,"Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. ",Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials, Ophthalmology ,2017,124,    ,['citation-journal']," Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials.  Ophthalmology 2017;124(1):97‐104. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2016.09.012', 'https://www.ncbi.nlm.nih.gov/pubmed/28079023', 'https://scholar.google.com/scholar_lookup?title=Incidence+and+growth+of+geographic+atrophy+during+5+years+of+Comparison+of+Age‐related+Macular+Degeneration+Treatments+Trials+&author=JE+Grunwald&author=M+Pistilli&author=E+Daniel&author=GS+Ying&author=W+Pan&author=GJ+Jaffe&publication_year=2017&hl=en']",28079023,https://doi.org/10.1016/j.ophtha.2016.09.012, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0056,"Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, et al. ",Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2015,122,    ,['citation-journal']," Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2015;122(4):809‐16. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2014.11.007', 'https://www.ncbi.nlm.nih.gov/pubmed/25542520', 'https://scholar.google.com/scholar_lookup?title=Growth+of+geographic+atrophy+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=JE+Grunwald&author=M+Pistilli&author=GS+Ying&author=MG+Maguire&author=E+Daniel&author=DF+Martin&publication_year=2015&hl=en']",25542520,https://doi.org/10.1016/j.ophtha.2014.11.007, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0057,"Hagstrom SA, Ying GS, Pauer GJ, Sturgill‐Short GM, Huang J, Callanan DG, et al. ",Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT),,2013,,    ,['citation-other']," Hagstrom SA, Ying GS, Pauer GJ, Sturgill‐Short GM, Huang J, Callanan DG, et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Pharmacogenetics+for+genes+associated+with+age‐related+macular+degeneration+in+the+Comparison+of+AMD+Treatments+Trials+(CATT)+&author=SA+Hagstrom&author=GS+Ying&author=GJ+Pauer&author=GM+Sturgill‐Short&author=J+Huang&author=DG+Callanan&publication_year=2013&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0058,"Huang J, Ying GS, Maguire MG, Stone RA, Martin DF. ",Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT), Investigative Ophthalmology and Visual Science ,2014,55(13),    ,['citation-journal']," Huang J, Ying GS, Maguire MG, Stone RA, Martin DF. Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT).  Investigative Ophthalmology and Visual Science 2014;55(13):657. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Impact+of+change+in+retinal+thickness+on+refractive+error+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+(CATT)+&author=J+Huang&author=GS+Ying&author=MG+Maguire&author=RA+Stone&author=DF+Martin&publication_year=2014&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0059,"Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al. ",Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2013,120,    ,['citation-journal']," Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2013;120(9):1860‐70. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.01.073', 'https://www.ncbi.nlm.nih.gov/pubmed/23642377', 'https://scholar.google.com/scholar_lookup?title=Macular+morphology+and+visual+acuity+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=GJ+Jaffe&author=DF+Martin&author=CA+Toth&author=E+Daniel&author=MG+Maguire&author=GS+Ying&publication_year=2013&hl=en']",23642377,https://doi.org/10.1016/j.ophtha.2013.01.073, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0061,Maguire MG. ,"Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost",,2012,,    ,['citation-other']," Maguire MG. Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Comparing+treatments+for+age‐related+macular+degeneration:+safety,+effectiveness+and+cost+&author=MG+Maguire&publication_year=2012&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0060,"Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, et al. ",Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2013,120,    ,['citation-journal']," Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2013;120(10):2035‐41. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.03.017', 'https://www.ncbi.nlm.nih.gov/pubmed/23706946', 'https://scholar.google.com/scholar_lookup?title=Incidence+of+choroidal+neovascularization+in+the+fellow+eye+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=MG+Maguire&author=E+Daniel&author=AR+Shah&author=JE+Grunwald&author=SA+Hagstrom&author=RL+Avery&publication_year=2013&hl=en']",23706946,https://doi.org/10.1016/j.ophtha.2013.03.017, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0062,"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. ",Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results, Ophthalmology ,2012,119,    ,['citation-journal']," Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results.  Ophthalmology 2012;119(7):1388‐98. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.03.053', 'https://www.ncbi.nlm.nih.gov/pubmed/22555112', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+and+bevacizumab+for+treatment+of+neovascular+age‐related+macular+degeneration:+two‐year+results+&author=DF+Martin&author=MG+Maguire&author=SL+Fine&author=GS+Ying&author=GJ+Jaffe&author=JE+Grunwald&publication_year=2012&hl=en']",22555112,https://doi.org/10.1016/j.ophtha.2012.03.053, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0063,"Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, et al. ",Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT), Ophthalmology ,2015,122,    ,['citation-journal']," Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT).  Ophthalmology 2015;122(4):817‐21. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2014.10.027', 'https://www.ncbi.nlm.nih.gov/pubmed/25600198', 'https://scholar.google.com/scholar_lookup?title=Postinjection+endophthalmitis+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+(CATT)+&author=TA+Meredith&author=CA+McCannel&author=C+Barr&author=BH+Doft&author=E+Peskin&author=MG+Maguire&publication_year=2015&hl=en']",25600198,https://doi.org/10.1016/j.ophtha.2014.10.027, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0064,"Pistilli M, Ying GS, Jaffe GJ, Toth CA, Martin DF. ",Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT), Investigative Ophthalmology and Visual Science ,2015,56(7),    ,['citation-journal']," Pistilli M, Ying GS, Jaffe GJ, Toth CA, Martin DF. Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT).  Investigative Ophthalmology and Visual Science 2015;56(7):1657. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Resolution+of+retinal+fluid+on+optical+coherence+tomography+in+the+Comparison+of+AMD+Treatments+Trials+(CATT)+&author=M+Pistilli&author=GS+Ying&author=GJ+Jaffe&author=CA+Toth&author=DF+Martin&publication_year=2015&hl=en']",,, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0065,"Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, et al. ",Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2016,123,    ,['citation-journal']," Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2016;123(4):858‐64. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.11.030', 'https://www.ncbi.nlm.nih.gov/pubmed/26778329', 'https://scholar.google.com/scholar_lookup?title=Angiographic+cystoid+macular+edema+and+outcomes+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=N+Shah&author=MG+Maguire&author=DF+Martin&author=J+Shaffer&author=GS+Ying&author=JE+Grunwald&publication_year=2016&hl=en']",26778329,https://doi.org/10.1016/j.ophtha.2015.11.030, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0066,"Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, et al. ",Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2016,123,    ,['citation-journal']," Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2016;123(4):865‐75. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.12.002', 'https://www.ncbi.nlm.nih.gov/pubmed/26783095', 'https://scholar.google.com/scholar_lookup?title=Macular+morphology+and+visual+acuity+in+the+second+year+of+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=S+Sharma&author=CA+Toth&author=E+Daniel&author=JE+Grunwald&author=MG+Maguire&author=GS+Ying&publication_year=2016&hl=en']",26783095,https://doi.org/10.1016/j.ophtha.2015.12.002, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0067,"Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. ",Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials, Ophthalmology ,2015,122,    ,['citation-journal']," Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials.  Ophthalmology 2015;122(9):1846‐53. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.05.042', 'https://www.ncbi.nlm.nih.gov/pubmed/26143666', 'https://scholar.google.com/scholar_lookup?title=Subretinal+hyperreflective+material+in+the+Comparison+of+Age‐Related+Macular+Degeneration+Treatments+Trials+&author=AS+Willoughby&author=GS+Ying&author=CA+Toth&author=MG+Maguire&author=RE+Burns&author=JE+Grunwald&publication_year=2015&hl=en']",26143666,https://doi.org/10.1016/j.ophtha.2015.05.042, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0068,"Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. ",Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration, Ophthalmology ,2013,120,    ,['citation-journal']," Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration.  Ophthalmology 2013;120(1):122‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.07.042', 'https://www.ncbi.nlm.nih.gov/pubmed/23047002', 'https://scholar.google.com/scholar_lookup?title=Baseline+predictors+for+one‐year+visual+outcomes+with+ranibizumab+or+bevacizumab+for+neovascular+age‐related+macular+degeneration+&author=GS+Ying&author=J+Huang&author=MG+Maguire&author=GJ+Jaffe&author=JE+Grunwald&author=C+Toth&publication_year=2013&hl=en']",23047002,https://doi.org/10.1016/j.ophtha.2012.07.042, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0069,"Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, et al. ",Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT), Ophthalmology ,2015,122,    ,['citation-journal']," Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT).  Ophthalmology 2015;122(12):2523‐31. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.08.015', 'https://www.ncbi.nlm.nih.gov/pubmed/26383996', 'https://scholar.google.com/scholar_lookup?title=Association+of+baseline+characteristics+and+early+vision+response+with+2‐year+vision+outcomes+in+the+Comparison+of+AMD+Treatments+Trials+(CATT)+&author=GS+Ying&author=MG+Maguire&author=E+Daniel&author=FL+Ferris&author=GJ+Jaffe&author=JE+Grunwald&publication_year=2015&hl=en']",26383996,https://doi.org/10.1016/j.ophtha.2015.08.015, CATT 2011 {published and unpublished data}  ,included,CD005139-bbs2-0005,
CD005139-bib-0070,"Kodjikian L, Souied EH, Mimoun G, Mauget‐Faysse M, Behar‐Cohen F, Decullier E, et al. ",Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial, Ophthalmology ,2013,120,    ,['citation-journal']," Kodjikian L, Souied EH, Mimoun G, Mauget‐Faysse M, Behar‐Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial.  Ophthalmology 2013;120(11):2300‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.06.020', 'https://www.ncbi.nlm.nih.gov/pubmed/23916488', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+versus+bevacizumab+for+neovascular+age‐related+macular+degeneration:+results+from+the+GEFAL+noninferiority+randomized+trial+&author=L+Kodjikian&author=EH+Souied&author=G+Mimoun&author=M+Mauget‐Faysse&author=F+Behar‐Cohen&author=E+Decullier&publication_year=2013&hl=en']",23916488,https://doi.org/10.1016/j.ophtha.2013.06.020, GEFAL 2013 {published and unpublished data}  ,included,CD005139-bbs2-0006,
CD005139-bib-0071,,A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation,,,,   ,['citation-other'], A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). CENTRAL    ,[''],,, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0075,,Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)), Ophthalmology ,2012,119,    ,['citation-journal'], Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)).  Ophthalmology 2012;119(8):1508. CENTRAL    Link to article     ,"['', 'https://doi.org/10.1016/j.ophtha.2012.06.029']",,https://doi.org/10.1016/j.ophtha.2012.06.029, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0072,"Chakravarthy U, Harding SP, Rogers CA, Downes S, Lotery AJ, Dakin HA, et al. ",A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN), Health Technology Assessment ,2015,19,    ,['citation-journal']," Chakravarthy U, Harding SP, Rogers CA, Downes S, Lotery AJ, Dakin HA, et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN).  Health Technology Assessment 2015;19(78):1‐298. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3310/hta19780', 'https://www.ncbi.nlm.nih.gov/pubmed/26445075', 'https://scholar.google.com/scholar_lookup?title=A+randomised+controlled+trial+to+assess+the+clinical+effectiveness+and+cost‐effectiveness+of+alternative+treatments+to+inhibit+VEGF+in+age‐related+choroidal+neovascularisation+(IVAN)+&author=U+Chakravarthy&author=SP+Harding&author=CA+Rogers&author=S+Downes&author=AJ+Lotery&author=HA+Dakin&publication_year=2015&hl=en']",26445075,https://doi.org/10.3310/hta19780, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0073,"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, on behalf of the IVAN study investigators. ",Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial, Lancet ,2013,382,    ,['citation-journal']," Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial.  Lancet 2013;382(9900):1258‐67. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(13)61501-9', 'https://www.ncbi.nlm.nih.gov/pubmed/23870813', 'https://scholar.google.com/scholar_lookup?title=Alternative+treatments+to+inhibit+VEGF+in+age‐related+choroidal+neovascularisation:+2‐year+findings+of+the+IVAN+randomised+controlled+trial+&author=U+Chakravarthy&author=SP+Harding&author=CA+Rogers&author=SM+Downes&author=AJ+Lotery&author=LA+Culliford&publication_year=2013&hl=en']",23870813,https://doi.org/10.1016/S0140-6736(13)61501-9, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0074,"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. ",Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial, Ophthalmology ,2012,119,    ,['citation-journal']," Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial.  Ophthalmology 2012;119(7):1399‐411. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.04.015', 'https://www.ncbi.nlm.nih.gov/pubmed/22578446', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+versus+bevacizumab+to+treat+neovascular+age‐related+macular+degeneration:+one‐year+findings+from+the+IVAN+randomized+trial+&author=U+Chakravarthy&author=SP+Harding&author=CA+Rogers&author=SM+Downes&author=AJ+Lotery&author=S+Wordsworth&publication_year=2012&hl=en']",22578446,https://doi.org/10.1016/j.ophtha.2012.04.015, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0076,"Foss AJ, Scott LJ, Rogers CA, Reeves BC, Ghanchi F, Gibson J, et al. ",Changes in intraocular pressure in study and fellow eyes in the IVAN trial, British Journal of Ophthalmology. ,2016,100,    ,['citation-journal']," Foss AJ, Scott LJ, Rogers CA, Reeves BC, Ghanchi F, Gibson J, et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial.  British Journal of Ophthalmology. 2016;100(12):1662‐7. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjophthalmol-2015-307595', 'https://scholar.google.com/scholar_lookup?title=Changes+in+intraocular+pressure+in+study+and+fellow+eyes+in+the+IVAN+trial&author=AJ+Foss&author=LJ+Scott&author=CA+Rogers&author=BC+Reeves&author=F+Ghanchi&author=J+Gibson&publication_year=2016&hl=en']",,https://doi.org/10.1136/bjophthalmol-2015-307595, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0077,"Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA, et al. ",Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study, Ophthalmology ,2013,120,    ,['citation-journal']," Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA, et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study.  Ophthalmology 2013;120(12):2637‐43. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.07.046', 'https://www.ncbi.nlm.nih.gov/pubmed/24070809', 'https://scholar.google.com/scholar_lookup?title=Pharmacogenetic+associations+with+vascular+endothelial+growth+factor+inhibition+in+participants+with+neovascular+age‐related+macular+degeneration+in+the+IVAN+study+&author=AJ+Lotery&author=J+Gibson&author=AJ+Cree&author=SM+Downes&author=SP+Harding&author=CA+Rogers&publication_year=2013&hl=en']",24070809,https://doi.org/10.1016/j.ophtha.2013.07.046, IVAN 2013 {published and unpublished data}  ,included,CD005139-bbs2-0007,
CD005139-bib-0078,"Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. ",Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results, Ophthalmology ,2016,123,    ,['citation-journal']," Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results.  Ophthalmology 2016;123(1):51‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.09.018', 'https://www.ncbi.nlm.nih.gov/pubmed/26477842', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+or+bevacizumab+for+neovascular+age‐related+macular+degeneration+according+to+the+Lucentis+Compared+to+Avastin+Study+treat‐and‐extend+protocol:+two‐year+results+&author=K+Berg&author=E+Hadzalic&author=I+Gjertsen&author=V+Forsaa&author=LH+Berger&author=B+Kinge&publication_year=2016&hl=en']",26477842,https://doi.org/10.1016/j.ophtha.2015.09.018, LUCAS 2015 {published and unpublished data}  ,included,CD005139-bbs2-0008,
CD005139-bib-0079,"Berg K, Pedersen TR, Sandvik L, Bragadottir R. ",Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol, Ophthalmology ,2015,122,    ,['citation-journal']," Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol.  Ophthalmology 2015;122(1):146‐52. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2014.07.041', 'https://www.ncbi.nlm.nih.gov/pubmed/25227499', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+ranibizumab+and+bevacizumab+for+neovascular+age‐related+macular+degeneration+according+to+LUCAS+treat‐and+extend+protocol+&author=K+Berg&author=TR+Pedersen&author=L+Sandvik&author=R+Bragadottir&publication_year=2015&hl=en']",25227499,https://doi.org/10.1016/j.ophtha.2014.07.041, LUCAS 2015 {published and unpublished data}  ,included,CD005139-bbs2-0008,
CD005139-bib-0080,"Krebs I, Schmetterer L, Boltz A, Told R, Vécsei‐Marlovits V, Egger S, et al. ",A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration, British Journal of Ophthalmology ,2013,97,    ,['citation-journal']," Krebs I, Schmetterer L, Boltz A, Told R, Vécsei‐Marlovits V, Egger S, et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration.  British Journal of Ophthalmology 2013;97(3):266‐71. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjophthalmol-2012-302391', 'https://scholar.google.com/scholar_lookup?title=A+randomised+double‐masked+trial+comparing+the+visual+outcome+after+treatment+with+ranibizumab+or+bevacizumab+in+patients+with+neovascular+age‐related+macular+degeneration+&author=I+Krebs&author=L+Schmetterer&author=A+Boltz&author=R+Told&author=V+Vécsei‐Marlovits&author=S+Egger&publication_year=2013&hl=en']",,https://doi.org/10.1136/bjophthalmol-2012-302391, MANTA 2013 {published and unpublished data}  ,included,CD005139-bbs2-0009,
CD005139-bib-0081,"Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. ",Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab, Retina ,2010,30,    ,['citation-journal']," Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab.  Retina 2010;30(9):1376‐85. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3181dcfb0b', 'https://www.ncbi.nlm.nih.gov/pubmed/20683380', 'https://scholar.google.com/scholar_lookup?title=Dosing+regimen+and+the+frequency+of+macular+hemorrhages+in+neovascular+age‐related+macular+degeneration+treated+with+ranibizumab+&author=I+Barbazetto&author=N+Saroj&author=H+Shapiro&author=P+Wong&author=KB+Freund&publication_year=2010&hl=en']",20683380,https://doi.org/10.1097/IAE.0b013e3181dcfb0b, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0082,"Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. ",Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials, American Journal of Ophthalmology ,2010,149,    ,['citation-journal']," Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.  American Journal of Ophthalmology 2010;149(6):939‐46. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2010.01.007', 'https://www.ncbi.nlm.nih.gov/pubmed/20378094', 'https://scholar.google.com/scholar_lookup?title=Incidence+of+new+choroidal+neovascularization+in+fellow+eyes+of+patients+treated+in+the+MARINA+and+ANCHOR+trials+&author=IA+Barbazetto&author=N+Saroj&author=H+Shapiro&author=P+Wong&author=AC+Ho&author=KB+Freund&publication_year=2010&hl=en']",20378094,https://doi.org/10.1016/j.ajo.2010.01.007, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0083,"Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group. ",Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration, Ophthalmology ,2007,114,    ,['citation-journal']," Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration.  Ophthalmology 2007;114(2):246‐52. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2006.10.045', 'https://www.ncbi.nlm.nih.gov/pubmed/17270674', 'https://scholar.google.com/scholar_lookup?title=Subgroup+analysis+of+the+MARINA+study+of+ranibizumab+in+neovascular+age‐related+macular+degeneration+&author=DS+Boyer&author=AN+Antoszyk&author=CC+Awh&author=RB+Bhisitkul&author=H+Shapiro&author=NR+Acharya&publication_year=2007&hl=en']",17270674,https://doi.org/10.1016/j.ophtha.2006.10.045, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0084,"Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al. ",Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials, Retina ,2012,32,    ,['citation-journal']," Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.  Retina 2012;32(9):1821‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e31825db6ba', 'https://www.ncbi.nlm.nih.gov/pubmed/23011184', 'https://scholar.google.com/scholar_lookup?title=Cerebrovascular+accidents+in+patients+treated+for+choroidal+neovascularization+with+ranibizumab+in+randomized+controlled+trials+&author=NM+Bressler&author=DS+Boyer&author=DF+Williams&author=S+Butler&author=SF+Francom&author=B+Brown&publication_year=2012&hl=en']",23011184,https://doi.org/10.1097/IAE.0b013e31825db6ba, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0085,"Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al. ",Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR, Ophthalmology ,2010,117,    ,['citation-journal']," Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR.  Ophthalmology 2010;117(4):747‐56. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2009.09.002', 'https://www.ncbi.nlm.nih.gov/pubmed/20189654', 'https://scholar.google.com/scholar_lookup?title=Vision‐related+function+after+ranibizumab+treatment+by+better‐+or+worse‐seeing+eye:+clinical+trial+results+from+MARINA+and+ANCHOR+&author=NM+Bressler&author=TS+Chang&author=IJ+Suñer&author=JT+Fine&author=CM+Dolan&author=J+Ward&publication_year=2010&hl=en']",20189654,https://doi.org/10.1016/j.ophtha.2009.09.002, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0086,"Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, et al. ",Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab, Ophthalmology ,2013,120,    ,['citation-journal']," Bressler NM, Chang TS, Varma R, Suner I, Lee P, Dolan CM, et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab.  Ophthalmology 2013;120(1):160‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.07.027', 'https://www.ncbi.nlm.nih.gov/pubmed/23009891', 'https://scholar.google.com/scholar_lookup?title=Driving+ability+reported+by+neovascular+age‐related+macular+degeneration+patients+after+treatment+with+ranibizumab+&author=NM+Bressler&author=TS+Chang&author=R+Varma&author=I+Suner&author=P+Lee&author=CM+Dolan&publication_year=2013&hl=en']",23009891,https://doi.org/10.1016/j.ophtha.2012.07.027, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0088,"Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J. ",Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J. Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 1830. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Self‐reported+perception+of+driving+function+following+ranibizumab+treatment+in+patients+with+neovascular+AMD+&author=TS+Chang&author=NM+Bressler&author=JT+Fine&author=CM+Dolan&author=J+Ward&publication_year=2007&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0087,"Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, et al. ",Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial, Archives of Ophthalmology ,2007,125,    ,['citation-journal']," Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial.  Archives of Ophthalmology 2007;125(11):1460‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archopht.125.11.1460', 'https://www.ncbi.nlm.nih.gov/pubmed/17998507', 'https://scholar.google.com/scholar_lookup?title=Improved+vision‐related+function+after+ranibizumab+treatment+of+neovascular+age‐related+macular+degeneration:+results+of+a+randomized+clinical+trial+&author=TS+Chang&author=NM+Bressler&author=JT+Fine&author=CM+Dolan&author=J+Ward&author=TR+Klesert&publication_year=2007&hl=en']",17998507,https://doi.org/10.1001/archopht.125.11.1460, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0089,"Chang TS, Fine JT, Alexander S, Bressler N. ",Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial,,2006,,    ,['citation-other']," Chang TS, Fine JT, Alexander S, Bressler N. Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+self‐reported+vision+specific+quality+of+life+through+12+months+in+age‐related+macular+degeneration+patients+with+minimally+classic+or+occult‐with‐no‐classic+choroidal+neovascularization+in+a+phase+III+randomized+clinical+trial+&author=TS+Chang&author=JT+Fine&author=S+Alexander&author=N+Bressler&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0090,"Chang TS, Fine JT, Bressler N. ",Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®), Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Chang TS, Fine JT, Bressler N. Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®).  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 5252. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Self‐reported+vision‐specific+quality+of+life+at+1+year+in+patients+with+neovascular+age‐related+macular+degeneration+in+2+phase+III+randomized+clinical+trials+of+ranibizumab+(Lucentis®)+&author=TS+Chang&author=JT+Fine&author=N+Bressler&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0091,"Chang TS, Fine JT, Dolan CM, Marceau C, Bressler NM. ",Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial,,,,   ,['citation-other']," Chang TS, Fine JT, Dolan CM, Marceau C, Bressler NM. Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0092,"Ciulla TA, Shapiro H, Schneider S. ",Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Ciulla TA, Shapiro H, Schneider S. Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 4573. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+for+neovascular+age‐related+macular+degeneration+(AMD):+1‐year+visual+acuity+(VA)+results+for+fellow+eyes+with+neovascular+AMD+in+MARINA+and+ANCHOR+&author=TA+Ciulla&author=H+Shapiro&author=S+Schneider&publication_year=2007&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0093,"Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. ",Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration, Ophthalmology ,2011,118,    ,['citation-journal']," Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration.  Ophthalmology 2011;118(12):2447‐52. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2011.05.026', 'https://www.ncbi.nlm.nih.gov/pubmed/21872935', 'https://scholar.google.com/scholar_lookup?title=Incidence+of+retinal+pigment+epithelial+tears+after+intravitreal+ranibizumab+injection+for+neovascular+age‐related+macular+degeneration+&author=ET+Cunningham&author=L+Feiner&author=C+Chung&author=L+Tuomi&author=JS+Ehrlich&publication_year=2011&hl=en']",21872935,https://doi.org/10.1016/j.ophtha.2011.05.026, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0094,"Heier JS, Shapiro H, Singh AA. ","Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study", Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Heier JS, Shapiro H, Singh AA. Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study.  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 2959. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Randomized,+controlled+phase+III+study+of+ranibizumab+(Lucentis®)+for+minimally+classic+or+occult+neovascular+age‐related+macular+degeneration:+two‐year+efficacy+results+of+the+MARINA+study+&author=JS+Heier&author=H+Shapiro&author=AA+Singh&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0095,"Ho A, Shapiro H, Acharya N. ",Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study,,2006,,    ,['citation-other']," Ho A, Shapiro H, Acharya N. Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+neovascular+age‐related+macular+degeneration:+one‐year+subanalysis+of+the+MARINA+study+&author=A+Ho&author=H+Shapiro&author=N+Acharya&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0096,"Holekamp NM, Acharya N, Shapiro H. ",Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD,,2006,,    ,['citation-other']," Holekamp NM, Acharya N, Shapiro H. Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Two‐year+FA/OCT+results+of+MARINA+study+of+ranibizumab+(Lucentis®)+in+neovascular+AMD+&author=NM+Holekamp&author=N+Acharya&author=H+Shapiro&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0097,"Hurley SF, Matthews JP, Guymer RH. ",Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration, Cost Effectiveness and Resource Allocation ,2008,6,    ,['citation-journal']," Hurley SF, Matthews JP, Guymer RH. Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration.  Cost Effectiveness and Resource Allocation 2008;6:12. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1478-7547-6-12', 'https://www.ncbi.nlm.nih.gov/pubmed/18573218', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+ranibizumab+for+neovascular+age‐related+macular+degeneration&author=SF+Hurley&author=JP+Matthews&author=RH+Guymer&publication_year=2008&hl=en']",18573218,https://doi.org/10.1186/1478-7547-6-12, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0098,"Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group. ",Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration, Ophthalmology ,2007,114,    ,['citation-journal']," Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration.  Ophthalmology 2007;114(10):1868‐75. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2007.04.030', 'https://www.ncbi.nlm.nih.gov/pubmed/17628683', 'https://scholar.google.com/scholar_lookup?title=Angiographic+and+optical+coherence+tomographic+results+of+the+MARINA+study+of+ranibizumab+in+neovascular+age‐related+macular+degeneration+&author=PK+Kaiser&author=BA+Blodi&author=H+Shapiro&author=NR+Acharya&publication_year=2007&hl=en']",17628683,https://doi.org/10.1016/j.ophtha.2007.04.030, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0099,Kokame GT. ,Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration,,2006,,    ,['citation-other'], Kokame GT. Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Anatomic+outcomes+from+the+MARINA+study+of+ranibizumab+(Lucentis®)+for+minimally+classic+or+occult+neovascular+age‐related+macular+degeneration+&author=GT+Kokame&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0100,Korobelnik JF. ,Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD,,,,   ,['citation-other'], Korobelnik JF. Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ,[''],,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0101,"Lanzetta P, MARINA and ANCHOR Study Groups. ",Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD,,,,   ,['citation-other']," Lanzetta P, MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0102,"Loewenstein A, MARINA and ANCHOR Study Groups. ",Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration,,,,   ,['citation-other']," Loewenstein A, MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0103,"Miller JW, Shapiro H, Acharya N. ","Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study", Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Miller JW, Shapiro H, Acharya N. Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study.  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 3539. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Randomized,+controlled+phase+III+study+of+ranibizumab+(Lucentis®)+for+minimally+classic+or+occult+neovascular+age‐related+macular+degeneration:+two‐year+safety+results+of+the+MARINA+study+&author=JW+Miller&author=H+Shapiro&author=N+Acharya&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0104,"Reichel E, Shapiro H, Acharya N. ",Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD,,2006,,    ,['citation-other']," Reichel E, Shapiro H, Acharya N. Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Subgroup+analyses+of+two‐year+results+of+MARINA+study+of+ranibizumab+in+neovascular+AMD+&author=E+Reichel&author=H+Shapiro&author=N+Acharya&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0105,"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. ","Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP)", Ophthalmology ,2013,120,    ,['citation-journal']," Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP).  Ophthalmology 2013;120(11):2292‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.03.046', 'https://www.ncbi.nlm.nih.gov/pubmed/23642856', 'https://scholar.google.com/scholar_lookup?title=Seven‐year+outcomes+in+ranibizumab‐treated+patients+in+ANCHOR,+MARINA,+and+HORIZON:+a+multicenter+cohort+study+(SEVEN‐UP)+&author=S+Rofagha&author=RB+Bhisitkul&author=DS+Boyer&author=SR+Sadda&author=K+Zhang&publication_year=2013&hl=en']",23642856,https://doi.org/10.1016/j.ophtha.2013.03.046, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0106,"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. ",Ranibizumab for neovascular age‐related macular degeneration, New England Journal of Medicine ,2006,355,    ,['citation-journal']," Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age‐related macular degeneration.  New England Journal of Medicine 2006;355(14):1419‐31. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa054481', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+neovascular+age‐related+macular+degeneration&author=PJ+Rosenfeld&author=DM+Brown&author=JS+Heier&author=DS+Boyer&author=PK+Kaiser&author=CY+Chung&publication_year=2006&hl=en']",,https://doi.org/10.1056/NEJMoa054481, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0107,"Rosenfeld PJ, Shapiro H, Shams N, Schneider S, Depperschmidt EE, MARINA and ANCHOR Study Groups. ",Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Rosenfeld PJ, Shapiro H, Shams N, Schneider S, Depperschmidt EE, MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 4576. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Baseline+and+treatment+characteristics+of+patients+losing+vision+at+year+1+of+the+MARINA+and+ANCHOR+trials+&author=PJ+Rosenfeld&author=H+Shapiro&author=N+Shams&author=S+Schneider&author=EE+Depperschmidt&publication_year=2007&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0108,"Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. ",Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials, Ophthalmology ,2011,118,    ,['citation-journal']," Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.  Ophthalmology 2011;118(3):523‐30. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2010.07.011', 'https://www.ncbi.nlm.nih.gov/pubmed/20920825', 'https://scholar.google.com/scholar_lookup?title=Characteristics+of+patients+losing+vision+after+2+years+of+monthly+dosing+in+the+phase+III+ranibizumab+clinical+trials+&author=PJ+Rosenfeld&author=H+Shapiro&author=L+Tuomi&author=M+Webster&author=J+Elledge&author=B+Blodi&publication_year=2011&hl=en']",20920825,https://doi.org/10.1016/j.ophtha.2010.07.011, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0109,"Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. ",Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 329. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Lesion+characteristics+in+ranibizumab+(Lucentis®)+treated+patients+with+a+visual+acuity+(VA)+gain+or+loss+in+the+MARINA+and+ANCHOR+trials+for+wet+age‐related+macular+degeneration+(AMD)+&author=PJ+Rosenfeld&author=H+Shapiro&author=L+Tuomi&author=M+Webster&author=J+Elledge&author=B+Blodi&publication_year=2008&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0110,"Schmidt‐Erfurth U, Williams GA, MARINA Study Group. ",Two‐year efficacy and safety results from the MARINA study,,,,   ,['citation-other']," Schmidt‐Erfurth U, Williams GA, MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0111,"Suner IJ, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. ",Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Suner IJ, Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 1808. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Vision‐related+function+after+ranibizumab+treatment+by+better‐+or+worse‐seeing+eye:+24+month+results+from+MARINA+&author=IJ+Suner&author=NM+Bressler&author=TS+Chang&author=JT+Fine&author=CM+Dolan&author=J+Ward&publication_year=2007&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0112,"Sutter FK, Kurz‐Levin MM. ",Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Sutter FK, Kurz‐Levin MM. Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 2884. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Towards+an+optimized+treatment+scheme+of+ranibizumab+in+patients+with+subfoveal+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration:+subanalysis+of+clinical+trial+data+and+clinical+routine+use+&author=FK+Sutter&author=MM+Kurz‐Levin&publication_year=2008&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0113,"Webster MK, Blodi BA, Glaeser Alexander S, Elledge KA, Hiner C, Hurtenbach CH, et al. ",Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data, Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Webster MK, Blodi BA, Glaeser Alexander S, Elledge KA, Hiner C, Hurtenbach CH, et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data.  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐abstract 2206. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+in+subjects+with+minimally+classic+or+occult+CNV+(MARINA):+reading+center+evaluation+of+angiographic+eligibility+characteristics+and+baseline+fluorescein+angiographic+data+&author=MK+Webster&author=BA+Blodi&author=S+GlaeserAlexander&author=KA+Elledge&author=C+Hiner&author=CH+Hurtenbach&publication_year=2006&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0114,"Weinberg DV, Shapiro H, Ehrlich JS. ",Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials, Ophthalmology ,2013,120,    ,['citation-journal']," Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.  Ophthalmology 2013;120(6):1278‐82. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.11.042', 'https://www.ncbi.nlm.nih.gov/pubmed/23453513', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+treatment+outcomes+in+phakic+versus+pseudophakic+eyes:+an+individual+patient+data+analysis+of+2+phase+3+trials+&author=DV+Weinberg&author=H+Shapiro&author=JS+Ehrlich&publication_year=2013&hl=en']",23453513,https://doi.org/10.1016/j.ophtha.2012.11.042, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0116,Wolf S. ,"Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD", Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Wolf S. Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐abstract 2883. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Visual+acuity+gain+with+ranibizumab+therapy:+two‐year+data+from+the+MARINA,+ANCHOR,+and+PIER+trials+in+patients+with+neovascular+AMD+&author=S+Wolf&publication_year=2008&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0115,"Wolf S, Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Prünte C, et al. ",Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR, British Journal of Ophthalmology ,2011,95,    ,['citation-journal']," Wolf S, Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Prünte C, et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR.  British Journal of Ophthalmology 2011;95(12):1713‐8. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjophthalmol-2011-300471', 'https://scholar.google.com/scholar_lookup?title=Outcomes+following+three‐line+vision+loss+during+treatment+of+neovascular+age‐related+macular+degeneration:+subgroup+analyses+from+MARINA+and+ANCHOR+&author=S+Wolf&author=FG+Holz&author=JF+Korobelnik&author=P+Lanzetta&author=P+Mitchell&author=C+Prünte&publication_year=2011&hl=en']",,https://doi.org/10.1136/bjophthalmol-2011-300471, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0117,"Yu EB, Bressler NM, Fine JT, Ward JF, Dolan CM, Klesert T, et al. ",Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Yu EB, Bressler NM, Fine JT, Ward JF, Dolan CM, Klesert T, et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐abstract 1174. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Relationship+between+patient‐reported+visual+function+and+visual+acuity+in+subjects+with+neovascular+AMD+&author=EB+Yu&author=NM+Bressler&author=JT+Fine&author=JF+Ward&author=CM+Dolan&author=T+Klesert&publication_year=2007&hl=en']",,, MARINA 2006 {published and unpublished data}  ,included,CD005139-bbs2-0010,
CD005139-bib-0118,"Abraham P, Yue H, Shams N. ",PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration,,,,   ,['citation-other']," Abraham P, Yue H, Shams N. PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ",[''],,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0119,"Abraham P, Yue H, Wilson L. ","Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2", American Journal of Ophthalmology ,2010,150,    ,['citation-journal']," Abraham P, Yue H, Wilson L. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2.  American Journal of Ophthalmology 2010;150(3):315‐24. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2010.04.011', 'https://www.ncbi.nlm.nih.gov/pubmed/20598667', 'https://scholar.google.com/scholar_lookup?title=Randomized,+double‐masked,+sham‐controlled+trial+of+ranibizumab+for+neovascular+age‐related+macular+degeneration:+PIER+study+year+2+&author=P+Abraham&author=H+Yue&author=L+Wilson&publication_year=2010&hl=en']",20598667,https://doi.org/10.1016/j.ajo.2010.04.011, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0120,"Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. ",Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab, Retina ,2010,30,    ,['citation-journal']," Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB. Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab.  Retina 2010;30(9):1376‐85. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3181dcfb0b', 'https://www.ncbi.nlm.nih.gov/pubmed/20683380', 'https://scholar.google.com/scholar_lookup?title=Dosing+regimen+and+the+frequency+of+macular+hemorrhages+in+neovascular+age‐related+macular+degeneration+treated+with+ranibizumab+&author=I+Barbazetto&author=N+Saroj&author=H+Shapiro&author=P+Wong&author=KB+Freund&publication_year=2010&hl=en']",20683380,https://doi.org/10.1097/IAE.0b013e3181dcfb0b, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0121,"Benz MS, Brown DM, Shapiro H, Tuomi L. ",Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Benz MS, Brown DM, Shapiro H, Tuomi L. Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 347. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+neovascular+age‐related+macular+degeneration+(AMD):+optical+coherence+tomography+(OCT)+vs.+visual+acuity+(VA)+changes+in+PIER+study+&author=MS+Benz&author=DM+Brown&author=H+Shapiro&author=L+Tuomi&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0122,"Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al. ",Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials, Retina ,2012,32,    ,['citation-journal']," Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.  Retina 2012;32(9):1821‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e31825db6ba', 'https://www.ncbi.nlm.nih.gov/pubmed/23011184', 'https://scholar.google.com/scholar_lookup?title=Cerebrovascular+accidents+in+patients+treated+for+choroidal+neovascularization+with+ranibizumab+in+randomized+controlled+trials+&author=NM+Bressler&author=DS+Boyer&author=DF+Williams&author=S+Butler&author=SF+Francom&author=B+Brown&publication_year=2012&hl=en']",23011184,https://doi.org/10.1097/IAE.0b013e31825db6ba, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0123,"Brown DM, Chung CY, Tuomi L. ",Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study,,2008,,    ,['citation-other']," Brown DM, Chung CY, Tuomi L. Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+for+neovascular+age‐related+macular+degeneration+(AMD):+optical+coherence+tomography+(OCT)+vs.+visual+acuity+(VA)+changes+in+PIER+study+&author=DM+Brown&author=CY+Chung&author=L+Tuomi&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0124,"Brown DM, Tuomi L, Shapiro H, PIER Study Group. ",Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration, Retina ,2013,33,    ,['citation-journal']," Brown DM, Tuomi L, Shapiro H, PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration.  Retina 2013;33(1):23‐34. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e318263cedf', 'https://www.ncbi.nlm.nih.gov/pubmed/23073338', 'https://scholar.google.com/scholar_lookup?title=Anatomical+measures+as+predictors+of+visual+outcomes+in+ranibizumab‐treated+eyes+with+neovascular+age‐related+macular+degeneration+&author=DM+Brown&author=L+Tuomi&author=H+Shapiro&publication_year=2013&hl=en']",23073338,https://doi.org/10.1097/IAE.0b013e318263cedf, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0125,"Brown DM, Yue H, Shams N. ",Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Brown DM, Yue H, Shams N. Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 4540. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+in+neovascular+age‐related+macular+degeneration+(AMD):+subgroup+analysis+of+year+1+PIER+efficacy+data+&author=DM+Brown&author=H+Yue&author=N+Shams&publication_year=2007&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0126,"Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. ",Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration, Ophthalmology ,2011,118,    ,['citation-journal']," Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration.  Ophthalmology 2011;118(12):2447‐52. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2011.05.026', 'https://www.ncbi.nlm.nih.gov/pubmed/21872935', 'https://scholar.google.com/scholar_lookup?title=Incidence+of+retinal+pigment+epithelial+tears+after+intravitreal+ranibizumab+injection+for+neovascular+age‐related+macular+degeneration+&author=ET+Cunningham&author=L+Feiner&author=C+Chung&author=L+Tuomi&author=JS+Ehrlich&publication_year=2011&hl=en']",21872935,https://doi.org/10.1016/j.ophtha.2011.05.026, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0127,"Ho AC, Shapiro H, Wilson L. ",Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study,,2008,,    ,['citation-other']," Ho AC, Shapiro H, Wilson L. Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+for+neovascular+age‐related+macular+degeneration+(AMD):+two‐year+angiographic+results+of+PIER+study+&author=AC+Ho&author=H+Shapiro&author=L+Wilson&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0128,"Ho AC, Yue H, Wilson L. ",Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Ho AC, Yue H, Wilson L. Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 368. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+in+wet+age‐related+macular+degeneration+(AMD):+crossover/rollover+patient+results+in+PIER+study+&author=AC+Ho&author=H+Yue&author=L+Wilson&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0129,"Kaiser PK, Yue H, Shams N. ",Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD,,2006,,    ,['citation-other']," Kaiser PK, Yue H, Shams N. Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Subgroup+analyses+of+one‐year+results+of+the+PIER+study+of+ranibizumab+in+neovascular+AMD+&author=PK+Kaiser&author=H+Yue&author=N+Shams&publication_year=2006&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0130,Lanzetta P. ,Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal'], Lanzetta P. Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 5571. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+and+patient‐reported+outcomes:+VFQ‐25+data+from+the+ANCHOR+and+PIER+trials+in+patients+with+neovascular+AMD+&author=P+Lanzetta&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0131,"Michels M, Shapiro H, Wilson L. ",Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Michels M, Shapiro H, Wilson L. Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 2882. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+for+neovascular+age‐related+macular+degeneration+(AMD):+2‐year+angiographic+results+of+PIER+study+&author=M+Michels&author=H+Shapiro&author=L+Wilson&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0132,Mieler WF. ,PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD,,,,   ,['citation-other'], Mieler WF. PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CENTRAL    ,[''],,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0133,"Regillo CD, Bressler NM, Fine JT, Dolan CM, Marceau C, Chang TS. ",Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™),,,,   ,['citation-other']," Regillo CD, Bressler NM, Fine JT, Dolan CM, Marceau C, Chang TS. Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). CENTRAL    ",[''],,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0134,"Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. ","Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1", American Journal of Ophthalmology ,2008,145,    ,['citation-journal']," Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1.  American Journal of Ophthalmology 2008;145(2):239‐48. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2007.10.004', 'https://www.ncbi.nlm.nih.gov/pubmed/18222192', 'https://scholar.google.com/scholar_lookup?title=Randomized,+double‐masked,+sham‐controlled+trial+of+ranibizumab+for+neovascular+age‐related+macular+degeneration:+PIER+study+year+1+&author=CD+Regillo&author=DM+Brown&author=P+Abraham&author=H+Yue&author=T+Ianchulev&author=S+Schneider&publication_year=2008&hl=en']",18222192,https://doi.org/10.1016/j.ajo.2007.10.004, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0135,"Regillo CD, Chung CY, Wilson L, PIER Study Group. ",Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study,,2008,,    ,['citation-other']," Regillo CD, Chung CY, Wilson L, PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+in+neovascular+age‐related+macular+degeneration+(AMD):+crossover/rollover+treatment+effects+in+PIER+study+&author=CD+Regillo&author=CY+Chung&author=L+Wilson&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0136,Wolf S. ,"Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD", Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Wolf S. Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 2883. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Visual+acuity+gain+with+ranibizumab+therapy:+two‐year+data+from+the+MARINA,+ANCHOR,+and+PIER+trials+in+patients+with+neovascular+AMD+&author=S+Wolf&publication_year=2008&hl=en']",,, PIER 2008 {published and unpublished data}  ,included,CD005139-bbs2-0011,
CD005139-bib-0137,"Michels SM, Weigert G, Geitzenauer W, Sacu S, Alina V, Schmidt‐Erfurth U. ",Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Michels SM, Weigert G, Geitzenauer W, Sacu S, Alina V, Schmidt‐Erfurth U. Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2007;48:ARVO E‐Abstract 1820. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin®)+therapy+versus+verteporfin+therapy+and+intravitreal+triamcinolone+for+neovascular+age‐related+macular+degeneration+&author=SM+Michels&author=G+Weigert&author=W+Geitzenauer&author=S+Sacu&author=V+Alina&author=U+Schmidt‐Erfurth&publication_year=2007&hl=en']",,, Sacu 2009 {published and unpublished data}  ,included,CD005139-bbs2-0012,
CD005139-bib-0138,"Prager F, Michels S, Sacu S, Weigert G, Dunavölgyi R, Geitzenauer W, et al. ","Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial", Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Prager F, Michels S, Sacu S, Weigert G, Dunavölgyi R, Geitzenauer W, et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 1168. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin®)+monotherapy+versus+photodynamic+therapy+plus+intravitreal+triamcinolone+for+neovascular+age‐related+macular+degeneration:+12+months+results+of+a+prospective,+randomized,+controlled+clinical+trial+&author=F+Prager&author=S+Michels&author=S+Sacu&author=G+Weigert&author=R+Dunavölgyi&author=W+Geitzenauer&publication_year=2008&hl=en']",,, Sacu 2009 {published and unpublished data}  ,included,CD005139-bbs2-0012,
CD005139-bib-0139,"Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, et al. ",Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results, Eye ,2009,23,    ,['citation-journal']," Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results.  Eye 2009;23(12):2223‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/eye.2008.423', 'https://www.ncbi.nlm.nih.gov/pubmed/19169239', 'https://scholar.google.com/scholar_lookup?title=Randomised+clinical+trial+of+intravitreal+Avastin®+vs+photodynamic+therapy+and+intravitreal+triamcinolone:+long‐term+results+&author=S+Sacu&author=S+Michels&author=F+Prager&author=G+Weigert&author=R+Dunavoelgyi&author=W+Geitzenauer&publication_year=2009&hl=en']",19169239,https://doi.org/10.1038/eye.2008.423, Sacu 2009 {published and unpublished data}  ,included,CD005139-bbs2-0012,
CD005139-bib-0140,"Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, et al. ","Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study", British Journal of Ophthalmology ,2008,92,    ,['citation-journal']," Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study.  British Journal of Ophthalmology 2008;92(3):356‐60. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjo.2007.125823', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin®)+therapy+versus+photodynamic+therapy+plus+intravitreal+triamcinolone+for+neovascular+age‐related+macular+degeneration:+6‐month+results+of+a+prospective,+randomised,+controlled+clinical+study+&author=G+Weigert&author=S+Michels&author=S+Sacu&author=A+Varga&author=F+Prager&author=W+Geitzenauer&publication_year=2008&hl=en']",,https://doi.org/10.1136/bjo.2007.125823, Sacu 2009 {published and unpublished data}  ,included,CD005139-bbs2-0012,
CD005139-bib-0141,"Enseleit F, Michels S, Sudano I, Stahel M, Zweifel S, Schlager O, et al. ",SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration, Ophthalmologica ,2017,238,    ,['citation-journal']," Enseleit F, Michels S, Sudano I, Stahel M, Zweifel S, Schlager O, et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration.  Ophthalmologica 2017;238:205‐16. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1159/000478665', 'https://www.ncbi.nlm.nih.gov/pubmed/28866675', 'https://scholar.google.com/scholar_lookup?title=SAVE‐AMD:+safety+of+VEGF+inhibitors+in+age‐related+macular+degeneration&author=F+Enseleit&author=S+Michels&author=I+Sudano&author=M+Stahel&author=S+Zweifel&author=O+Schlager&publication_year=2017&hl=en']",28866675,https://doi.org/10.1159/000478665, SAVE‐AMD 2017 {published data only (unpublished sought but not used)}  ,included,CD005139-bbs2-0013,
CD005139-bib-0142,"Scholler A, Richter‐Mueksch S, Weingessel B, Vecsei‐Marlovits P‐V. ",Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD, Wiener Klinische Wochenschrift (Central European Journal of Medicine) ,2014,126,    ,['citation-journal']," Scholler A, Richter‐Mueksch S, Weingessel B, Vecsei‐Marlovits P‐V. Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD.  Wiener Klinische Wochenschrift (Central European Journal of Medicine) 2014;126:355‐9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1007/s00508-014-0539-z', 'https://scholar.google.com/scholar_lookup?title=Differences+of+frequency+in+administration+of+ranibizumab+and+bevacizumab+in+patients+with+neovascular+AMD+&author=A+Scholler&author=S+Richter‐Mueksch&author=B+Weingessel&author=P‐V+Vecsei‐Marlovits&publication_year=2014&hl=en']",,https://doi.org/10.1007/s00508-014-0539-z, Scholler 2014 {published data only}  ,included,CD005139-bbs2-0014,
CD005139-bib-0143,"Donahue SP, Recchia F, Sternberg P. ","Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial", American Journal of Ophthalmology ,2010,150,    ,['citation-journal']," Donahue SP, Recchia F, Sternberg P. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial.  American Journal of Ophthalmology 2010;150(2):287. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2010.04.006', 'https://www.ncbi.nlm.nih.gov/pubmed/20670740', 'https://scholar.google.com/scholar_lookup?title=Bevacizumab+vs+ranibizumab+for+age‐related+macular+degeneration:+early+results+of+a+prospective+double‐masked,+randomized+clinical+trial+&author=SP+Donahue&author=F+Recchia&author=P+Sternberg&publication_year=2010&hl=en']",20670740,https://doi.org/10.1016/j.ajo.2010.04.006, Subramanian 2010 {published and unpublished data}  ,included,CD005139-bbs2-0015,
CD005139-bib-0144,"Messori A, Fadda V, Trippoli S. ",Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions, American Journal of Ophthalmology ,2010,149,    ,['citation-journal']," Messori A, Fadda V, Trippoli S. Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions.  American Journal of Ophthalmology 2010;149(5):867. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2009.12.039', 'https://www.ncbi.nlm.nih.gov/pubmed/20399931', 'https://scholar.google.com/scholar_lookup?title=Randomized+study+of+bevacizumab+vs+ranibizumab+for+age‐related+macular+degeneration:+inappropriate+conclusions+&author=A+Messori&author=V+Fadda&author=S+Trippoli&publication_year=2010&hl=en']",20399931,https://doi.org/10.1016/j.ajo.2009.12.039, Subramanian 2010 {published and unpublished data}  ,included,CD005139-bbs2-0015,
CD005139-bib-0145,"Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. ","Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial", Eye ,2010,24,    ,['citation-journal']," Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial.  Eye 2010;24(11):1708‐15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/eye.2010.147', 'https://www.ncbi.nlm.nih.gov/pubmed/20885427', 'https://scholar.google.com/scholar_lookup?title=Bevacizumab+vs+ranibizumab+for+age‐related+macular+degeneration:+1‐year+outcomes+of+a+prospective,+double‐masked+randomised+clinical+trial+&author=ML+Subramanian&author=G+Abedi&author=S+Ness&author=E+Ahmed&author=M+Fenberg&author=MK+Daly&publication_year=2010&hl=en']",20885427,https://doi.org/10.1038/eye.2010.147, Subramanian 2010 {published and unpublished data}  ,included,CD005139-bbs2-0015,
CD005139-bib-0146,"Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al. ","Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial", American Journal of Ophthalmology ,2009,148,    ,['citation-journal']," Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial.  American Journal of Ophthalmology 2009;148(6):875‐82. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2009.07.009', 'https://www.ncbi.nlm.nih.gov/pubmed/19800611', 'https://scholar.google.com/scholar_lookup?title=Bevacizumab+vs+ranibizumab+for+age‐related+macular+degeneration:+early+results+of+a+prospective+double‐masked,+randomized+clinical+trial+&author=ML+Subramanian&author=S+Ness&author=G+Abedi&author=E+Ahmed&author=M+Daly&author=E+Feinberg&publication_year=2009&hl=en']",19800611,https://doi.org/10.1016/j.ajo.2009.07.009, Subramanian 2010 {published and unpublished data}  ,included,CD005139-bbs2-0015,
CD005139-bib-0147,"Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al. ",Reply, American Journal of Ophthalmology ,2010,149,    ,['citation-journal']," Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, et al. Reply.  American Journal of Ophthalmology 2010;149(5):867. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2009.12.040', 'https://scholar.google.com/scholar_lookup?title=Reply&author=ML+Subramanian&author=S+Ness&author=G+Abedi&author=E+Ahmed&author=M+Daly&author=E+Feinberg&publication_year=2010&hl=en']",,https://doi.org/10.1016/j.ajo.2009.12.040, Subramanian 2010 {published and unpublished data}  ,included,CD005139-bbs2-0015,
CD005139-bib-0148,Chakravarthy U. ,Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials,,2006,,    ,['citation-other'], Chakravarthy U. Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+pegaptanib+in+age‐related+macular+degeneration:+three‐year+results+of+the+V.I.S.I.O.N.+trials+&author=U+Chakravarthy&publication_year=2006&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0149,D'Amico DF. ,Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses,,2005,,    ,['citation-other'], D'Amico DF. Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. CENTRAL    Google Scholar     ,"['', ""https://scholar.google.com/scholar_lookup?title=Macugen®+in+neovascular+age‐related+macular+degeneration:+exploratory+subgroup+analyses+&author=DF+D'Amico&publication_year=2005&hl=en""]",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0151,D'Amico DJ. ,VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data, Investigative Ophthalmology and Visual Science ,2005,46,    ,['citation-journal'], D'Amico DJ. VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data.  Investigative Ophthalmology and Visual Science 2005;46:ARVO E‐abstract 2309. CENTRAL    Google Scholar     ,"['', ""https://scholar.google.com/scholar_lookup?title=VEGF+Inhibition+Study+in+Ocular+Neovascularization+(VISION):+second+year+efficacy+data+&author=DJ+D'Amico&publication_year=2005&hl=en""]",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0150,"D'Amico DJ, Bird AC. ",VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials, Investigative Ophthalmology and Visual Science ,2004,45,    ,['citation-journal']," D'Amico DJ, Bird AC. VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials.  Investigative Ophthalmology and Visual Science 2004;45:ARVO E‐Abstract 2363. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=VEGF+Inhibition+Study+in+Ocular+Neovascularization‐1+(VISION‐1):+safety+evaluation+from+the+pivotal+Macugen®+(pegaptanib+sodium)+clinical+trials+&author=DJ+D'Amico&author=AC+Bird&publication_year=2004&hl=en""]",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0152,"Eyetech Pharmaceuticals, Inc, Pfizer. Inc. ",Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration,,,,   ,['citation-other']," Eyetech Pharmaceuticals, Inc, Pfizer. Inc. Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). CENTRAL    ",[''],,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0153,FDA. ,Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration,,,,   ,['citation-other'], FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). CENTRAL    ,[''],,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0155,Gragoudas ES. ,VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials, Investigative Ophthalmology and Visual Science ,2004,45,    ,['citation-journal'], Gragoudas ES. VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials.  Investigative Ophthalmology and Visual Science 2004;45:ARVO E‐abstract 2364. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=VEGF+Inhibition+Study+in+Ocular+Neovascularization‐1+(VISION‐1):+efficacy+results+from+phase+II/III+Macugen®+(pegaptanib+sodium)+clinical+trials+&author=ES+Gragoudas&publication_year=2004&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0154,"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. ",Pegaptanib for neovascular age‐related macular degeneration, New England Journal of Medicine ,2004,351,    ,['citation-journal']," Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age‐related macular degeneration.  New England Journal of Medicine 2004;351(27):2805‐16. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa042760', 'https://scholar.google.com/scholar_lookup?title=Pegaptanib+for+neovascular+age‐related+macular+degeneration&author=ES+Gragoudas&author=AP+Adamis&author=ET+Cunningham&author=M+Feinsod&author=DR+Guyer&publication_year=2004&hl=en']",,https://doi.org/10.1056/NEJMoa042760, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0156,"Jackson TL, Danis RP, Goldbaum M, Slakter JS, Shusterman EM, Oeshaughnessy DJ, et al. ",Retinal vascular abnormalities in neovascular age‐related macular degeneration, Retina ,2014,34,    ,['citation-journal']," Jackson TL, Danis RP, Goldbaum M, Slakter JS, Shusterman EM, Oeshaughnessy DJ, et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration.  Retina 2014;34(3):568‐75. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3182a487be', 'https://www.ncbi.nlm.nih.gov/pubmed/24045343', 'https://scholar.google.com/scholar_lookup?title=Retinal+vascular+abnormalities+in+neovascular+age‐related+macular+degeneration&author=TL+Jackson&author=RP+Danis&author=M+Goldbaum&author=JS+Slakter&author=EM+Shusterman&author=DJ+Oeshaughnessy&publication_year=2014&hl=en']",24045343,https://doi.org/10.1097/IAE.0b013e3182a487be, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0157,Kuppermann BD. ,The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease,,2005,,    ,['citation-other'], Kuppermann BD. The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=The+V.I.S.I.O.N.+Study:+results+with+two+years+of+Macugen®+and+outcomes+of+earlier+treatment+in+early+disease+&author=BD+Kuppermann&publication_year=2005&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0158,"Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund‐Andersen H, et al. ",Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication, Ugeskrift for Laeger ,2005,167,    ,['citation-journal']," Larsen M, Sander B, Villumsen JE, Haamann PH, la Cour M, Lund‐Andersen H, et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication.  Ugeskrift for Laeger 2005;167(35):3301‐5. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/16138974', 'https://scholar.google.com/scholar_lookup?title=Treatment+of+neovascular+age‐related+macular+degeneration+with+intravitreal+vascular+endothelial+growth+factor+inhibitor+‐+secondary+publication+&author=M+Larsen&author=B+Sander&author=JE+Villumsen&author=PH+Haamann&author=M+Cour&author=H+Lund‐Andersen&publication_year=2005&hl=en']",16138974,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0159,"Leys A, Zlateva G, Shah SN, Patel M. ",Quality of life in patients with age‐related macular degeneration: results from the VISION study, Eye ,2008,22,    ,['citation-journal']," Leys A, Zlateva G, Shah SN, Patel M. Quality of life in patients with age‐related macular degeneration: results from the VISION study.  Eye 2008;22(6):792‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/sj.eye.6702900', 'https://www.ncbi.nlm.nih.gov/pubmed/17585313', 'https://scholar.google.com/scholar_lookup?title=Quality+of+life+in+patients+with+age‐related+macular+degeneration:+results+from+the+VISION+study+&author=A+Leys&author=G+Zlateva&author=SN+Shah&author=M+Patel&publication_year=2008&hl=en']",17585313,https://doi.org/10.1038/sj.eye.6702900, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0160,"Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, et al. ",Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration, Ophthalmology ,2007,114,    ,['citation-journal']," Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration.  Ophthalmology 2007;114(9):1702‐12. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/17509689', 'https://scholar.google.com/scholar_lookup?title=Pegaptanib+1‐year+systemic+safety+results+from+a+safety‐pharmacokinetic+trial+in+patients+with+neovascular+age‐related+macular+degeneration+&author=RS+Apte&author=M+Modi&author=H+Masonson&author=M+Patel&author=L+Whitfield&publication_year=2007&hl=en']",17509689,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0161,Marcus DM. ,Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal'], Marcus DM. Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐ Abstract 5069. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Four‐year+safety+of+pegaptanib+sodium+in+neovascular+age‐related+macular+degeneration+(AMD):+results+of+the+V.I.S.I.O.N.+trial+&author=DM+Marcus&publication_year=2008&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0162,Mieler W. ,Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION), Investigative Ophthalmology and Visual Science ,2005,46,    ,['citation-journal'], Mieler W. Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION).  Investigative Ophthalmology and Visual Science 2005;46:ARVO E‐Abstract 1380. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Safety+evaluation+of+second+year+treatment+of+age‐related+macular+degeneration+with+pegaptanib+sodium+(Macugen®):+VEGF+Inhibition+Study+in+Ocular+Neovascularization+(VISION)+&author=W+Mieler&publication_year=2005&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0163,"Mills E, Heels‐Ansdell D, Kelly S, Guyatt G. ",A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects, Journal of Clinical Epidemiology ,2007,60,    ,['citation-journal']," Mills E, Heels‐Ansdell D, Kelly S, Guyatt G. A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects.  Journal of Clinical Epidemiology 2007;60(5):456‐60. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jclinepi.2006.09.001', 'https://www.ncbi.nlm.nih.gov/pubmed/17419956', 'https://scholar.google.com/scholar_lookup?title=A+randomized+trial+of+pegaptanib+sodium+for+age‐related+macular+degeneration+used+an+innovative+design+to+explore+disease‐modifying+effects+&author=E+Mills&author=D+Heels‐Ansdell&author=S+Kelly&author=G+Guyatt&publication_year=2007&hl=en']",17419956,https://doi.org/10.1016/j.jclinepi.2006.09.001, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0164,"Patel M, Mones J, Leys A, Zlateva G, Shah SN. ",Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial,,,,   ,['citation-other']," Patel M, Mones J, Leys A, Zlateva G, Shah SN. Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). CENTRAL    ",[''],,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0165,"Rakic JM, Blaise P, Foidart JM, Gragoudas ES, Adamis AP, Feinsod M. ",Pegaptanib and age‐related macular degeneration, New England Journal of Medicine ,2005,352,    ,['citation-journal']," Rakic JM, Blaise P, Foidart JM, Gragoudas ES, Adamis AP, Feinsod M. Pegaptanib and age‐related macular degeneration.  New England Journal of Medicine 2005;352(16):1720‐1. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Pegaptanib+and+age‐related+macular+degeneration&author=JM+Rakic&author=P+Blaise&author=JM+Foidart&author=ES+Gragoudas&author=AP+Adamis&author=M+Feinsod&publication_year=2005&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0166,Singerman LI. ,Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials,,2006,,    ,['citation-other'], Singerman LI. Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Two‐year+systemic+safety+of+pegaptanib+in+patients+with+neovascular+age‐related+macular+degeneration:+results+of+the+V.I.S.I.O.N.+trials+&author=LI+Singerman&publication_year=2006&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0167,"Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, et al. ",Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial, British Journal of Ophthalmology ,2008,92,    ,['citation-journal']," Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.  British Journal of Ophthalmology 2008;92(12):1606‐11. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjo.2007.132597', 'https://scholar.google.com/scholar_lookup?title=Pegaptanib+sodium+for+neovascular+age‐related+macular+degeneration:+third‐year+safety+results+of+the+VEGF+Inhibition+Study+in+Ocular+Neovascularisation+(VISION)+trial+&author=LJ+Singerman&author=H+Masonson&author=M+Patel&author=AP+Adamis&author=R+Buggage&author=E+Cunningham&publication_year=2008&hl=en']",,https://doi.org/10.1136/bjo.2007.132597, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0168,"Sjolie AK, Mortensen KK, Hansen MH. ",Antiangiogenesis therapy of age‐related macular degeneration, Ugeskrift for Laeger ,2005,167,    ,['citation-journal']," Sjolie AK, Mortensen KK, Hansen MH. Antiangiogenesis therapy of age‐related macular degeneration.  Ugeskrift for Laeger 2005;167(35):3267. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/16138964', 'https://scholar.google.com/scholar_lookup?title=Antiangiogenesis+therapy+of+age‐related+macular+degeneration&author=AK+Sjolie&author=KK+Mortensen&author=MH+Hansen&publication_year=2005&hl=en']",16138964,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0169,"VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, et al. ",Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration,,2006,,    ,['citation-other']," VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Year+2+efficacy+results+of+2+randomized+controlled+clinical+trials+of+pegaptanib+for+neovascular+age‐related+macular+degeneration+&author=U+Chakravarthy&author=AP+Adamis&author=ET+Cunningham&author=M+Goldbaum&author=DR+Guyer&publication_year=2006&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0170,"VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, et al. ","Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials", Ophthalmology ,2006,113,    ,['citation-journal']," VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials.  Ophthalmology 2006;113(6):1001. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Pegaptanib+sodium+for+neovascular+age‐related+macular+degeneration:+two‐year+safety+results+of+the+two+prospective,+multicenter,+controlled+clinical+trials+&author=DJ+D'Amico&author=HN+Masonson&author=M+Patel&author=AP+Adamis&author=ET+Cunningham&publication_year=2006&hl=en""]",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0171,"Zlateva G, Patel M, Shah SN. ",Quality of life in patients with age‐related macular degeneration: results from the VISION study, Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Zlateva G, Patel M, Shah SN. Quality of life in patients with age‐related macular degeneration: results from the VISION study.  Investigative Ophthalmology and Visual Science 2006;47:ARVO E‐Abstract 2152. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Quality+of+life+in+patients+with+age‐related+macular+degeneration:+results+from+the+VISION+study+&author=G+Zlateva&author=M+Patel&author=SN+Shah&publication_year=2006&hl=en']",,, VISION 2004 {published and unpublished data}  ,included,CD005139-bbs2-0016,
CD005139-bib-0172,,Safety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration (AMD) (ADVANCE),,,,   ,['citation-other'], Safety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration (AMD) (ADVANCE). ClinicalTrials.gov NCT00138632. [NCT00531336]CENTRAL    ,[''],,, ADVANCE 2008 {unpublished data only}  ,excluded,CD005139-bbs2-0017, Not intravitreal injection of an anti‐VEGF agent 
CD005139-bib-0173,,Photodynamic therapy combined with bevacizumab vs bevacizumab alone for neovascular age‐related macular degeneration (ARMAST),,,,   ,['citation-other'], Photodynamic therapy combined with bevacizumab vs bevacizumab alone for neovascular age‐related macular degeneration (ARMAST). ClinicalTrials.gov NCT0069592. CENTRAL    ,[''],,, ARMAST 2008 {unpublished data only}  ,excluded,CD005139-bbs2-0018, Bevacizumab vs bevacizumab + PDT 
CD005139-bib-0174,"Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar R, Noureddin BN. ",Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age‐related macular degeneration, Archives of Ophthalmology ,2007,125,    ,['citation-journal']," Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar R, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age‐related macular degeneration.  Archives of Ophthalmology 2007;125(10):1357‐61. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archopht.125.10.1357', 'https://www.ncbi.nlm.nih.gov/pubmed/17923543', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+vs+verteporfin+photodynamic+therapy+for+neovascular+age‐related+macular+degeneration+&author=ZF+Bashshur&author=A+Schakal&author=RN+Hamam&author=CP+Haibi&author=R+Jaafar&author=BN+Noureddin&publication_year=2007&hl=en']",17923543,https://doi.org/10.1001/archopht.125.10.1357, Bashshur 2007 {published data only}  ,excluded,CD005139-bbs2-0019, Follow‐up less than 1 year 
CD005139-bib-0175,"Schmid‐Kubista KE, Krebs I, Gruenberger B, Schueller J, Binder S. ",Systemic bevacizumab therapy for exudative neovascular age‐related macular degeneration (BEAT‐AMD‐Study), Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Schmid‐Kubista KE, Krebs I, Gruenberger B, Schueller J, Binder S. Systemic bevacizumab therapy for exudative neovascular age‐related macular degeneration (BEAT‐AMD‐Study).  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 304. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Systemic+bevacizumab+therapy+for+exudative+neovascular+age‐related+macular+degeneration+(BEAT‐AMD‐Study)+&author=KE+Schmid‐Kubista&author=I+Krebs&author=B+Gruenberger&author=J+Schueller&author=S+Binder&publication_year=2008&hl=en']",,, BEAT‐AMD 2009 {published data only}  ,excluded,CD005139-bbs2-0020," Follow‐up less than 1 year; also, systemic bevacizumab "
CD005139-bib-0176,"Schmid‐Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. ",Systemic bevacizumab (Avastin®) therapy for exudative neovascular age‐related macular degeneration. The BEAT‐AMD‐Study, British Journal of Ophthalmology ,2009,93,    ,['citation-journal']," Schmid‐Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. Systemic bevacizumab (Avastin®) therapy for exudative neovascular age‐related macular degeneration. The BEAT‐AMD‐Study.  British Journal of Ophthalmology 2009;93(7):914‐9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjo.2008.144410', 'https://scholar.google.com/scholar_lookup?title=Systemic+bevacizumab+(Avastin®)+therapy+for+exudative+neovascular+age‐related+macular+degeneration.+The+BEAT‐AMD‐Study+&author=KE+Schmid‐Kubista&author=I+Krebs&author=B+Gruenberger&author=F+Zeiler&author=J+Schueller&author=S+Binder&publication_year=2009&hl=en']",,https://doi.org/10.1136/bjo.2008.144410, BEAT‐AMD 2009 {published data only}  ,excluded,CD005139-bbs2-0020," Follow‐up less than 1 year; also, systemic bevacizumab "
CD005139-bib-0177,"Berger BB, Yanni SE, Wenzel A, Weichselberger A, Hubschman JP. ","Efficacy of RTH258 (ESBA1008), an anti‐VEGF agent, applied by microvolume injection or infusion in subjects with neovascular AMD", Investigative Ophthalmology and Visual Science ,2015,56 (7),    ,['citation-journal']," Berger BB, Yanni SE, Wenzel A, Weichselberger A, Hubschman JP. Efficacy of RTH258 (ESBA1008), an anti‐VEGF agent, applied by microvolume injection or infusion in subjects with neovascular AMD.  Investigative Ophthalmology and Visual Science 2015;56 (7):821. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+RTH258+(ESBA1008),+an+anti‐VEGF+agent,+applied+by+microvolume+injection+or+infusion+in+subjects+with+neovascular+AMD+&author=BB+Berger&author=SE+Yanni&author=A+Wenzel&author=A+Weichselberger&author=JP+Hubschman&publication_year=2015&hl=en']",,, Berger 2015 {published data only}  ,excluded,CD005139-bbs2-0021, Injection vs infusion of anti‐VEGF agent 
CD005139-bib-0178,"Blaha GR, Brooks NO, Mackel CE, Pani A, Stewart AP, Price LL, et al. ",Changes in flare after intravitreal injection of three different anti‐vascular endothelial growth factor medications, Retina ,2015,35,    ,['citation-journal']," Blaha GR, Brooks NO, Mackel CE, Pani A, Stewart AP, Price LL, et al. Changes in flare after intravitreal injection of three different anti‐vascular endothelial growth factor medications.  Retina 2015;35(3):577‐81. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0000000000000334', 'https://www.ncbi.nlm.nih.gov/pubmed/25158942', 'https://scholar.google.com/scholar_lookup?title=Changes+in+flare+after+intravitreal+injection+of+three+different+anti‐vascular+endothelial+growth+factor+medications+&author=GR+Blaha&author=NO+Brooks&author=CE+Mackel&author=A+Pani&author=AP+Stewart&author=LL+Price&publication_year=2015&hl=en']",25158942,https://doi.org/10.1097/IAE.0000000000000334, Blaha 2015 {published data only}  ,excluded,CD005139-bbs2-0022, Not an RCT 
CD005139-bib-0179,"Bolz M, Pruente C, Benesch T, Ritter M, Deak G, Golbaz I, et al. ",The relevance of measuring central retinal thickness during intra‐vitreal therapy with ranibizumab: analyzing a multi‐center clinical trial, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal']," Bolz M, Pruente C, Benesch T, Ritter M, Deak G, Golbaz I, et al. The relevance of measuring central retinal thickness during intra‐vitreal therapy with ranibizumab: analyzing a multi‐center clinical trial.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 5576. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=The+relevance+of+measuring+central+retinal+thickness+during+intra‐vitreal+therapy+with+ranibizumab:+analyzing+a+multi‐center+clinical+trial+&author=M+Bolz&author=C+Pruente&author=T+Benesch&author=M+Ritter&author=G+Deak&author=I+Golbaz&publication_year=2008&hl=en']",,, Bolz 2008 {published data only}  ,excluded,CD005139-bbs2-0023, Dosing study: 0.3 mg or 0.5 mg intravitreal ranibizumab 
CD005139-bib-0180,"Brown DM, Ingerman A, Shearn SP, Slakter JS. ",CNV lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti‐VEGF therapy and topical Squalamine lactate ophthalmic solution, Investigative Ophthalmology and Visual Science ,2016,57(12),    ,['citation-journal']," Brown DM, Ingerman A, Shearn SP, Slakter JS. CNV lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti‐VEGF therapy and topical Squalamine lactate ophthalmic solution.  Investigative Ophthalmology and Visual Science 2016;57(12):4419. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=CNV+lesion+characteristics+as+a+predictor+of+visual+outcome+in+wet+AMD+patients+receiving+combination+therapy+of+intravitreal+anti‐VEGF+therapy+and+topical+Squalamine+lactate+ophthalmic+solution+&author=DM+Brown&author=A+Ingerman&author=SP+Shearn&author=JS+Slakter&publication_year=2016&hl=en']",,, Brown 2016 {published data only}  ,excluded,CD005139-bbs2-0024, Not an RCT 
CD005139-bib-0181,"Cohen SY, Bremond‐Gignac D, Quentel G, Mimoun G, Citterio T, Bisot‐Locard S, et al. ",Cost‐effectiveness sequential modeling of ranibizumab versus usual care in age‐related macular degeneration, Graefe's Archive for Clinical and Experimental Ophthalmology ,2008,246,    ,['citation-journal']," Cohen SY, Bremond‐Gignac D, Quentel G, Mimoun G, Citterio T, Bisot‐Locard S, et al. Cost‐effectiveness sequential modeling of ranibizumab versus usual care in age‐related macular degeneration.  Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(11):1527‐34. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s00417-008-0890-8', 'https://www.ncbi.nlm.nih.gov/pubmed/18642019', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+sequential+modeling+of+ranibizumab+versus+usual+care+in+age‐related+macular+degeneration+&author=SY+Cohen&author=D+Bremond‐Gignac&author=G+Quentel&author=G+Mimoun&author=T+Citterio&author=S+Bisot‐Locard&publication_year=2008&hl=en']",18642019,https://doi.org/10.1007/s00417-008-0890-8, Cohen 2008 {published data only}  ,excluded,CD005139-bbs2-0025, Not an RCT: cost‐effectiveness assessment. States that analysis used data from a small RCT but RCT data not reported  
CD005139-bib-0182,"Costagliola C, Romano MR, Rinaldi M, dell'Omo R, Chiosi F, Menzione M, Semeraro F. ",Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age‐related macular degeneration, British Journal of Ophthalmology ,2010,94,    ,['citation-journal']," Costagliola C, Romano MR, Rinaldi M, dell'Omo R, Chiosi F, Menzione M, Semeraro F. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age‐related macular degeneration.  British Journal of Ophthalmology 2010;94(2):180‐4. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjo.2009.159343', ""https://scholar.google.com/scholar_lookup?title=Low+fluence+rate+photodynamic+therapy+combined+with+intravitreal+bevacizumab+for+neovascular+age‐related+macular+degeneration+&author=C+Costagliola&author=MR+Romano&author=M+Rinaldi&author=R+dell'Omo&author=F+Chiosi&author=M+Menzione&author=F+Semeraro&publication_year=2010&hl=en""]",,https://doi.org/10.1136/bjo.2009.159343, Costagliola 2010 {published data only}  ,excluded,CD005139-bbs2-0026, Combination therapy: intravitreal bevacizumab alone vs intravitreal bevacizumab plus low‐fluence PDT  
CD005139-bib-0183,"Csaky KG, Dugel PU, Pierce AJ, Fries MA, Kelly DS, Danis RP, et al. ",Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age‐related macular degeneration, Ophthalmology ,2015,122,    ,['citation-journal']," Csaky KG, Dugel PU, Pierce AJ, Fries MA, Kelly DS, Danis RP, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age‐related macular degeneration.  Ophthalmology 2015;122(3):579‐88. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2014.09.036', 'https://www.ncbi.nlm.nih.gov/pubmed/25432081', 'https://scholar.google.com/scholar_lookup?title=Clinical+evaluation+of+pazopanib+eye+drops+versus+ranibizumab+intravitreal+injections+in+subjects+with+neovascular+age‐related+macular+degeneration+&author=KG+Csaky&author=PU+Dugel&author=AJ+Pierce&author=MA+Fries&author=DS+Kelly&author=RP+Danis&publication_year=2015&hl=en']",25432081,https://doi.org/10.1016/j.ophtha.2014.09.036, Csaky 2015 {published data only}  ,excluded,CD005139-bbs2-0027, RCT of pazopanib eye drops (6 different doses regimens) vs intravitreal ranibizumab with 1‐year follow‐up; excluded because pazopanib eye drops for treatment of AMD; not eligible for this review  
CD005139-bib-0184,"Earnshaw SR, Moride Y, Rochon S. ",Cost‐effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age‐related macular degeneration in Canada, Clinical Therapeutics ,2007,29,    ,['citation-journal']," Earnshaw SR, Moride Y, Rochon S. Cost‐effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age‐related macular degeneration in Canada.  Clinical Therapeutics 2007;29(9):2096‐106. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.clinthera.2007.09.001', 'https://www.ncbi.nlm.nih.gov/pubmed/18035208', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+pegaptanib+compared+to+photodynamic+therapy+with+verteporfin+and+to+standard+care+in+the+treatment+of+subfoveal+wet+age‐related+macular+degeneration+in+Canada+&author=SR+Earnshaw&author=Y+Moride&author=S+Rochon&publication_year=2007&hl=en']",18035208,https://doi.org/10.1016/j.clinthera.2007.09.001, Earnshaw 2007 {published data only}  ,excluded,CD005139-bbs2-0028, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0185,"Eibenberger K, Sulzbacher F, Rezar S, Roberts PK, Sacu S, Schmidt‐Erfurth U. ",Randomized comparison of anterior chamber inflammatory activity in eyes treated with intravitreal aflibercept or ranibizumab, Investigative Ophthalmology and Visual Science ,2015,56(7),    ,['citation-journal']," Eibenberger K, Sulzbacher F, Rezar S, Roberts PK, Sacu S, Schmidt‐Erfurth U. Randomized comparison of anterior chamber inflammatory activity in eyes treated with intravitreal aflibercept or ranibizumab.  Investigative Ophthalmology and Visual Science 2015;56(7):1517. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Randomized+comparison+of+anterior+chamber+inflammatory+activity+in+eyes+treated+with+intravitreal+aflibercept+or+ranibizumab+&author=K+Eibenberger&author=F+Sulzbacher&author=S+Rezar&author=PK+Roberts&author=S+Sacu&author=U+Schmidt‐Erfurth&publication_year=2015&hl=en']",,, Eibenberger 2015 {published data only}  ,excluded,CD005139-bbs2-0029, No outcomes targeted for this review 
CD005139-bib-0186,Christmas NJ. ,A phase 2 study (EMERGE) evaluating repeated intravitreal administration of ICON‐1 in patients with choroidal neovascularization (CNV) secondary to age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2016,57(12),    ,['citation-journal'], Christmas NJ. A phase 2 study (EMERGE) evaluating repeated intravitreal administration of ICON‐1 in patients with choroidal neovascularization (CNV) secondary to age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2016;57(12):4434. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=A+phase+2+study+(EMERGE)+evaluating+repeated+intravitreal+administration+of+ICON‐1+in+patients+with+choroidal+neovascularization+(CNV)+secondary+to+age‐related+macular+degeneration+(AMD)+&author=NJ+Christmas&publication_year=2016&hl=en']",,, EMERGE 2016 {published data only}  ,excluded,CD005139-bbs2-0030, Not an RCT to evaluate any targeted anti‐VEGF agent 
CD005139-bib-0187,NCT02358889. ,Study evaluating intravitreal hl‐con1TM in patients with ehoroidal neovascularization secondary to age‐related macular degeneration (EMERGE),,,,   ,['citation-other'], NCT02358889. Study evaluating intravitreal hl‐con1TM in patients with ehoroidal neovascularization secondary to age‐related macular degeneration (EMERGE). ClinicalTrials.gov (accessed 24 August 2018). CENTRAL    ,[''],,, EMERGE 2016 {published data only}  ,excluded,CD005139-bbs2-0030, Not an RCT to evaluate any targeted anti‐VEGF agent 
CD005139-bib-0188,"Wells JA, Gonzale CR, Berger BB, Gonzalez VH, Sippy BD, Burian G. ","A phase I, open‐label, dose‐excalation trial to investigate safety and tolerability of single intravitreous injections of ICON‐1 targeting tissue factor in wet AMD"," Ophthalmic Surgery, Lasers and Imaging Retina ",2018,49,    ,['citation-journal']," Wells JA, Gonzale CR, Berger BB, Gonzalez VH, Sippy BD, Burian G. A phase I, open‐label, dose‐excalation trial to investigate safety and tolerability of single intravitreous injections of ICON‐1 targeting tissue factor in wet AMD.  Ophthalmic Surgery, Lasers and Imaging Retina 2018;49:336‐45. [DOI 10.3928/23258160‐20180501‐07; PUBMED: PMID 29772044]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.3928/23258160-20180501-07', 'https://scholar.google.com/scholar_lookup?title=A+phase+I,+open‐label,+dose‐excalation+trial+to+investigate+safety+and+tolerability+of+single+intravitreous+injections+of+ICON‐1+targeting+tissue+factor+in+wet+AMD+&author=JA+Wells&author=CR+Gonzale&author=BB+Berger&author=VH+Gonzalez&author=BD+Sippy&author=G+Burian&publication_year=2018&hl=en']",,https://doi.org/10.3928/23258160-20180501-07, EMERGE 2016 {published data only}  ,excluded,CD005139-bbs2-0030, Not an RCT to evaluate any targeted anti‐VEGF agent 
CD005139-bib-0189,"Erdokur O, Tetikoglu M, Ozturk M, Elcioglu M. ",Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age‐related macular degeneration, Retina‐Vitreus ,2009,17,    ,['citation-journal']," Erdokur O, Tetikoglu M, Ozturk M, Elcioglu M. Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age‐related macular degeneration.  Retina‐Vitreus 2009;17(4):245‐50. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Results+of+comparison+in+use+to+alternative+therapy+methods+for+subfoveal+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration+&author=O+Erdokur&author=M+Tetikoglu&author=M+Ozturk&author=M+Elcioglu&publication_year=2009&hl=en']",,, Erdokur 2009 {published data only}  ,excluded,CD005139-bbs2-0031, Not an RCT 
CD005139-bib-0191,Tano Y. ,The safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: 12‐month results from the phase I/II EXTEND‐I study, Investigative Ophthalmology and Visual Science ,2008,49,    ,['citation-journal'], Tano Y. The safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: 12‐month results from the phase I/II EXTEND‐I study.  Investigative Ophthalmology and Visual Science 2008;49:ARVO E‐Abstract 272. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=The+safety+and+efficacy+of+ranibizumab+in+Japanese+patients+with+subfoveal+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration:+12‐month+results+from+the+phase+I/II+EXTEND‐I+study+&author=Y+Tano&publication_year=2008&hl=en']",,, EXTEND‐I 2008 {published data only}  ,excluded,CD005139-bbs2-0032, Dosing study: 0.3 mg or 0.5 mg intravitreal ranibizumab 
CD005139-bib-0190,"Tano Y, Ohji M, EXTEND‐I Study Group. ",EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration, Acta Ophthalmologica ,2010,88,    ,['citation-journal']," Tano Y, Ohji M, EXTEND‐I Study Group. EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration.  Acta Ophthalmologica 2010;88(3):309‐16. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1755-3768.2009.01843.x', 'https://www.ncbi.nlm.nih.gov/pubmed/20163368', 'https://scholar.google.com/scholar_lookup?title=EXTEND‐I:+safety+and+efficacy+of+ranibizumab+in+Japanese+patients+with+subfoveal+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration+&author=Y+Tano&author=M+Ohji&publication_year=2010&hl=en']",20163368,https://doi.org/10.1111/j.1755-3768.2009.01843.x, EXTEND‐I 2008 {published data only}  ,excluded,CD005139-bbs2-0032, Dosing study: 0.3 mg or 0.5 mg intravitreal ranibizumab 
CD005139-bib-0192,Eyetech Study Group. ,Anti‐vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age‐related macular degeneration: phase II study results, Ophthalmology ,2003,110,    ,['citation-journal'], Eyetech Study Group. Anti‐vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age‐related macular degeneration: phase II study results.  Ophthalmology 2003;110(5):979‐86. CENTRAL    Link to article     PubMed     ,"['', 'https://doi.org/10.1016/S0161-6420(03)00085-X', 'https://www.ncbi.nlm.nih.gov/pubmed/12750101']",12750101,https://doi.org/10.1016/S0161-6420(03)00085-X, Eyetech Study 2003 {published data only}  ,excluded,CD005139-bbs2-0033, Not an RCT 
CD005139-bib-0193,"Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR. ",Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin®) treatment for choroidal neovascularization in age‐related macular degeneration, Retina ,2007,27,    ,['citation-journal']," Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR. Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin®) treatment for choroidal neovascularization in age‐related macular degeneration.  Retina 2007;27(6):701‐6. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3180654240', 'https://www.ncbi.nlm.nih.gov/pubmed/17621178', 'https://scholar.google.com/scholar_lookup?title=Standardized+visual+acuity+results+associated+with+primary+versus+secondary+bevacizumab+(Avastin®)+treatment+for+choroidal+neovascularization+in+age‐related+macular+degeneration+&author=IA+Falkenstein&author=L+Cheng&author=VL+Morrison&author=I+Kozak&author=AM+Tammewar&author=WR+Freeman&publication_year=2007&hl=en']",17621178,https://doi.org/10.1097/IAE.0b013e3180654240, Falkenstein 2007 {published data only}  ,excluded,CD005139-bbs2-0034, Not an RCT 
CD005139-bib-0194,"Fletcher EC, Lade RJ, Adewoyin T, Chong NV. ",Computerized model of cost‐utility analysis for treatment of age‐related macular degeneration, Ophthalmology ,2008,115,    ,['citation-journal']," Fletcher EC, Lade RJ, Adewoyin T, Chong NV. Computerized model of cost‐utility analysis for treatment of age‐related macular degeneration.  Ophthalmology 2008;115(12):2192‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2008.07.018', 'https://www.ncbi.nlm.nih.gov/pubmed/18930556', 'https://scholar.google.com/scholar_lookup?title=Computerized+model+of+cost‐utility+analysis+for+treatment+of+age‐related+macular+degeneration&author=EC+Fletcher&author=RJ+Lade&author=T+Adewoyin&author=NV+Chong&publication_year=2008&hl=en']",18930556,https://doi.org/10.1016/j.ophtha.2008.07.018, Fletcher 2008 {published data only}  ,excluded,CD005139-bbs2-0035, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0195,"Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group. ",Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration (FOCUS): year 2 results, American Journal of Ophthalmology ,2008,145,    ,['citation-journal']," Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration (FOCUS): year 2 results.  American Journal of Ophthalmology 2008;145(5):862‐74. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2007.12.029', 'https://www.ncbi.nlm.nih.gov/pubmed/18321465', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+combined+with+verteporfin+photodynamic+therapy+in+neovascular+age‐related+macular+degeneration+(FOCUS):+year+2+results+&author=AN+Antoszyk&author=L+Tuomi&author=CY+Chung&author=A+Singh&publication_year=2008&hl=en']",18321465,https://doi.org/10.1016/j.ajo.2007.12.029, FOCUS 2006 {published and unpublished data}  ,excluded,CD005139-bbs2-0036, Combination therapy: intravitreal ranibizumab alone vs intravitreal ranibizumab plus verteporfin PDT  
CD005139-bib-0196,"Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumber MJ, Gentile RC, et al. ",Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration: year 1 results of the FOCUS study, Archives of Ophthalmology ,2006,124,    ,['citation-journal']," Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumber MJ, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration: year 1 results of the FOCUS study.  Archives of Ophthalmology 2006;124(11):1532‐42. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archopht.124.11.1532', 'https://www.ncbi.nlm.nih.gov/pubmed/17101999', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+combined+with+verteporfin+photodynamic+therapy+in+neovascular+age‐related+macular+degeneration:+year+1+results+of+the+FOCUS+study+&author=JS+Heier&author=DS+Boyer&author=TA+Ciulla&author=PJ+Ferrone&author=MJ+Jumber&author=RC+Gentile&publication_year=2006&hl=en']",17101999,https://doi.org/10.1001/archopht.124.11.1532, FOCUS 2006 {published and unpublished data}  ,excluded,CD005139-bbs2-0036, Combination therapy: intravitreal ranibizumab alone vs intravitreal ranibizumab plus verteporfin PDT  
CD005139-bib-0197,"Heier JS, FOCUS Study Group. ",Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age‐related macular degeneration: year one results,,2005,,    ,['citation-other']," Heier JS, FOCUS Study Group. Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age‐related macular degeneration: year one results. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; 2005 July 16‐20; Montreal. 2005. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+ranibizumab+with+verteporfin+photodynamic+therapy+for+neovascular+age‐related+macular+degeneration:+year+one+results+&author=JS+Heier&publication_year=2005&hl=en']",,, FOCUS 2006 {published and unpublished data}  ,excluded,CD005139-bbs2-0036, Combination therapy: intravitreal ranibizumab alone vs intravitreal ranibizumab plus verteporfin PDT  
CD005139-bib-0198,NCT02036723. ,"Multicentre double blind randomized clinical study evaluating the efficacy and safety of BCD‐021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in patients with neovascular wet age‐related macular degeneration (GALATIR)",,,,   ,['citation-other']," NCT02036723. Multicentre double blind randomized clinical study evaluating the efficacy and safety of BCD‐021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in patients with neovascular wet age‐related macular degeneration (GALATIR). clinicaltrials.gov/show/NCT02036723 (accessed 5 February 2017). CENTRAL    ",[''],,, GALATIR 2014 {unpublished data only}  ,excluded,CD005139-bbs2-0037," Clinical trial registry record reported that the ""study has been withdrawn prior to enrollment""; trial investigators had planned to compare an anti‐VEGF agent biosimilar to bevacizumab and manufactured in Russia vs 0.50 mg intravitreal ranibizumab in participants with neovascular AMD, and to evaluate the proportion losing fewer than 15 letters at 12 months as the primary outcome  "
CD005139-bib-0199,"Gallemore RP, Elman MJ, Milton M, Zamiri P, Grosskreutz CL. ",A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age related macular degeneration (NAMD), Investigative Ophthalmology and Visual Science ,2016,57(12),    ,['citation-journal']," Gallemore RP, Elman MJ, Milton M, Zamiri P, Grosskreutz CL. A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age related macular degeneration (NAMD).  Investigative Ophthalmology and Visual Science 2016;57(12):4985. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+proof+of+concept+study+of+intravitreal+(IVT)+LFG316+in+patients+with+neovascular+age+related+macular+degeneration+(NAMD)+&author=RP+Gallemore&author=MJ+Elman&author=M+Milton&author=P+Zamiri&author=CL+Grosskreutz&publication_year=2016&hl=en']",,, Gallemore 2016 {published data only}  ,excluded,CD005139-bbs2-0038, Follow‐up < 1 year; not an anti‐VEGF agent targeted for this review 
CD005139-bib-0200,"Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, et al. ",Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age‐related macula degeneration, Der Ophthalmologe ,2007,104,    ,['citation-journal']," Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age‐related macula degeneration.  Der Ophthalmologe 2007;104(7):588‐93. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1007/s00347-007-1547-4', 'https://www.ncbi.nlm.nih.gov/pubmed/17564719', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+versus+verteporfin+and+intravitreal+triamcinolone+acetonide+in+patients+with+neovascular+age‐related+macula+degeneration+&author=R+Hahn&author=S+Sacu&author=S+Michels&author=A+Varga&author=G+Weigert&author=W+Geitzenauer&publication_year=2007&hl=en']",17564719,https://doi.org/10.1007/s00347-007-1547-4, Hahn 2007 {published data only}  ,excluded,CD005139-bbs2-0039, Follow‐up less than 1 year 
CD005139-bib-0201,"Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H. ",Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography, Retina ,2010,30,    ,['citation-journal']," Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.  Retina 2010;30(3):495‐502. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3181bcedbe', 'https://www.ncbi.nlm.nih.gov/pubmed/19996828', 'https://scholar.google.com/scholar_lookup?title=Effect+of+photodynamic+therapy+alone+or+combined+with+posterior+subtenon+triamcinolone+acetonide+or+intravitreal+bevacizumab+on+choroidal+hypofluorescence+by+indocyanine+green+angiography+&author=Y+Hatta&author=K+Ishikawa&author=H+Nishihara&author=S+Ozawa&author=Y+Ito&author=H+Terasaki&publication_year=2010&hl=en']",19996828,https://doi.org/10.1097/IAE.0b013e3181bcedbe, Hatta 2010 {published data only}  ,excluded,CD005139-bbs2-0040, Not an RCT 
CD005139-bib-0202,"Dugel PU, Warburton J, Weichselberger A, Sallstig P. ",A 2‐year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age‐related macular degeneration: testing an alternative treatment regimen, Investigative Ophthalmology and Visual Science ,2016,57(12),    ,['citation-journal']," Dugel PU, Warburton J, Weichselberger A, Sallstig P. A 2‐year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age‐related macular degeneration: testing an alternative treatment regimen.  Investigative Ophthalmology and Visual Science 2016;57(12):5018. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+2‐year+study+comparing+the+efficacy+and+safety+of+brolucizumab+vs+aflibercept+in+subjects+with+neovascular+age‐related+macular+degeneration:+testing+an+alternative+treatment+regimen+&author=PU+Dugel&author=J+Warburton&author=A+Weichselberger&author=P+Sallstig&publication_year=2016&hl=en']",,, HAWK 2018 {published data only}  ,excluded,CD005139-bbs2-0041, Neither intervention (brolucizumab) nor control (aflibercept) targeted for this review 
CD005139-bib-0203,"Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. ","Ranibizumab for treatment of neovascular age‐related macular degeneration: a phase I/II multicenter, controlled, multidose study", Ophthalmology ,2006,113,    ,['citation-journal']," Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age‐related macular degeneration: a phase I/II multicenter, controlled, multidose study.  Ophthalmology 2006;113(4):642. e1‐4. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2005.10.052', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+for+treatment+of+neovascular+age‐related+macular+degeneration:+a+phase+I/II+multicenter,+controlled,+multidose+study+&author=JS+Heier&author=AN+Antoszyk&author=PR+Pavan&author=SR+Leff&author=PJ+Rosenfeld&author=TA+Ciulla&publication_year=2006&hl=en']",,https://doi.org/10.1016/j.ophtha.2005.10.052, Heier 2006 {published data only}  ,excluded,CD005139-bbs2-0042, Follow‐up less than 1 year 
CD005139-bib-0204,"Hernandez‐Pastor LJ, Ortega A, Garcia‐Layana A, Giraldez J. ",Cost‐effectiveness of ranibizumab compared with photodynamic treatment of neovascular age‐related macular degeneration, Clinical Therapeutics ,2008,30,    ,['citation-journal']," Hernandez‐Pastor LJ, Ortega A, Garcia‐Layana A, Giraldez J. Cost‐effectiveness of ranibizumab compared with photodynamic treatment of neovascular age‐related macular degeneration.  Clinical Therapeutics 2008;30(12):2436‐51. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.clinthera.2008.12.025', 'https://www.ncbi.nlm.nih.gov/pubmed/19167602', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+ranibizumab+compared+with+photodynamic+treatment+of+neovascular+age‐related+macular+degeneration+&author=LJ+Hernandez‐Pastor&author=A+Ortega&author=A+Garcia‐Layana&author=J+Giraldez&publication_year=2008&hl=en']",19167602,https://doi.org/10.1016/j.clinthera.2008.12.025, Hernandez‐Pastor 2008 {published data only}  ,excluded,CD005139-bbs2-0043, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0205,"Hernandez‐Pastor LJ, Ortega A, Garcia‐Layana A, Giraldez J. ",Cost‐effectiveness of ranibizumab compared with pegaptanib in neovascular age‐related macular degeneration, Investigative Ophthalmology and Visual Science ,2010,248,    ,['citation-journal']," Hernandez‐Pastor LJ, Ortega A, Garcia‐Layana A, Giraldez J. Cost‐effectiveness of ranibizumab compared with pegaptanib in neovascular age‐related macular degeneration.  Investigative Ophthalmology and Visual Science 2010;248(4):467‐76. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1007/s00417-009-1156-9', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+ranibizumab+compared+with+pegaptanib+in+neovascular+age‐related+macular+degeneration+&author=LJ+Hernandez‐Pastor&author=A+Ortega&author=A+Garcia‐Layana&author=J+Giraldez&publication_year=2010&hl=en']",,https://doi.org/10.1007/s00417-009-1156-9, Hernandez‐Pastor 2010 {published data only}  ,excluded,CD005139-bbs2-0044, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0206,"Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. ",Single‐chain antibody fragment VEGF inhibitor RTH258 for neovascular age‐related macular degeneration: a randomized controlled study, Ophthalmology ,2016,123,    ,['citation-journal']," Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. Single‐chain antibody fragment VEGF inhibitor RTH258 for neovascular age‐related macular degeneration: a randomized controlled study.  Ophthalmology 2016;123(5):1080‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2015.12.030', 'https://www.ncbi.nlm.nih.gov/pubmed/26906165', 'https://scholar.google.com/scholar_lookup?title=Single‐chain+antibody+fragment+VEGF+inhibitor+RTH258+for+neovascular+age‐related+macular+degeneration:+a+randomized+controlled+study+&author=FG+Holz&author=PU+Dugel&author=G+Weissgerber&author=R+Hamilton&author=R+Silva&author=F+Bandello&publication_year=2016&hl=en']",26906165,https://doi.org/10.1016/j.ophtha.2015.12.030, Holz 2016 {published data only}  ,excluded,CD005139-bbs2-0045, Follow‐up less than 1 year: comparison of novel anti‐VEGF agent (referred to as both RTH258 and ESBA1008) vs intravitreal ranibizumab  
CD005139-bib-0207,"Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, et al. ",Cost‐effectiveness model for neovascular age‐related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity, Value in Health ,2008,11,    ,['citation-journal']," Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, et al. Cost‐effectiveness model for neovascular age‐related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.  Value in Health 2008;11(4):563‐74. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1524-4733.2007.00283.x', 'https://www.ncbi.nlm.nih.gov/pubmed/18179676', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+model+for+neovascular+age‐related+macular+degeneration:+comparing+early+and+late+treatment+with+pegaptanib+sodium+based+on+visual+acuity+&author=JC+Javitt&author=GP+Zlateva&author=SR+Earnshaw&author=AM+Pleil&author=CN+Graham&author=AJ+Brogan&publication_year=2008&hl=en']",18179676,https://doi.org/10.1111/j.1524-4733.2007.00283.x, Javitt 2008 {published data only}  ,excluded,CD005139-bbs2-0046, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0208,"Kralinger MT, Zehetner C, Waltl I, Kirchmayr R, Kieselbach GF. ",VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab, Investigative Ophthalmology and Visual Science ,2014,55(13),    ,['citation-journal']," Kralinger MT, Zehetner C, Waltl I, Kirchmayr R, Kieselbach GF. VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab.  Investigative Ophthalmology and Visual Science 2014;55(13):4965. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=VEGF+Plasma+levels+after+intravitreal+injection+of+aflibercept+and+ranibizumab&author=MT+Kralinger&author=C+Zehetner&author=I+Waltl&author=R+Kirchmayr&author=GF+Kieselbach&publication_year=2014&hl=en']",,, Kralinger 2014 {published data only}  ,excluded,CD005139-bbs2-0047, Follow‐up less than 1 year; no outcome targeted for this review 
CD005139-bib-0209,"Lai TY, Liu DT, Chan KP, Luk FO, Pang CP, Lam DS. ","Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age‐related macular degeneration: a randomized, controlled trial", Retina ,2009,29,    ,['citation-journal']," Lai TY, Liu DT, Chan KP, Luk FO, Pang CP, Lam DS. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age‐related macular degeneration: a randomized, controlled trial.  Retina 2009;29(9):1218‐26. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e3181b32c45', 'https://www.ncbi.nlm.nih.gov/pubmed/19934816', 'https://scholar.google.com/scholar_lookup?title=Visual+outcomes+and+growth+factor+changes+of+two+dosages+of+intravitreal+bevacizumab+for+neovascular+age‐related+macular+degeneration:+a+randomized,+controlled+trial+&author=TY+Lai&author=DT+Liu&author=KP+Chan&author=FO+Luk&author=CP+Pang&author=DS+Lam&publication_year=2009&hl=en']",19934816,https://doi.org/10.1097/IAE.0b013e3181b32c45, Lai 2009 {published data only}  ,excluded,CD005139-bbs2-0048, Dosing study: 1.25 mg (n = 24) or 2.5 mg (n = 26) intravitreal bevacizumab; follow‐up less than 1 year  
CD005139-bib-0210,"Lazic R, Gabric N. ",Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age‐related macular degeneration, Ophthalmology ,2007,114,    ,['citation-journal']," Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age‐related macular degeneration.  Ophthalmology 2007;114(6):1179‐85. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2007.03.006', 'https://www.ncbi.nlm.nih.gov/pubmed/17544776', 'https://scholar.google.com/scholar_lookup?title=Verteporfin+therapy+and+intravitreal+bevacizumab+combined+and+alone+in+choroidal+neovascularization+due+to+age‐related+macular+degeneration+&author=R+Lazic&author=N+Gabric&publication_year=2007&hl=en']",17544776,https://doi.org/10.1016/j.ophtha.2007.03.006, Lazic 2007 {published data only}  ,excluded,CD005139-bbs2-0049, Follow‐up less than 1 year 
CD005139-bib-0211,"Fang K, Tian J, Qing X, Li S, Hou J, Li J, et al. ",Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age‐related macular degeneration, Journal of Ophthalmology ,2013,2013,    ,['citation-journal']," Fang K, Tian J, Qing X, Li S, Hou J, Li J, et al. Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age‐related macular degeneration.  Journal of Ophthalmology 2013;2013:676049. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1155/2013/676049', 'https://www.ncbi.nlm.nih.gov/pubmed/24069533', 'https://scholar.google.com/scholar_lookup?title=Predictors+of+visual+response+to+intravitreal+bevacizumab+for+treatment+of+neovascular+age‐related+macular+degeneration+&author=K+Fang&author=J+Tian&author=X+Qing&author=S+Li&author=J+Hou&author=J+Li&publication_year=2013&hl=en']",24069533,https://doi.org/10.1155/2013/676049, Li 2012 {published data only}  ,excluded,CD005139-bbs2-0050, Comparison of injection schedules 
CD005139-bib-0212,"Li X, Hu Y, Sun X, Zhang J, Zhang M, Neovascular Age‐Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB). ",Bevacizumab for neovascular age‐related macular degeneration in China, Ophthalmology ,2012,119,    ,['citation-journal']," Li X, Hu Y, Sun X, Zhang J, Zhang M, Neovascular Age‐Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB). Bevacizumab for neovascular age‐related macular degeneration in China.  Ophthalmology 2012;119(10):2087‐93. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2012.05.016', 'https://www.ncbi.nlm.nih.gov/pubmed/22818896', 'https://scholar.google.com/scholar_lookup?title=Bevacizumab+for+neovascular+age‐related+macular+degeneration+in+China&author=X+Li&author=Y+Hu&author=X+Sun&author=J+Zhang&author=M+Zhang&publication_year=2012&hl=en']",22818896,https://doi.org/10.1016/j.ophtha.2012.05.016, Li 2012 {published data only}  ,excluded,CD005139-bbs2-0050, Comparison of injection schedules 
CD005139-bib-0213,"Li J, Zhang H, Sun P, Gu F, Liu ZL. ",Bevacizumab vs ranibizumab for neovascular age‐related macular degeneration in Chinese patients, International Journal of Ophthalmology ,2013,6,    ,['citation-journal']," Li J, Zhang H, Sun P, Gu F, Liu ZL. Bevacizumab vs ranibizumab for neovascular age‐related macular degeneration in Chinese patients.  International Journal of Ophthalmology 2013;6(2):169‐73. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/23638418', 'https://scholar.google.com/scholar_lookup?title=Bevacizumab+vs+ranibizumab+for+neovascular+age‐related+macular+degeneration+in+Chinese+patients+&author=J+Li&author=H+Zhang&author=P+Sun&author=F+Gu&author=ZL+Liu&publication_year=2013&hl=en']",23638418,, Li 2013 {published data only}  ,excluded,CD005139-bbs2-0051, Not an RCT 
CD005139-bib-0214,"Matthe E, Sandner D. ",Monotherapy of exudative age‐related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib, Der Ophthalmologe ,2011,108,    ,['citation-journal']," Matthe E, Sandner D. Monotherapy of exudative age‐related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib.  Der Ophthalmologe 2011;108(4):337‐41. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/21181168', 'https://scholar.google.com/scholar_lookup?title=Monotherapy+of+exudative+age‐related+macular+degeneration+with+ranibizumab+in+patients+at+cardiovascular+risk.+Advantages+of+ranibizumab+compared+to+a+combination+with+pegaptanib+&author=E+Matthe&author=D+Sandner&publication_year=2011&hl=en']",21181168,, Matthe 2011 {published data only}  ,excluded,CD005139-bbs2-0052, Not an RCT 
CD005139-bib-0215,"Pulido JS, Anderson WB, Flynn JT, Lichter PR, Sanders D. ","Multicenter prospective, randomized, double‐masked, placebo‐controlled study of rheopheresis to treat neovascular age‐related macular degeneration: interim analysis", Transactions of the American Ophthalmological Society ,2002,100,    ,['citation-journal']," Pulido JS, Anderson WB, Flynn JT, Lichter PR, Sanders D. Multicenter prospective, randomized, double‐masked, placebo‐controlled study of rheopheresis to treat neovascular age‐related macular degeneration: interim analysis.  Transactions of the American Ophthalmological Society 2002;100:85‐107. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/12545682', 'https://scholar.google.com/scholar_lookup?title=Multicenter+prospective,+randomized,+double‐masked,+placebo‐controlled+study+of+rheopheresis+to+treat+neovascular+age‐related+macular+degeneration:+interim+analysis+&author=JS+Pulido&author=WB+Anderson&author=JT+Flynn&author=PR+Lichter&author=D+Sanders&publication_year=2002&hl=en']",12545682,, MIRA‐1 2005 {published data only}  ,excluded,CD005139-bbs2-0053, Not an RCT of anti‐VEGF intravitreous injections for patients with neovascular AMD 
CD005139-bib-0216,"Pulido JS, Sanders D, Klingel R. ",Rheopheresis for age‐related macular degeneration: clinical results and putative mechanism of action, Canadian Journal of Ophthalmology ,2005,40,    ,['citation-journal']," Pulido JS, Sanders D, Klingel R. Rheopheresis for age‐related macular degeneration: clinical results and putative mechanism of action.  Canadian Journal of Ophthalmology 2005;40(3):332‐40. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0008-4182(05)80076-6', 'https://www.ncbi.nlm.nih.gov/pubmed/15947803', 'https://scholar.google.com/scholar_lookup?title=Rheopheresis+for+age‐related+macular+degeneration:+clinical+results+and+putative+mechanism+of+action+&author=JS+Pulido&author=D+Sanders&author=R+Klingel&publication_year=2005&hl=en']",15947803,https://doi.org/10.1016/S0008-4182(05)80076-6, MIRA‐1 2005 {published data only}  ,excluded,CD005139-bbs2-0053, Not an RCT of anti‐VEGF intravitreous injections for patients with neovascular AMD 
CD005139-bib-0217,"Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. ",Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin®) for treatment of CNV associated with AMD, Retina ,2009,29,    ,['citation-journal']," Modarres M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin®) for treatment of CNV associated with AMD.  Retina 2009;29(3):319‐24. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/IAE.0b013e318198148e', 'https://www.ncbi.nlm.nih.gov/pubmed/19287288', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+injection+of+2.5+mg+versus+1.25+mg+bevacizumab+(Avastin®)+for+treatment+of+CNV+associated+with+AMD+&author=M+Modarres&author=M+Naseripour&author=KG+Falavarjani&author=A+Nikeghbali&author=M+Hashemi&author=MM+Parvaresh&publication_year=2009&hl=en']",19287288,https://doi.org/10.1097/IAE.0b013e318198148e, Modarres 2009 {published data only}  ,excluded,CD005139-bbs2-0054, Dosing study 
CD005139-bib-0218,NCT00087763. ,"A phase II prospective, randomized, double‐masked, sham‐controlled, dose‐ranging, multi‐center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age‐related macular degeneration (AMD)",,,,   ,['citation-other']," NCT00087763. A phase II prospective, randomized, double‐masked, sham‐controlled, dose‐ranging, multi‐center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age‐related macular degeneration (AMD). clinicaltrials.gov/show/NCT00087763 (accessed 5 February 2017). CENTRAL    ",[''],,, NCT00087763 {unpublished data only}  ,excluded,CD005139-bbs2-0055, Dosing study: all participants treated with pegaptanib 
CD005139-bib-0219,"Constable IJ, Pierce CM, Lai CM, Magno AL, Degli‐Esposti MA, French MA, et al. ",Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT‐1 for wet age‐related macular degeneration, EBioMedicine ,2016,14,    ,['citation-journal']," Constable IJ, Pierce CM, Lai CM, Magno AL, Degli‐Esposti MA, French MA, et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT‐1 for wet age‐related macular degeneration.  EBioMedicine 2016;14:168‐75. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ebiom.2016.11.016', 'https://www.ncbi.nlm.nih.gov/pubmed/27865764', 'https://scholar.google.com/scholar_lookup?title=Phase+2a+randomized+clinical+trial:+safety+and+post+hoc+analysis+of+subretinal+rAAV.sFLT‐1+for+wet+age‐related+macular+degeneration+&author=IJ+Constable&author=CM+Pierce&author=CM+Lai&author=AL+Magno&author=MA+Degli‐Esposti&author=MA+French&publication_year=2016&hl=en']",27865764,https://doi.org/10.1016/j.ebiom.2016.11.016, NCT01494805 {published data only}  ,excluded,CD005139-bbs2-0056, Gene therapy intervention vs ranibizumab 
CD005139-bib-0220,"Lai CM, Magno A, Pierce C, Samulski RJ, Chalberg TW, Blumenkranz MS, et al. ",Results from a phase I/II clinical trial on anti‐vascular endothelial growth factor gene therapy in patients with exudative age‐related macular degeneration, Journal of Gene Medicine ,2013,15(8‐9),    ,['citation-journal']," Lai CM, Magno A, Pierce C, Samulski RJ, Chalberg TW, Blumenkranz MS, et al. Results from a phase I/II clinical trial on anti‐vascular endothelial growth factor gene therapy in patients with exudative age‐related macular degeneration.  Journal of Gene Medicine 2013;15(8‐9):319. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Results+from+a+phase+I/II+clinical+trial+on+anti‐vascular+endothelial+growth+factor+gene+therapy+in+patients+with+exudative+age‐related+macular+degeneration+&author=CM+Lai&author=A+Magno&author=C+Pierce&author=RJ+Samulski&author=TW+Chalberg&author=MS+Blumenkranz&publication_year=2013&hl=en']",,, NCT01494805 {published data only}  ,excluded,CD005139-bbs2-0056, Gene therapy intervention vs ranibizumab 
CD005139-bib-0221,"Lai CM, Magno AL, Barone SB, Schwartz SD, Blumenkranz MS, Constable IJ, et al. ","Optical coherence tomography profiles, visual acuity and ranibizumab usage during 3‐year follow‐up in a rAAV.sFLT‐1 gene therapy clinical trial for wet age‐related macular degeneration"," Molecular therapy. Conference: 20th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT 2017. United States ",2017,25,    ,['citation-journal']," Lai CM, Magno AL, Barone SB, Schwartz SD, Blumenkranz MS, Constable IJ, et al. Optical coherence tomography profiles, visual acuity and ranibizumab usage during 3‐year follow‐up in a rAAV.sFLT‐1 gene therapy clinical trial for wet age‐related macular degeneration.  Molecular therapy. Conference: 20th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT 2017. United States 2017;25:315. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Optical+coherence+tomography+profiles,+visual+acuity+and+ranibizumab+usage+during+3‐year+follow‐up+in+a+rAAV.sFLT‐1+gene+therapy+clinical+trial+for+wet+age‐related+macular+degeneration+&author=CM+Lai&author=AL+Magno&author=SB+Barone&author=SD+Schwartz&author=MS+Blumenkranz&author=IJ+Constable&publication_year=2017&hl=en']",,, NCT01494805 {published data only}  ,excluded,CD005139-bbs2-0056, Gene therapy intervention vs ranibizumab 
CD005139-bib-0222,"Rakoczy EP, Lai CM, Magno A, French M, Barone SB, Schwartz SD, et al. ",Association of serum neutralizing antibodies with safety and efficacy outcomes in a Phase 2a trial of rAAV.sFlt‐ 1 in the treatment of wet AMD, Investigative Ophthalmology and Visual Science ,2016,57(12),    ,['citation-journal']," Rakoczy EP, Lai CM, Magno A, French M, Barone SB, Schwartz SD, et al. Association of serum neutralizing antibodies with safety and efficacy outcomes in a Phase 2a trial of rAAV.sFlt‐ 1 in the treatment of wet AMD.  Investigative Ophthalmology and Visual Science 2016;57(12):526. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Association+of+serum+neutralizing+antibodies+with+safety+and+efficacy+outcomes+in+a+Phase+2a+trial+of+rAAV.sFlt‐+1+in+the+treatment+of+wet+AMD+&author=EP+Rakoczy&author=CM+Lai&author=A+Magno&author=M+French&author=SB+Barone&author=SD+Schwartz&publication_year=2016&hl=en']",,, NCT01494805 {published data only}  ,excluded,CD005139-bbs2-0056, Gene therapy intervention vs ranibizumab 
CD005139-bib-0223,"Dugel PU, Jaffe GJ, Salistig P, Warburton J, Weichselberger A, Wieland M, et al. ",Brolucizumab versus aflibercept in participants with neovascular age‐related macular degeneration: a randomized trial, Ophthalmology ,2017,124,    ,['citation-journal']," Dugel PU, Jaffe GJ, Salistig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age‐related macular degeneration: a randomized trial.  Ophthalmology 2017;124(9):1296‐304. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2017.03.057', 'https://www.ncbi.nlm.nih.gov/pubmed/28551167', 'https://scholar.google.com/scholar_lookup?title=Brolucizumab+versus+aflibercept+in+participants+with+neovascular+age‐related+macular+degeneration:+a+randomized+trial+&author=PU+Dugel&author=GJ+Jaffe&author=P+Salistig&author=J+Warburton&author=A+Weichselberger&author=M+Wieland&publication_year=2017&hl=en']",28551167,https://doi.org/10.1016/j.ophtha.2017.03.057, NCT01796964 {published data only}  ,excluded,CD005139-bbs2-0057, Neither intervention (brolucizumab) nor control (aflibercept) targeted for this review 
CD005139-bib-0224,"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. ",Brolucizumab versus aflibercept in participants with neovascular age‐related macular degeneration: a randomized trial, Ophthalmology ,2017,124,    ,['citation-journal']," Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab versus aflibercept in participants with neovascular age‐related macular degeneration: a randomized trial.  Ophthalmology 2017;124(9):1296‐304. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2017.03.057', 'https://www.ncbi.nlm.nih.gov/pubmed/28551167', 'https://scholar.google.com/scholar_lookup?title=Brolucizumab+versus+aflibercept+in+participants+with+neovascular+age‐related+macular+degeneration:+a+randomized+trial+&author=PU+Dugel&author=GJ+Jaffe&author=P+Sallstig&author=J+Warburton&author=A+Weichselberger&author=M+Wieland&publication_year=2017&hl=en']",28551167,https://doi.org/10.1016/j.ophtha.2017.03.057, NCT01796964 {published data only}  ,excluded,CD005139-bbs2-0057, Neither intervention (brolucizumab) nor control (aflibercept) targeted for this review 
CD005139-bib-0225,"Neubauer AS, Holz FG, Schrader W, Back EI, Kuhn T, Hirneiss C, et al. ",Cost‐utility analysis of ranibizumab (Lucentis®) in neovascular macular degeneration,,2007,,    ,['citation-other']," Neubauer AS, Holz FG, Schrader W, Back EI, Kuhn T, Hirneiss C, et al. Cost‐utility analysis of ranibizumab (Lucentis®) in neovascular macular degeneration. Klinische Monatsblatter fur Augenheilkunde2007; Vol. 224, issue 9:727‐32. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Cost‐utility+analysis+of+ranibizumab+(Lucentis®)+in+neovascular+macular+degeneration+&author=AS+Neubauer&author=FG+Holz&author=W+Schrader&author=EI+Back&author=T+Kuhn&author=C+Hirneiss&publication_year=2007&hl=en']",,, Neubauer 2007 {published data only}  ,excluded,CD005139-bbs2-0058, Not an RCT: statistical modeling using ANCHOR 2006 and MARINA 2006 cost data  
CD005139-bib-0226,"Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, et al. ",A phase I trial of an IV‐administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age‐related macular degeneration, Ophthalmology ,2006,113,    ,['citation-journal']," Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, et al. A phase I trial of an IV‐administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age‐related macular degeneration.  Ophthalmology 2006;113(9):1522. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2006.05.055', 'https://www.ncbi.nlm.nih.gov/pubmed/16876249', 'https://scholar.google.com/scholar_lookup?title=A+phase+I+trial+of+an+IV‐administered+vascular+endothelial+growth+factor+trap+for+treatment+in+patients+with+choroidal+neovascularization+due+to+age‐related+macular+degeneration+&author=QD+Nguyen&author=SM+Shah&author=G+Hafiz&author=E+Quinlan&author=J+Sung&author=K+Chu&publication_year=2006&hl=en']",16876249,https://doi.org/10.1016/j.ophtha.2006.05.055, Nguyen 2006 {published data only}  ,excluded,CD005139-bbs2-0059, Follow‐up less than 1 year: VEGF Trap® (aflibercept) vs placebo  
CD005139-bib-0227,"Nowak MS, Jurowski P, Grzybowski A, Goś R, Pastuszka M, Kapica A, et al. ","A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age‐related macular degeneration", Medical Science Monitor ,2012,18,    ,['citation-journal']," Nowak MS, Jurowski P, Grzybowski A, Goś R, Pastuszka M, Kapica A, et al. A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age‐related macular degeneration.  Medical Science Monitor 2012;18(6):CR374‐80. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/22648253', 'https://scholar.google.com/scholar_lookup?title=A+prospective+study+on+different+methods+for+the+treatment+of+choroidal+neovascularization.+The+efficacy+of+verteporfin+photodynamic+therapy,+intravitreal+bevacizumab+and+transpupillary+thermotherapy+in+patients+with+neovascular+age‐related+macular+degeneration+&author=MS+Nowak&author=P+Jurowski&author=A+Grzybowski&author=R+Goś&author=M+Pastuszka&author=A+Kapica&publication_year=2012&hl=en']",22648253,, Nowak 2012 {published data only}  ,excluded,CD005139-bbs2-0060, Not an RCT 
CD005139-bib-0228,"Nunes RP, Rodrigues E, Hirai FE, Barroso LF, Novais E, Badaro E, et al. ",Efficacy and cost‐effectiveness of anti‐VEGF treatments for age‐related macular degeneration (AMD), Investigative Ophthalmology and Visual Science ,2014,55(13),    ,['citation-journal']," Nunes RP, Rodrigues E, Hirai FE, Barroso LF, Novais E, Badaro E, et al. Efficacy and cost‐effectiveness of anti‐VEGF treatments for age‐related macular degeneration (AMD).  Investigative Ophthalmology and Visual Science 2014;55(13):4939. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+cost‐effectiveness+of+anti‐VEGF+treatments+for+age‐related+macular+degeneration+(AMD)+&author=RP+Nunes&author=E+Rodrigues&author=FE+Hirai&author=LF+Barroso&author=E+Novais&author=E+Badaro&publication_year=2014&hl=en']",,, Nunes 2014 {published data only}  ,excluded,CD005139-bbs2-0061, Cost analysis based on outcomes from a small RCT. No RCT data found 
CD005139-bib-0229,"Singerman LJ, Weichselberger A, Sallstig P. ","OSPREY trial: randomized, active‐controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single chain anti‐VEGF antibody fragment, in patients with neovascular AMD", Investigative Ophthalmology and Visual Science ,2015,56(7),    ,['citation-journal']," Singerman LJ, Weichselberger A, Sallstig P. OSPREY trial: randomized, active‐controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single chain anti‐VEGF antibody fragment, in patients with neovascular AMD.  Investigative Ophthalmology and Visual Science 2015;56(7):4801. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=OSPREY+trial:+randomized,+active‐controlled,+phase+II+study+to+evaluate+safety+and+efficacy+of+RTH258,+a+humanized+single+chain+anti‐VEGF+antibody+fragment,+in+patients+with+neovascular+AMD+&author=LJ+Singerman&author=A+Weichselberger&author=P+Sallstig&publication_year=2015&hl=en']",,, OSPREY 2014 {published data only}  ,excluded,CD005139-bbs2-0062, Follow‐up < 1 year; neither intervention nor control targeted for this review 
CD005139-bib-0230,"Parodi MB, Cascavilla M, Papayannis A, Kontadakis DS, Bandello F, Iacono P. ",Intravitreal bevacizumab in advanced‐stage neovascular age‐related macular degeneration with visual acuity lower than 20/200, Archives of Ophthalmology ,2012,130,    ,['citation-journal']," Parodi MB, Cascavilla M, Papayannis A, Kontadakis DS, Bandello F, Iacono P. Intravitreal bevacizumab in advanced‐stage neovascular age‐related macular degeneration with visual acuity lower than 20/200.  Archives of Ophthalmology 2012;130(7):934‐5. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/archophthalmol.2011.2617', 'https://www.ncbi.nlm.nih.gov/pubmed/22776937', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+in+advanced‐stage+neovascular+age‐related+macular+degeneration+with+visual+acuity+lower+than+20/200+&author=MB+Parodi&author=M+Cascavilla&author=A+Papayannis&author=DS+Kontadakis&author=F+Bandello&author=P+Iacono&publication_year=2012&hl=en']",22776937,https://doi.org/10.1001/archophthalmol.2011.2617, Parodi 2012 {published data only}  ,excluded,CD005139-bbs2-0063, Follow‐up less than 1 year 
CD005139-bib-0231,"Chakravarthy U, Staurenghi G, Kwok K, Tressler CS, Buggage R, PERSPECTIVES Study Group. ",Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age‐related macular degeneration: findings of the PERSPECTIVES study, British Journal of Ophthalmology ,2012,96,    ,['citation-journal']," Chakravarthy U, Staurenghi G, Kwok K, Tressler CS, Buggage R, PERSPECTIVES Study Group. Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age‐related macular degeneration: findings of the PERSPECTIVES study.  British Journal of Ophthalmology 2012;96(10):1351‐4. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjophthalmol-2011-301444', 'https://scholar.google.com/scholar_lookup?title=Treating+early+choroidal+neovascularisation+with+pegaptanib+sodium+in+patients+with+neovascular+age‐related+macular+degeneration:+findings+of+the+PERSPECTIVES+study+&author=U+Chakravarthy&author=G+Staurenghi&author=K+Kwok&author=CS+Tressler&author=R+Buggage&publication_year=2012&hl=en']",,https://doi.org/10.1136/bjophthalmol-2011-301444, PERSPECTIVES 2012 {published data only}  ,excluded,CD005139-bbs2-0064, Not an RCT 
CD005139-bib-0232,"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. ",A variable‐dosing regimen with intravitreal ranibizumab for neovascular age‐related macular degeneration: year 2 of the PrONTO study, American Journal of Ophthalmology ,2009,148,    ,['citation-journal']," Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable‐dosing regimen with intravitreal ranibizumab for neovascular age‐related macular degeneration: year 2 of the PrONTO study.  American Journal of Ophthalmology 2009;148(1):43‐58.e1. [10.1016/j.ajo.2009.01.024.Epub 2009 Apr 18]CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ajo.2009.01.024', 'https://www.ncbi.nlm.nih.gov/pubmed/19376495', 'https://scholar.google.com/scholar_lookup?title=A+variable‐dosing+regimen+with+intravitreal+ranibizumab+for+neovascular+age‐related+macular+degeneration:+year+2+of+the+PrONTO+study+&author=GA+Lalwani&author=PJ+Rosenfeld&author=AE+Fung&author=SR+Dubovy&author=S+Michels&author=W+Feuer&publication_year=2009&hl=en']",19376495,https://doi.org/10.1016/j.ajo.2009.01.024, PrONTO Study 2009 {published data only}  ,excluded,CD005139-bbs2-0065, Not an RCT 
CD005139-bib-0233,"Raftery J, Clegg A, Jones J, Tan SC, Lotery A. ",Ranibizumab (Lucentis®) versus bevacizumab (Avastin®): modelling cost effectiveness, British Journal of Ophthalmology ,2007,91,    ,['citation-journal']," Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis®) versus bevacizumab (Avastin®): modelling cost effectiveness.  British Journal of Ophthalmology 2007;91(9):1244‐6. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjo.2007.116616', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+versus+bevacizumab+(Avastin®):+modelling+cost+effectiveness+&author=J+Raftery&author=A+Clegg&author=J+Jones&author=SC+Tan&author=A+Lotery&publication_year=2007&hl=en']",,https://doi.org/10.1136/bjo.2007.116616, Raftery 2007 {published data only}  ,excluded,CD005139-bbs2-0066, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0234,NCT01319188. ,Ranibizumab for age‐related macular degeneration and the risk of arterial thromboembolic events (RATE),,,,   ,['citation-other'], NCT01319188. Ranibizumab for age‐related macular degeneration and the risk of arterial thromboembolic events (RATE). clinicaltrials.gov/show/NCT01319188 (accessed 5 February 2017). CENTRAL    ,[''],,, RATE 2011 {unpublished data only}  ,excluded,CD005139-bbs2-0067," Clinical trial registry record reported that the ""study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology""; trial investigators had planned to compare 0.50 mg intravitreal ranibizumab vs 0.50 mg intravitreal ranibizumab plus PDT vs sham injection in participants with a history of coronary artery disease or cerebrovascular events, and to evaluate arterial thromboembolic events as the primary outcome  "
CD005139-bib-0235,"Gillies MC, Hunyor AP, Arnold JJ, Pecheur F, Underhill K, Guymer RH, et al. ",Comparison of ranibizumab and aflibercept in patients with neovascular age‐related macular degeneration treated following a 'treat and extend' protocol: efficacy variables from the pre‐specified 12‐month interim analysis of the rival study, Clinical and Experimental Ophthalmology. Conference: 49th Annual Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists. Australia ,2017,45,    ,['citation-journal']," Gillies MC, Hunyor AP, Arnold JJ, Pecheur F, Underhill K, Guymer RH, et al. Comparison of ranibizumab and aflibercept in patients with neovascular age‐related macular degeneration treated following a 'treat and extend' protocol: efficacy variables from the pre‐specified 12‐month interim analysis of the rival study.  Clinical and Experimental Ophthalmology. Conference: 49th Annual Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists. Australia 2017;45(1):29. CENTRAL    Google Scholar     ","['', ""https://scholar.google.com/scholar_lookup?title=Comparison+of+ranibizumab+and+aflibercept+in+patients+with+neovascular+age‐related+macular+degeneration+treated+following+a+'treat+and+extend'+protocol:+efficacy+variables+from+the+pre‐specified+12‐month+interim+analysis+of+the+rival+study+&author=MC+Gillies&author=AP+Hunyor&author=JJ+Arnold&author=F+Pecheur&author=K+Underhill&author=RH+Guymer&publication_year=2017&hl=en""]",,, RIVAL 2017 {published data only}  ,excluded,CD005139-bbs2-0068, RCT of ranibizumab vs aflibercept; aflibercept excluded from this review 
CD005139-bib-0236,"Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. ",A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age‐related macular degeneration, Ophthalmology ,2009,116,    ,['citation-journal']," Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age‐related macular degeneration.  Ophthalmology 2009;116(9):1731‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2009.05.024', 'https://www.ncbi.nlm.nih.gov/pubmed/19643495', 'https://scholar.google.com/scholar_lookup?title=A+Phase+IIIb+study+to+evaluate+the+safety+of+ranibizumab+in+subjects+with+neovascular+age‐related+macular+degeneration+&author=DS+Boyer&author=JS+Heier&author=DM+Brown&author=SF+Francom&author=T+Ianchulev&author=RG+Rubio&publication_year=2009&hl=en']",19643495,https://doi.org/10.1016/j.ophtha.2009.05.024, SAILOR 2009 {published data only}  ,excluded,CD005139-bbs2-0069, Dosing study: 0.3 mg (n = 1169) or 0.5 mg (n = 1209) intravitreal ranibizumab 
CD005139-bib-0237,"Reichel E, Francom S, Rubio R. ",Ranibizumab (Lucentis®) safety in previously treated and newly diagnosed patients with neovascular age‐related macular degeneration (AMD): the SAILOR study,,2008,,    ,['citation-other']," Reichel E, Francom S, Rubio R. Ranibizumab (Lucentis®) safety in previously treated and newly diagnosed patients with neovascular age‐related macular degeneration (AMD): the SAILOR study. The Macula Society. 2008:168. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Ranibizumab+(Lucentis®)+safety+in+previously+treated+and+newly+diagnosed+patients+with+neovascular+age‐related+macular+degeneration+(AMD):+the+SAILOR+study+&author=E+Reichel&author=S+Francom&author=R+Rubio&publication_year=2008&hl=en']",,, SAILOR 2009 {published data only}  ,excluded,CD005139-bbs2-0069, Dosing study: 0.3 mg (n = 1169) or 0.5 mg (n = 1209) intravitreal ranibizumab 
CD005139-bib-0238,"Schmid‐Kubista KE, Krebs I, Ansari‐Shahrezaei S, Haas P, Hagen S, Binder S. ",Comparing treatment of neovascular age‐related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono‐therapy ‐ a pilot study, Current Eye Research ,2011,36,    ,['citation-journal']," Schmid‐Kubista KE, Krebs I, Ansari‐Shahrezaei S, Haas P, Hagen S, Binder S. Comparing treatment of neovascular age‐related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono‐therapy ‐ a pilot study.  Current Eye Research 2011;36(10):958‐63. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3109/02713683.2011.597536', 'https://www.ncbi.nlm.nih.gov/pubmed/21950702', 'https://scholar.google.com/scholar_lookup?title=Comparing+treatment+of+neovascular+age‐related+macular+degeneration+with+sequential+intravitreal+Avastin+and+Macugen+versus+intravitreal+mono‐therapy+‐+a+pilot+study+&author=KE+Schmid‐Kubista&author=I+Krebs&author=S+Ansari‐Shahrezaei&author=P+Haas&author=S+Hagen&author=S+Binder&publication_year=2011&hl=en']",21950702,https://doi.org/10.3109/02713683.2011.597536, Schmid‐Kubista 2011 {published and unpublished data}  ,excluded,CD005139-bbs2-0070, Follow‐up less than 1 year; RCT comparing sequential administration of intravitreal bevacizumab and pegaptanib vs intravitreal bevacizumab or pegaptanib alone  
CD005139-bib-0239,"Sengul A, Rasier R, Ciftci C, Artunay O, Kockar A, Bahcecioglu H, et al. ",Short‐term effects of intravitreal ranibizumab and bevacizumab administration on 24‐h ambulatory blood pressure monitoring recordings in normotensive patients with age‐related macular degeneration," Eye (London, England) ",2017,31,    ,['citation-journal']," Sengul A, Rasier R, Ciftci C, Artunay O, Kockar A, Bahcecioglu H, et al. Short‐term effects of intravitreal ranibizumab and bevacizumab administration on 24‐h ambulatory blood pressure monitoring recordings in normotensive patients with age‐related macular degeneration.  Eye (London, England) 2017;31(5):677‐83. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/eye.2016.305', 'https://www.ncbi.nlm.nih.gov/pubmed/28060360', 'https://scholar.google.com/scholar_lookup?title=Short‐term+effects+of+intravitreal+ranibizumab+and+bevacizumab+administration+on+24‐h+ambulatory+blood+pressure+monitoring+recordings+in+normotensive+patients+with+age‐related+macular+degeneration+&author=A+Sengul&author=R+Rasier&author=C+Ciftci&author=O+Artunay&author=A+Kockar&author=H+Bahcecioglu&publication_year=2017&hl=en']",28060360,https://doi.org/10.1038/eye.2016.305, Sengul 2017 {published data only}  ,excluded,CD005139-bbs2-0071, Follow‐up less than 1 year; no data for any outcomes targeted for this review 
CD005139-bib-0240,"Li X, Chen Y, Zhang J, Xu X, Zhang F, Cheung CMG, et al. ",Intravitreal aflibercept versus photodynamic therapy in Chinese patients with neovascular age‐related macular degeneration: outcomes of the sight study, Journal of Ocular Pharmacology and Therapeutics ,2017,33,    ,['citation-journal']," Li X, Chen Y, Zhang J, Xu X, Zhang F, Cheung CMG, et al. Intravitreal aflibercept versus photodynamic therapy in Chinese patients with neovascular age‐related macular degeneration: outcomes of the sight study.  Journal of Ocular Pharmacology and Therapeutics 2017;33(6):435‐44. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1089/jop.2016.0071', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+aflibercept+versus+photodynamic+therapy+in+Chinese+patients+with+neovascular+age‐related+macular+degeneration:+outcomes+of+the+sight+study+&author=X+Li&author=Y+Chen&author=J+Zhang&author=X+Xu&author=F+Zhang&author=CMG+Cheung&publication_year=2017&hl=en']",,https://doi.org/10.1089/jop.2016.0071, SIGHT 2014 {published data only}  ,excluded,CD005139-bbs2-0072, Intervention (aflibercept) not targeted for this review 
CD005139-bib-0241,"Slakter JS, DENALI Study Group. ",Combination therapy with verteporfin PDT and ranibizumab for subfoveal choroidal neovascularization due to AMD, Investigative Ophthalmology and Visual Science ,2007,48,    ,['citation-journal']," Slakter JS, DENALI Study Group. Combination therapy with verteporfin PDT and ranibizumab for subfoveal choroidal neovascularization due to AMD.  Investigative Ophthalmology and Visual Science 2007;48:E‐Abstract 1817. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Combination+therapy+with+verteporfin+PDT+and+ranibizumab+for+subfoveal+choroidal+neovascularization+due+to+AMD+&author=JS+Slakter&publication_year=2007&hl=en']",,, SUMMIT 2007 {published data only}  ,excluded,CD005139-bbs2-0073, 3 RCTs compared intravitreal ranibizumab alone vs intravitreal ranibizumab plus PDT 
CD005139-bib-0242,"Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. ",Responsiveness of NEI VFQ‐25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials, Investigative Ophthalmology and Visual Science ,2009,50,    ,['citation-journal']," Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ‐25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials.  Investigative Ophthalmology and Visual Science 2009;50(8):3629‐35. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1167/iovs.08-3225', 'https://www.ncbi.nlm.nih.gov/pubmed/19255158', 'https://scholar.google.com/scholar_lookup?title=Responsiveness+of+NEI+VFQ‐25+to+changes+in+visual+acuity+in+neovascular+AMD:+validation+studies+from+two+phase+3+clinical+trials+&author=IJ+Suñer&author=GT+Kokame&author=E+Yu&author=J+Ward&author=C+Dolan&author=NM+Bressler&publication_year=2009&hl=en']",19255158,https://doi.org/10.1167/iovs.08-3225, Suñer 2009 {published data only}  ,excluded,CD005139-bbs2-0074, Not an RCT: validation of NEI Visual Function Questionnaire using ANCHOR 2006 and MARINA 2006 data  
CD005139-bib-0243,"Tano Y, Pegaptanib Sodium Multi‐center Study Group. ",Pegaptanib sodium one‐year treatment study for neovascular age‐related macular degeneration, Nippon Ganka Gakkai Zasshi ,2008,112,    ,['citation-journal']," Tano Y, Pegaptanib Sodium Multi‐center Study Group. Pegaptanib sodium one‐year treatment study for neovascular age‐related macular degeneration.  Nippon Ganka Gakkai Zasshi 2008;112(7):590‐600. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/18702350', 'https://scholar.google.com/scholar_lookup?title=Pegaptanib+sodium+one‐year+treatment+study+for+neovascular+age‐related+macular+degeneration&author=Y+Tano&publication_year=2008&hl=en']",18702350,, Tano 2008 {published data only}  ,excluded,CD005139-bbs2-0075, Dosing study: 0.3 mg (n = 47) or 1.0 mg (n = 48) pegaptanib sodium 
CD005139-bib-0244,"Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC. ",A randomised prospective double‐masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age‐related macular degeneration, Eye ,2010,24,    ,['citation-journal']," Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC. A randomised prospective double‐masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age‐related macular degeneration.  Eye 2010;24(10):1561‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/eye.2010.84', 'https://www.ncbi.nlm.nih.gov/pubmed/20577273', 'https://scholar.google.com/scholar_lookup?title=A+randomised+prospective+double‐masked+exploratory+study+comparing+combination+photodynamic+treatment+and+intravitreal+ranibizumab+vs+intravitreal+ranibizumab+monotherapy+in+the+treatment+of+neovascular+age‐related+macular+degeneration+&author=JH+Vallance&author=B+Johnson&author=MA+Majid&author=S+Banerjee&author=K+Mandal&author=CC+Bailey&publication_year=2010&hl=en']",20577273,https://doi.org/10.1038/eye.2010.84, Vallance 2010 {published data only}  ,excluded,CD005139-bbs2-0076, RCT of intravitreal ranibizumab + sham PDT vs intravitreal ranibizumab + standard‐fluence verteporfin PDT  
CD005139-bib-0245,"Mieler WF, The VERITAS trial. ",VERITAS ‐ The rationale and design of a combination therapy trial for wet AMD, Investigative Ophthalmology and Visual Science ,2006,47,    ,['citation-journal']," Mieler WF, The VERITAS trial. VERITAS ‐ The rationale and design of a combination therapy trial for wet AMD.  Investigative Ophthalmology and Visual Science 2006;47:E‐Abstract 5232. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=VERITAS+‐+The+rationale+and+design+of+a+combination+therapy+trial+for+wet+AMD&author=WF+Mieler&publication_year=2006&hl=en']",,, VERITAS 2006 {published data only}  ,excluded,CD005139-bbs2-0077, Not an RCT of anti‐VEGF intravitreous injections 
CD005139-bib-0246,Marcus DM. ,Long‐term follow‐up of intravitreal aflibercept injection (IAI) for neovascular age‐related macular degeneration (nAMD) in an open‐label extension of the VIEW1 study,,2014,,    ,['citation-other'], Marcus DM. Long‐term follow‐up of intravitreal aflibercept injection (IAI) for neovascular age‐related macular degeneration (nAMD) in an open‐label extension of the VIEW1 study. Investigative Ophthalmology and Visual Science. 2014; Vol. 55(13):3943. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Long‐term+follow‐up+of+intravitreal+aflibercept+injection+(IAI)+for+neovascular+age‐related+macular+degeneration+(nAMD)+in+an+open‐label+extension+of+the+VIEW1+study+&author=DM+Marcus&publication_year=2014&hl=en']",,, VIEW 2014 {published data only}  ,excluded,CD005139-bbs2-0078, 2 RCTs of intravitreal aflibercept vs intravitreal ranibizumab; aflibercept not eligible for this review  
CD005139-bib-0247,"Schmidt‐Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. ",Intravitreal aflibercept injection for neovascular age‐related macular degeneration: ninety‐six‐week results of the VIEW studies, Ophthalmology ,2014,121,    ,['citation-journal']," Schmidt‐Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age‐related macular degeneration: ninety‐six‐week results of the VIEW studies.  Ophthalmology 2014;121(1):193‐201. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ophtha.2013.08.011', 'https://www.ncbi.nlm.nih.gov/pubmed/24084500', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+aflibercept+injection+for+neovascular+age‐related+macular+degeneration:+ninety‐six‐week+results+of+the+VIEW+studies+&author=U+Schmidt‐Erfurth&author=PK+Kaiser&author=JF+Korobelnik&author=DM+Brown&author=V+Chong&author=QD+Nguyen&publication_year=2014&hl=en']",24084500,https://doi.org/10.1016/j.ophtha.2013.08.011, VIEW 2014 {published data only}  ,excluded,CD005139-bbs2-0078, 2 RCTs of intravitreal aflibercept vs intravitreal ranibizumab; aflibercept not eligible for this review  
CD005139-bib-0248,"Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, et al. ","Intravitreal bevacizumab (Avastin) versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomized controlled clinical trial", British Journal of Ophthalmology ,2008,92,    ,['citation-journal']," Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, et al. Intravitreal bevacizumab (Avastin) versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomized controlled clinical trial.  British Journal of Ophthalmology 2008;92(3):356‐8. [PUBMED: PMID: 18201136]CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjo.2007.125823', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+versus+photodynamic+therapy+plus+intravitreal+triamcinolone+for+neovascular+age‐related+macular+degeneration:+6‐month+results+of+a+prospective,+randomized+controlled+clinical+trial+&author=G+Weigert&author=S+Michels&author=S+Sacu&author=A+Varga&author=F+Prager&author=W+Geitzenauer&publication_year=2008&hl=en']",,https://doi.org/10.1136/bjo.2007.125823, Weigert 2008 {published data only}  ,excluded,CD005139-bbs2-0079, Follow‐up less than 1 year 
CD005139-bib-0249,"Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. ",Cost effectiveness of pegaptanib for the treatment of age‐related macular degeneration in the UK, Pharmacoeconomics ,2007,25,    ,['citation-journal']," Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age‐related macular degeneration in the UK.  Pharmacoeconomics 2007;25(10):863‐79. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2165/00019053-200725100-00005', 'https://www.ncbi.nlm.nih.gov/pubmed/17887807', 'https://scholar.google.com/scholar_lookup?title=Cost+effectiveness+of+pegaptanib+for+the+treatment+of+age‐related+macular+degeneration+in+the+UK+&author=SE+Wolowacz&author=N+Roskell&author=S+Kelly&author=FM+Maciver&author=CS+Brand&publication_year=2007&hl=en']",17887807,https://doi.org/10.2165/00019053-200725100-00005, Wolowacz 2007 {published data only}  ,excluded,CD005139-bbs2-0080, Not an RCT: cost‐effectiveness assessment 
CD005139-bib-0250,"Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. ","Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age‐related macular degeneration, and in patients with diabetic macular oedema", British Journal of Ophthalmology ,2013,97,    ,['citation-journal']," Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age‐related macular degeneration, and in patients with diabetic macular oedema.  British Journal of Ophthalmology 2013;97(4):454‐9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/bjophthalmol-2012-302451', 'https://scholar.google.com/scholar_lookup?title=Plasma+levels+of+vascular+endothelial+growth+factor+before+and+after+intravitreal+injection+of+bevacizumab,+ranibizumab+and+pegaptanib+in+patients+with+age‐related+macular+degeneration,+and+in+patients+with+diabetic+macular+oedema+&author=C+Zehetner&author=R+Kirchmair&author=S+Huber&author=MT+Kralinger&author=GF+Kieselbach&publication_year=2013&hl=en']",,https://doi.org/10.1136/bjophthalmol-2012-302451, Zehetner 2013 {published data only}  ,excluded,CD005139-bbs2-0081, Follow‐up less than 1 year 
CD005139-bib-0252,"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. ",Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, New England Journal of Medicine ,1994,331,    ,['citation-journal']," Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  New England Journal of Medicine 1994;331(22):1480‐7.    Link to article     Google Scholar     ","['https://doi.org/10.1056/NEJM199412013312203', 'https://scholar.google.com/scholar_lookup?title=Vascular+endothelial+growth+factor+in+ocular+fluid+of+patients+with+diabetic+retinopathy+and+other+retinal+disorders+&author=LP+Aiello&author=RL+Avery&author=PG+Arrigg&author=BA+Keyt&author=HD+Jampel&author=ST+Shah&publication_year=1994&hl=en']",,https://doi.org/10.1056/NEJM199412013312203, Aiello 1994 ,additional,CD005139-bbs2-0083,
CD005139-bib-0253,Age‐Related Eye Disease Study Research Group. ,"A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8", Archives of Ophthalmology ,2001,119,(10):1414‐36.   ,['citation-journal']," Age‐Related Eye Disease Study Research Group. A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8.  Archives of Ophthalmology 2001;119(10):1414‐36.    ",[],,, AREDS 2001 ,additional,CD005139-bbs2-0084,
CD005139-bib-0254,Age‐Related Eye Disease Study 2 Research Group. ,Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial, JAMA ,2013,309,    ,['citation-journal'], Age‐Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial.  JAMA 2013;309(19):2005‐15.    Link to article     PubMed     ,"['https://doi.org/10.1001/jama.2013.4997', 'https://www.ncbi.nlm.nih.gov/pubmed/23644932']",23644932,https://doi.org/10.1001/jama.2013.4997, AREDS2 2013 ,additional,CD005139-bbs2-0085,
CD005139-bib-0255,"Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A, de Jong PT. ",C‐reactive protein level and risk of aging macula disorder: the Rotterdam study, Archives of Ophthalmology ,2007,125,    ,['citation-journal']," Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A, de Jong PT. C‐reactive protein level and risk of aging macula disorder: the Rotterdam study.  Archives of Ophthalmology 2007;125(10):1396‐401.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.125.10.1396', 'https://www.ncbi.nlm.nih.gov/pubmed/17923549', 'https://scholar.google.com/scholar_lookup?title=C‐reactive+protein+level+and+risk+of+aging+macula+disorder:+the+Rotterdam+study&author=SS+Boekhoorn&author=JR+Vingerling&author=JCM+Witteman&author=A+Hofman&author=PT+Jong&publication_year=2007&hl=en']",17923549,https://doi.org/10.1001/archopht.125.10.1396, Boekhoorn 2007 ,additional,CD005139-bbs2-0086,
CD005139-bib-0256,"Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. ",Prevalence and causes of vision loss in high‐income countries and in Eastern and Central Europe: 1990‐2010, British Journal of Ophthalmology ,2014,98,    ,['citation-journal']," Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Prevalence and causes of vision loss in high‐income countries and in Eastern and Central Europe: 1990‐2010.  British Journal of Ophthalmology 2014;98(5):629‐38.    Link to article     Google Scholar     ","['https://doi.org/10.1136/bjophthalmol-2013-304033', 'https://scholar.google.com/scholar_lookup?title=Prevalence+and+causes+of+vision+loss+in+high‐income+countries+and+in+Eastern+and+Central+Europe:+1990‐2010+&author=RR+Bourne&author=JB+Jonas&author=SR+Flaxman&author=J+Keeffe&author=J+Leasher&author=K+Naidoo&publication_year=2014&hl=en']",,https://doi.org/10.1136/bjophthalmol-2013-304033, Bourne 2014 ,additional,CD005139-bbs2-0087,
CD005139-bib-0257,"Brown MM, Brown GC, Brown HC, Peet J. ",A value‐based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration, Ophthalmology ,2008,115,    ,['citation-journal']," Brown MM, Brown GC, Brown HC, Peet J. A value‐based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.  Ophthalmology 2008;115(6):1039‐45.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ophtha.2007.08.033', 'https://www.ncbi.nlm.nih.gov/pubmed/17976724', 'https://scholar.google.com/scholar_lookup?title=A+value‐based+medicine+analysis+of+ranibizumab+for+the+treatment+of+subfoveal+neovascular+macular+degeneration+&author=MM+Brown&author=GC+Brown&author=HC+Brown&author=J+Peet&publication_year=2008&hl=en']",17976724,https://doi.org/10.1016/j.ophtha.2007.08.033, Brown 2008 ,additional,CD005139-bbs2-0088,
CD005139-bib-0258,"Bunce C, Wormald R. ",Leading causes of certification for blindness and partial sight in England & Wales, BMC Public Health ,2006,6,    ,['citation-journal']," Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales.  BMC Public Health 2006;6:58.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1471-2458-6-58', 'https://www.ncbi.nlm.nih.gov/pubmed/16524463', 'https://scholar.google.com/scholar_lookup?title=Leading+causes+of+certification+for+blindness+and+partial+sight+in+England+&+Wales&author=C+Bunce&author=R+Wormald&publication_year=2006&hl=en']",16524463,https://doi.org/10.1186/1471-2458-6-58, Bunce 2006 ,additional,CD005139-bbs2-0089,
CD005139-bib-0259,"Carneiro AM, Mendonca LS, Falcao MS, Fonseca SL, Brandao EM, Falcao‐Reis FM. ",Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting, Clinical Ophthalmology ,2012,6,    ,['citation-journal']," Carneiro AM, Mendonca LS, Falcao MS, Fonseca SL, Brandao EM, Falcao‐Reis FM. Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting.  Clinical Ophthalmology 2012;6:1149‐57.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/22973087', 'https://scholar.google.com/scholar_lookup?title=Comparative+study+of+1+PRN+ranibizumab+versus+bevacizumab+in+the+clinical+setting&author=AM+Carneiro&author=LS+Mendonca&author=MS+Falcao&author=SL+Fonseca&author=EM+Brandao&author=FM+Falcao‐Reis&publication_year=2012&hl=en']",22973087,, Carneiro 2012 ,additional,CD005139-bbs2-0090,
CD005139-bib-0260,Centers for Medicare and Medicaid Services. ,"Billing and coding information regarding uses, including off‐label uses, of bevacizumab and ranibizumab, for the treatment of ophthalmological diseases. Document ID A49034",,,,. www.cms.gov/medicare‐coverage‐database (accessed 9 April 2014).   ,['citation-other']," Centers for Medicare and Medicaid Services. Billing and coding information regarding uses, including off‐label uses, of bevacizumab and ranibizumab, for the treatment of ophthalmological diseases. Document ID A49034. www.cms.gov/medicare‐coverage‐database (accessed 9 April 2014).    ",[],,, CMS 2014 ,additional,CD005139-bbs2-0091,
CD005139-bib-0261,Cohen D. ,"Roche and Novartis colluded over wet AMD drugs, says Italian regulator", BMJ ,2014,348,    ,['citation-journal']," Cohen D. Roche and Novartis colluded over wet AMD drugs, says Italian regulator.  BMJ 2014;348:g2006.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.g2006', 'https://www.ncbi.nlm.nih.gov/pubmed/24615827', 'https://scholar.google.com/scholar_lookup?title=Roche+and+Novartis+colluded+over+wet+AMD+drugs,+says+Italian+regulator&author=D+Cohen&publication_year=2014&hl=en']",24615827,https://doi.org/10.1136/bmj.g2006, Cohen 2014 ,additional,CD005139-bbs2-0092,
CD005139-bib-0262,"Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al. ",Causes and prevalence of visual impairment among adults in the United States, Archives of Ophthalmology ,2004,122,    ,['citation-journal']," Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States.  Archives of Ophthalmology 2004;122(4):477‐85.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/15078664', ""https://scholar.google.com/scholar_lookup?title=Causes+and+prevalence+of+visual+impairment+among+adults+in+the+United+States&author=N+Congdon&author=B+O'Colmain&author=CC+Klaver&author=R+Klein&author=B+Muñoz&author=DS+Friedman&publication_year=2004&hl=en""]",15078664,, Congdon 2004 ,additional,CD005139-bbs2-0093,
CD005139-bib-0263,"de Juan E, Laganovska G, Loewenstein A, Alster Y, Erickson S. ",First in‐human results of a refillable drug delivery implant providing sustained release of ranibizumab in patients with neovascular AMD,,2013,,    ,['citation-other']," de Juan E, Laganovska G, Loewenstein A, Alster Y, Erickson S. First in‐human results of a refillable drug delivery implant providing sustained release of ranibizumab in patients with neovascular AMD. Macula Society. 2013:136‐7.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=First+in‐human+results+of+a+refillable+drug+delivery+implant+providing+sustained+release+of+ranibizumab+in+patients+with+neovascular+AMD+&author=E+Juan&author=G+Laganovska&author=A+Loewenstein&author=Y+Alster&author=S+Erickson&publication_year=2013&hl=en'],,, de Juan 2013 ,additional,CD005139-bbs2-0094,
CD005139-bib-0264,"Deangelis MM, Ji F, Kim IK, Adams S, Capone A, Ott J, et al. ","Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age‐related macular degeneration", Archives of Ophthalmology ,2007,125,    ,['citation-journal']," Deangelis MM, Ji F, Kim IK, Adams S, Capone A, Ott J, et al. Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age‐related macular degeneration.  Archives of Ophthalmology 2007;125(1):49‐54.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.125.1.49', 'https://www.ncbi.nlm.nih.gov/pubmed/17210851', 'https://scholar.google.com/scholar_lookup?title=Cigarette+smoking,+CFH,+APOE,+ELOVL4,+and+risk+of+neovascular+age‐related+macular+degeneration+&author=MM+Deangelis&author=F+Ji&author=IK+Kim&author=S+Adams&author=A+Capone&author=J+Ott&publication_year=2007&hl=en']",17210851,https://doi.org/10.1001/archopht.125.1.49, Deangelis 2007 ,additional,CD005139-bbs2-0095,
CD005139-bib-0265,"Deeks JJ, Higgins JP, Altman DG, editor(s). ","Chapter 9. Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011",,,,. Available from handbook.cochrane.org.   ,['citation-other']," Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 9. Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.    ",[],,, Deeks 2011 ,additional,CD005139-bbs2-0096,
CD005139-bib-0266,"Eyetech Pharmaceuticals, Inc, Pfizer, Inc. ",Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration,,,,. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011).   ,['citation-other']," Eyetech Pharmaceuticals, Inc, Pfizer, Inc. Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011).    ",[],,, EOP 1003 ,additional,CD005139-bbs2-0097,
CD005139-bib-0267,"Eyetech Pharmaceuticals, Inc, Pfizer, Inc. ",Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration,,,,. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011).   ,['citation-other']," Eyetech Pharmaceuticals, Inc, Pfizer, Inc. Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011).    ",[],,, EOP 1004 ,additional,CD005139-bbs2-0098,
CD005139-bib-0268,"Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. ",Prevalence of age‐related macular degeneration in the United States, Archives of Ophthalmology ,2004,122,    ,['citation-journal']," Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age‐related macular degeneration in the United States.  Archives of Ophthalmology 2004;122(4):564‐72.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.1941.00870100042005', 'https://www.ncbi.nlm.nih.gov/pubmed/15078675', ""https://scholar.google.com/scholar_lookup?title=Prevalence+of+age‐related+macular+degeneration+in+the+United+States&author=DS+Friedman&author=BJ+O'Colmain&author=B+Muñoz&author=SC+Tomany&author=C+McCarty&author=PT+Jong&publication_year=2004&hl=en""]",15078675,https://doi.org/10.1001/archopht.1941.00870100042005, Friedman 2004 ,additional,CD005139-bbs2-0099,
CD005139-bib-0269,"Ghafour IM, Allan D, Foulds WS. ",Common causes of blindness and visual handicap in the west of Scotland, British Journal of Ophthalmology ,1983,67,    ,['citation-journal']," Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland.  British Journal of Ophthalmology 1983;67(4):209‐13.    Link to article     Google Scholar     ","['https://doi.org/10.1136/bjo.67.4.209', 'https://scholar.google.com/scholar_lookup?title=Common+causes+of+blindness+and+visual+handicap+in+the+west+of+Scotland&author=IM+Ghafour&author=D+Allan&author=WS+Foulds&publication_year=1983&hl=en']",,https://doi.org/10.1136/bjo.67.4.209, Ghafour 1983 ,additional,CD005139-bbs2-0100,
CD005139-bib-0270,"Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al. ","Comparison of outcomes from a phase 3 study of age‐related macular degeneration with a matched, observational cohort", Ophthalmology ,2014,121,    ,['citation-journal']," Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al. Comparison of outcomes from a phase 3 study of age‐related macular degeneration with a matched, observational cohort.  Ophthalmology 2014;121(3):676‐81.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ophtha.2013.09.050', 'https://www.ncbi.nlm.nih.gov/pubmed/24290801', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+outcomes+from+a+phase+3+study+of+age‐related+macular+degeneration+with+a+matched,+observational+cohort+&author=MC+Gillies&author=RJ+Walton&author=JJ+Arnold&author=IL+McAllister&author=JM+Simpson&author=AP+Hunyor&publication_year=2014&hl=en']",24290801,https://doi.org/10.1016/j.ophtha.2013.09.050, Gillies 2014 ,additional,CD005139-bbs2-0101,
CD005139-bib-0271,"Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. ",How to identify randomized controlled trials in MEDLINE: ten years on, Journal of the Medical Library Association ,2006,94,    ,['citation-journal']," Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on.  Journal of the Medical Library Association 2006;94(2):130‐6.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/16636704', 'https://scholar.google.com/scholar_lookup?title=How+to+identify+randomized+controlled+trials+in+MEDLINE:+ten+years+on&author=JM+Glanville&author=C+Lefebvre&author=JN+Miles&author=J+Camosso‐Stefinovic&publication_year=2006&hl=en']",16636704,, Glanville 2006 ,additional,CD005139-bbs2-0102,
CD005139-bib-0272,"GRADE Working Group, McMaster University. ",GRADEpro,,2014,,.   ,['citation-other']," GRADE Working Group, McMaster University. GRADEpro. Version accessed 11 December 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.    ",[],,, GRADEpro 2014 [Computer program] ,additional,CD005139-bbs2-0103,
CD005139-bib-0273,"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. ",Pegaptanib for neovascular age‐related macular degeneration, New England Journal of Medicine ,2004,351,    ,['citation-journal']," Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age‐related macular degeneration.  New England Journal of Medicine 2004;351(27):2805‐16.    Link to article     Google Scholar     ","['https://doi.org/10.1056/NEJMoa042760', 'https://scholar.google.com/scholar_lookup?title=Pegaptanib+for+neovascular+age‐related+macular+degeneration&author=ES+Gragoudas&author=AP+Adamis&author=ET+Cunningham&author=M+Feinsod&author=DR+Guyer&publication_year=2004&hl=en']",,https://doi.org/10.1056/NEJMoa042760, Gragoudas 2004 ,additional,CD005139-bbs2-0104,
CD005139-bib-0274,"Haddad S, Chen CA, Santangelo SL, Seddon JM. ",The genetics of age‐related macular degeneration: a review of progress to date, Survey of Ophthalmology ,2006,51,    ,['citation-journal']," Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age‐related macular degeneration: a review of progress to date.  Survey of Ophthalmology 2006;51(4):316‐63.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.survophthal.2006.05.001', 'https://www.ncbi.nlm.nih.gov/pubmed/16818082', 'https://scholar.google.com/scholar_lookup?title=The+genetics+of+age‐related+macular+degeneration:+a+review+of+progress+to+date&author=S+Haddad&author=CA+Chen&author=SL+Santangelo&author=JM+Seddon&publication_year=2006&hl=en']",16818082,https://doi.org/10.1016/j.survophthal.2006.05.001, Haddad 2006 ,additional,CD005139-bbs2-0105,
CD005139-bib-0275,"Higgins JP, Altman DG, Sterne JAC, editor(s). ","Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011",,,,. Available from handbook.cochrane.org.   ,['citation-other']," Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.    ",[],,, Higgins 2011 ,additional,CD005139-bbs2-0106,
CD005139-bib-0276,"Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al. ",Safety of ranibizumab in routine clinical practice: 1‐year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme, British Journal of Ophthalmology ,2013,97,    ,['citation-journal']," Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al. Safety of ranibizumab in routine clinical practice: 1‐year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme.  British Journal of Ophthalmology 2013;97(9):1161‐7.    Link to article     Google Scholar     ","['https://doi.org/10.1136/bjophthalmol-2013-303232', 'https://scholar.google.com/scholar_lookup?title=Safety+of+ranibizumab+in+routine+clinical+practice:+1‐year+retrospective+pooled+analysis+of+four+European+neovascular+AMD+registries+within+the+LUMINOUS+programme+&author=FG+Holz&author=F+Bandello&author=M+Gillies&author=P+Mitchell&author=A+Osborne&author=T+Sheidow&publication_year=2013&hl=en']",,https://doi.org/10.1136/bjophthalmol-2013-303232, Holz 2013 ,additional,CD005139-bbs2-0107,
CD005139-bib-0277,Hyman L. ,Epidemiology of eye disease in the elderly, Eye ,1987,1,    ,['citation-journal'], Hyman L. Epidemiology of eye disease in the elderly.  Eye 1987;1(Pt 2):330‐41.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1038/eye.1987.53', 'https://www.ncbi.nlm.nih.gov/pubmed/3653439', 'https://scholar.google.com/scholar_lookup?title=Epidemiology+of+eye+disease+in+the+elderly&author=L+Hyman&publication_year=1987&hl=en']",3653439,https://doi.org/10.1038/eye.1987.53, Hyman 1987 ,additional,CD005139-bbs2-0108,
CD005139-bib-0278,"Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al. ",Anti‐vascular endothelial growth factor pharmacotherapy for age‐related macular degeneration: a report by the American Academy of Ophthalmology, Ophthalmology ,2008,115,    ,['citation-journal']," Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al. Anti‐vascular endothelial growth factor pharmacotherapy for age‐related macular degeneration: a report by the American Academy of Ophthalmology.  Ophthalmology 2008;115(10):1837‐46.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ophtha.2008.08.012', 'https://www.ncbi.nlm.nih.gov/pubmed/18929163', 'https://scholar.google.com/scholar_lookup?title=Anti‐vascular+endothelial+growth+factor+pharmacotherapy+for+age‐related+macular+degeneration:+a+report+by+the+American+Academy+of+Ophthalmology+&author=MS+Ip&author=IU+Scott&author=GC+Brown&author=MM+Brown&author=AC+Ho&author=SS+Huang&publication_year=2008&hl=en']",18929163,https://doi.org/10.1016/j.ophtha.2008.08.012, Ip 2008 ,additional,CD005139-bbs2-0109,
CD005139-bib-0279,"Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. ",Further observations on the association between smoking and the long‐term incidence and progression of age‐related macular degeneration, Archives of Ophthalmology ,2008,126,    ,['citation-journal']," Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long‐term incidence and progression of age‐related macular degeneration.  Archives of Ophthalmology 2008;126(1):115‐21.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.126.1.115', 'https://www.ncbi.nlm.nih.gov/pubmed/18195228', 'https://scholar.google.com/scholar_lookup?title=Further+observations+on+the+association+between+smoking+and+the+long‐term+incidence+and+progression+of+age‐related+macular+degeneration+&author=R+Klein&author=MD+Knudtson&author=KJ+Cruickshanks&author=BE+Klein&publication_year=2008&hl=en']",18195228,https://doi.org/10.1001/archopht.126.1.115, Klein 2008 ,additional,CD005139-bbs2-0110,
CD005139-bib-0280,"Kvanta A, Algvere PV, Berglin L, Seregard S. ",Subfoveal fibrovascular membranes in age‐related macular degeneration express vascular endothelial growth factor, Investigative Ophthalmology and Visual Science ,1996,37,    ,['citation-journal']," Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age‐related macular degeneration express vascular endothelial growth factor.  Investigative Ophthalmology and Visual Science 1996;37(9):1929‐34.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0002-9394(14)70522-7', 'https://www.ncbi.nlm.nih.gov/pubmed/8759365', 'https://scholar.google.com/scholar_lookup?title=Subfoveal+fibrovascular+membranes+in+age‐related+macular+degeneration+express+vascular+endothelial+growth+factor+&author=A+Kvanta&author=PV+Algvere&author=L+Berglin&author=S+Seregard&publication_year=1996&hl=en']",8759365,https://doi.org/10.1016/S0002-9394(14)70522-7, Kvanta 1996 ,additional,CD005139-bbs2-0111,
CD005139-bib-0281,"Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. ","The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973‐1975", Survey of Ophthalmology ,1980,24,    ,['citation-journal']," Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973‐1975.  Survey of Ophthalmology 1980;24(Suppl):335‐610.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/7444756', 'https://scholar.google.com/scholar_lookup?title=The+Framingham+Eye+Study+monograph:+an+ophthalmological+and+epidemiological+study+of+cataract,+glaucoma,+diabetic+retinopathy,+macular+degeneration,+and+visual+acuity+in+a+general+population+of+2631+adults,+1973‐1975+&author=HM+Leibowitz&author=DE+Krueger&author=LR+Maunder&author=RC+Milton&author=MM+Kini&author=HA+Kahn&publication_year=1980&hl=en']",7444756,, Leibowitz 1980 ,additional,CD005139-bbs2-0112,
CD005139-bib-0282,"Li E, Donati S, Virgili G, Krzystolik MG. ",Treatment schedules for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2016,,    ,['citation-journal']," Li E, Donati S, Virgili G, Krzystolik MG. Treatment schedules for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012208]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD012208', 'https://scholar.google.com/scholar_lookup?title=Treatment+schedules+for+administration+of+anti‐vascular+endothelial+growth+factor+agents+for+neovascular+age‐related+macular+degeneration+&author=E+Li&author=S+Donati&author=G+Virgili&author=MG+Krzystolik&publication_year=2016&hl=en']",,https://doi.org/10.1002/14651858.CD012208, Li 2016 ,additional,CD005139-bbs2-0113,
CD005139-bib-0283,"Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. ",Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age‐related macular degeneration‐related choroidal neovascular membranes, Investigative Ophthalmology and Visual Science ,1996,37,    ,['citation-journal']," Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age‐related macular degeneration‐related choroidal neovascular membranes.  Investigative Ophthalmology and Visual Science 1996;37(5):855‐68.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/8603870', 'https://scholar.google.com/scholar_lookup?title=Transdifferentiated+retinal+pigment+epithelial+cells+are+immunoreactive+for+vascular+endothelial+growth+factor+in+surgically+excised+age‐related+macular+degeneration‐related+choroidal+neovascular+membranes+&author=PF+Lopez&author=BD+Sippy&author=HM+Lambert&author=AB+Thach&author=DR+Hinton&publication_year=1996&hl=en']",8603870,, Lopez 1996 ,additional,CD005139-bbs2-0114,
CD005139-bib-0284,"Mitchell P, Wang JJ, Smith W, Leeder SR. ",Smoking and the 5‐year incidence of age‐related maculopathy: the Blue Mountains Eye Study, Archives of Ophthalmology ,2002,120,    ,['citation-journal']," Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5‐year incidence of age‐related maculopathy: the Blue Mountains Eye Study.  Archives of Ophthalmology 2002;120(10):1357‐63.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.120.10.1357', 'https://www.ncbi.nlm.nih.gov/pubmed/12365915', 'https://scholar.google.com/scholar_lookup?title=Smoking+and+the+5‐year+incidence+of+age‐related+maculopathy:+the+Blue+Mountains+Eye+Study+&author=P+Mitchell&author=JJ+Wang&author=W+Smith&author=SR+Leeder&publication_year=2002&hl=en']",12365915,https://doi.org/10.1001/archopht.120.10.1357, Mitchell 2002 ,additional,CD005139-bbs2-0115,
CD005139-bib-0285,Mitchell P. ,A systematic review of the efficacy and safety outcomes of anti‐VEGF agents used for treating neovascular age‐related macular degeneration: comparison of ranibizumab and bevacizumab, Current Medical Research and Opinion ,2011,27,    ,['citation-journal'], Mitchell P. A systematic review of the efficacy and safety outcomes of anti‐VEGF agents used for treating neovascular age‐related macular degeneration: comparison of ranibizumab and bevacizumab.  Current Medical Research and Opinion 2011;27(7):1465‐75.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1185/03007995.2011.585394', 'https://www.ncbi.nlm.nih.gov/pubmed/21623685', 'https://scholar.google.com/scholar_lookup?title=A+systematic+review+of+the+efficacy+and+safety+outcomes+of+anti‐VEGF+agents+used+for+treating+neovascular+age‐related+macular+degeneration:+comparison+of+ranibizumab+and+bevacizumab+&author=P+Mitchell&publication_year=2011&hl=en']",21623685,https://doi.org/10.1185/03007995.2011.585394, Mitchell 2011 ,additional,CD005139-bbs2-0116,
CD005139-bib-0286,"Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. ",Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011230', 'https://scholar.google.com/scholar_lookup?title=Systemic+safety+of+bevacizumab+versus+ranibizumab+for+neovascular+age‐related+macular+degeneration+&author=L+Moja&author=E+Lucenteforte&author=KH+Kwag&author=V+Bertele&author=A+Campomori&author=U+Chakravarthy&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD011230, Moja 2014 ,additional,CD005139-bbs2-0117,
CD005139-bib-0287,Macular Photocoagulation Study Group. ,Argon laser photocoagulation for neovascular maculopathy: five‐year results from randomized clinical trials, Archives of Ophthalmology ,1991,109,    ,['citation-journal'], Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five‐year results from randomized clinical trials.  Archives of Ophthalmology 1991;109(8):1109‐14.    Link to article     PubMed     ,"['https://doi.org/10.1001/archopht.1991.01080080069030', 'https://www.ncbi.nlm.nih.gov/pubmed/1714270']",1714270,https://doi.org/10.1001/archopht.1991.01080080069030, MPSG 1991 ,additional,CD005139-bbs2-0118,
CD005139-bib-0288,"Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. ",How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?, British Journal of Ophthalmology ,2003,87,    ,['citation-journal']," Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?.  British Journal of Ophthalmology 2003;87(3):312‐7.    Link to article     Google Scholar     ","['https://doi.org/10.1136/bjo.87.3.312', 'https://scholar.google.com/scholar_lookup?title=How+big+is+the+burden+of+visual+loss+caused+by+age+related+macular+degeneration+in+the+United+Kingdom?+&author=CG+Owen&author=AE+Fletcher&author=M+Donoghue&author=AR+Rudnicka&publication_year=2003&hl=en']",,https://doi.org/10.1136/bjo.87.3.312, Owen 2003 ,additional,CD005139-bbs2-0119,
CD005139-bib-0289,"Rasmussen A, Sander B. ",Long‐term longitudinal study of patients treated with ranibizumab for neovascular age‐related macular degeneration, Current Opinion in Ophthalmology ,2014,25,    ,['citation-journal']," Rasmussen A, Sander B. Long‐term longitudinal study of patients treated with ranibizumab for neovascular age‐related macular degeneration.  Current Opinion in Ophthalmology 2014;25(3):158‐63.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/ICU.0000000000000050', 'https://www.ncbi.nlm.nih.gov/pubmed/24663065', 'https://scholar.google.com/scholar_lookup?title=Long‐term+longitudinal+study+of+patients+treated+with+ranibizumab+for+neovascular+age‐related+macular+degeneration+&author=A+Rasmussen&author=B+Sander&publication_year=2014&hl=en']",24663065,https://doi.org/10.1097/ICU.0000000000000050, Rasmussen 2014 ,additional,CD005139-bbs2-0120,
CD005139-bib-0290,"Nordic Cochrane Centre, The Cochrane Collaboration. ",Review Manager 5 (RevMan 5),,2014,,.   ,['citation-other']," Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.    ",[],,, Review Manager 5 2014 [Computer program] ,additional,CD005139-bbs2-0121,
CD005139-bib-0291,"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. ","Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP)", Ophthalmology ,2013,120,    ,['citation-journal']," Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP).  Ophthalmology 2013;120(11):2292‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ophtha.2013.03.046', 'https://www.ncbi.nlm.nih.gov/pubmed/23642856', 'https://scholar.google.com/scholar_lookup?title=Seven‐year+outcomes+in+ranibizumab‐treated+patients+in+ANCHOR,+MARINA,+and+HORIZON:+a+multicenter+cohort+study+(SEVEN‐UP)+&author=S+Rofagha&author=RB+Bhisitkul&author=DS+Boyer&author=SR+Sadda&author=K+Zhang&publication_year=2013&hl=en']",23642856,https://doi.org/10.1016/j.ophtha.2013.03.046, Rofagha 2013 ,additional,CD005139-bbs2-0122,
CD005139-bib-0292,"Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. ",Aflibercept for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2016,,    ,['citation-journal']," Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, et al. Aflibercept for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD011346.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD011346.pub2', 'https://scholar.google.com/scholar_lookup?title=Aflibercept+for+neovascular+age‐related+macular+degeneration&author=S+Sarwar&author=E+Clearfield&author=MK+Soliman&author=MA+Sadiq&author=AJ+Baldwin&author=M+Hanout&publication_year=2016&hl=en']",,https://doi.org/10.1002/14651858.CD011346.pub2, Sarwar 2016 ,additional,CD005139-bbs2-0123,
CD005139-bib-0293,"Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. ",A prospective study of 2 major age‐related macular degeneration susceptibility alleles and interactions with modifiable risk factors, Archives of Ophthalmology ,2007,125,    ,['citation-journal']," Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. A prospective study of 2 major age‐related macular degeneration susceptibility alleles and interactions with modifiable risk factors.  Archives of Ophthalmology 2007;125(1):55‐62.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.125.1.55', 'https://www.ncbi.nlm.nih.gov/pubmed/17210852', 'https://scholar.google.com/scholar_lookup?title=A+prospective+study+of+2+major+age‐related+macular+degeneration+susceptibility+alleles+and+interactions+with+modifiable+risk+factors+&author=DA+Schaumberg&author=SE+Hankinson&author=Q+Guo&author=E+Rimm&author=DJ+Hunter&publication_year=2007&hl=en']",17210852,https://doi.org/10.1001/archopht.125.1.55, Schaumberg 2007 ,additional,CD005139-bbs2-0124,
CD005139-bib-0294,"Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. ",Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age‐related macular degeneration: a systematic review, Current Opinion in Ophthalmology ,2010,21,    ,['citation-journal']," Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age‐related macular degeneration: a systematic review.  Current Opinion in Ophthalmology 2010;21(3):218‐26.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/ICU.0b013e3283386783', 'https://www.ncbi.nlm.nih.gov/pubmed/20393293', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+vs.+ranibizumab+(Lucentis)+for+the+treatment+of+age‐related+macular+degeneration:+a+systematic+review+&author=C+Schmucker&author=C+Ehlken&author=LL+Hansen&author=G+Antes&author=HT+Agostini&author=M+Lelgemann&publication_year=2010&hl=en']",20393293,https://doi.org/10.1097/ICU.0b013e3283386783, Schmucker 2010 ,additional,CD005139-bbs2-0125,
CD005139-bib-0295,"Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. ",A safety review and meta‐analyses of bevacizumab and ranibizumab: off‐label versus gold standard, PloS One ,2012,7,    ,['citation-journal']," Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta‐analyses of bevacizumab and ranibizumab: off‐label versus gold standard.  PloS One 2012;7(8):e42701.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0042701', 'https://www.ncbi.nlm.nih.gov/pubmed/22880086', 'https://scholar.google.com/scholar_lookup?title=A+safety+review+and+meta‐analyses+of+bevacizumab+and+ranibizumab:+off‐label+versus+gold+standard+&author=C+Schmucker&author=C+Ehlken&author=HT+Agostini&author=G+Antes&author=G+Ruecker&author=M+Lelgemann&publication_year=2012&hl=en']",22880086,https://doi.org/10.1371/journal.pone.0042701, Schmucker 2012 ,additional,CD005139-bbs2-0126,
CD005139-bib-0296,"Seddon JM, George S, Rosner B, Klein ML. ","CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age‐related macular degeneration", Human Heredity ,2006,61,    ,['citation-journal']," Seddon JM, George S, Rosner B, Klein ML. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age‐related macular degeneration.  Human Heredity 2006;61(3):157‐65.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1159/000094141', 'https://www.ncbi.nlm.nih.gov/pubmed/16816528', 'https://scholar.google.com/scholar_lookup?title=CFH+gene+variant,+Y402H,+and+smoking,+body+mass+index,+environmental+associations+with+advanced+age‐related+macular+degeneration+&author=JM+Seddon&author=S+George&author=B+Rosner&author=ML+Klein&publication_year=2006&hl=en']",16816528,https://doi.org/10.1159/000094141, Seddon 2006 ,additional,CD005139-bbs2-0127,
CD005139-bib-0297,"Smith W, Mitchell P, Leeder SR. ",Smoking and age‐related maculopathy. The Blue Mountains Eye Study, Archives of Ophthalmology ,1996,114,    ,['citation-journal']," Smith W, Mitchell P, Leeder SR. Smoking and age‐related maculopathy. The Blue Mountains Eye Study.  Archives of Ophthalmology 1996;114(12):1518‐23.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.1996.01100140716016', 'https://www.ncbi.nlm.nih.gov/pubmed/8953988', 'https://scholar.google.com/scholar_lookup?title=Smoking+and+age‐related+maculopathy.+The+Blue+Mountains+Eye+Study&author=W+Smith&author=P+Mitchell&author=SR+Leeder&publication_year=1996&hl=en']",8953988,https://doi.org/10.1001/archopht.1996.01100140716016, Smith 1996 ,additional,CD005139-bbs2-0128,
CD005139-bib-0298,"Submacular Surgery Trials Research Group, Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. ",Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age‐related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group, Archives of Ophthalmology ,2007,125,    ,['citation-journal']," Submacular Surgery Trials Research Group, Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age‐related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group.  Archives of Ophthalmology 2007;125(10):1323‐30.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/17923538', 'https://scholar.google.com/scholar_lookup?title=Incident+choroidal+neovascularization+in+fellow+eyes+of+patients+with+unilateral+subfoveal+choroidal+neovascularization+secondary+to+age‐related+macular+degeneration:+SST+report+No.+20+from+the+Submacular+Surgery+Trials+Research+Group+&author=SD+Solomon&author=JL+Jefferys&author=BS+Hawkins&author=NM+Bressler&publication_year=2007&hl=en']",17923538,, SST 20 ,additional,CD005139-bbs2-0129,
CD005139-bib-0299,"Stein JD, Newman‐Casey PA, Mrinalini T, Lee PP, Hutton DW. ",Cost‐effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration, Ophthalmology ,2014,121,    ,['citation-journal']," Stein JD, Newman‐Casey PA, Mrinalini T, Lee PP, Hutton DW. Cost‐effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.  Ophthalmology 2014;121(4):936‐45.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ophtha.2013.10.037', 'https://www.ncbi.nlm.nih.gov/pubmed/24405740', 'https://scholar.google.com/scholar_lookup?title=Cost‐effectiveness+of+bevacizumab+and+ranibizumab+for+newly+diagnosed+neovascular+macular+degeneration+&author=JD+Stein&author=PA+Newman‐Casey&author=T+Mrinalini&author=PP+Lee&author=DW+Hutton&publication_year=2014&hl=en']",24405740,https://doi.org/10.1016/j.ophtha.2013.10.037, Stein 2014 ,additional,CD005139-bbs2-0130,
CD005139-bib-0300,Tielsch JA. ,Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older,Prevent Blindness,1994,,    ,['citation-book']," Tielsch JA. Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older. Prevent Blindness. Illinois: Schaumberg, 1994.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Vision+problems+in+the+US:+a+report+on+blindness+and+vision+impairment+in+adults+age+40+and+older+&author=JA+Tielsch&publication_year=1994&hl=en'],,, Tielsch 1994 ,additional,CD005139-bbs2-0131,
CD005139-bib-0301,"Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. ",Decreased visual acuity associated with cystoid macular edema in neovascular age‐related macular degeneration, Archives of Ophthalmology ,2002,120,    ,['citation-journal']," Ting TD, Oh M, Cox TA, Meyer CH, Toth CA. Decreased visual acuity associated with cystoid macular edema in neovascular age‐related macular degeneration.  Archives of Ophthalmology 2002;120(6):731‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archopht.120.6.731', 'https://www.ncbi.nlm.nih.gov/pubmed/12049577', 'https://scholar.google.com/scholar_lookup?title=Decreased+visual+acuity+associated+with+cystoid+macular+edema+in+neovascular+age‐related+macular+degeneration+&author=TD+Ting&author=M+Oh&author=TA+Cox&author=CH+Meyer&author=CA+Toth&publication_year=2002&hl=en']",12049577,https://doi.org/10.1001/archopht.120.6.731, Ting 2002 ,additional,CD005139-bbs2-0132,
CD005139-bib-0302,"Van Kerckhoven W, Lafaut B, Follens I, De Laey JJ. ",Features of age‐related macular degeneration on optical coherence tomography, Bulletin de la Societe Belge d'Ophtalmologie ,2001,281,    ,['citation-journal']," Van Kerckhoven W, Lafaut B, Follens I, De Laey JJ. Features of age‐related macular degeneration on optical coherence tomography.  Bulletin de la Societe Belge d'Ophtalmologie 2001;281:75‐84.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Features+of+age‐related+macular+degeneration+on+optical+coherence+tomography&author=W+Kerckhoven&author=B+Lafaut&author=I+Follens&author=JJ+Laey&publication_year=2001&hl=en'],,, Van Kerckhoven 2001 ,additional,CD005139-bbs2-0133,
CD005139-bib-0303,"Virgili G, Bini A. ",Laser photocoagulation for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2007,,    ,['citation-journal']," Virgili G, Bini A. Laser photocoagulation for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004763.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD004763.pub2', 'https://scholar.google.com/scholar_lookup?title=Laser+photocoagulation+for+neovascular+age‐related+macular+degeneration&author=G+Virgili&author=A+Bini&publication_year=2007&hl=en']",,https://doi.org/10.1002/14651858.CD004763.pub2, Virgili 2007 ,additional,CD005139-bbs2-0134,
CD005139-bib-0304,"Wormald R, Evans J, Smeeth L, Henshaw K. ",Photodynamic therapy for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2007,,    ,['citation-journal']," Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD002030.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD002030.pub3', 'https://scholar.google.com/scholar_lookup?title=Photodynamic+therapy+for+neovascular+age‐related+macular+degeneration&author=R+Wormald&author=J+Evans&author=L+Smeeth&author=K+Henshaw&publication_year=2007&hl=en']",,https://doi.org/10.1002/14651858.CD002030.pub3, Wormald 2007 ,additional,CD005139-bbs2-0135,
CD005139-bib-0305,"Krzystolik MG, Woodcome HA, Reddy U. ",Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2005,,    ,['citation-journal']," Krzystolik MG, Woodcome HA, Reddy U. Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD005139]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Antiangiogenic+therapy+with+anti‐vascular+endothelial+growth+factor+modalities+for+neovascular+age‐related+macular+degeneration+&author=MG+Krzystolik&author=HA+Woodcome&author=U+Reddy&publication_year=2005&hl=en'],,, Krzystolik 2005 ,other_versions,CD005139-bbs2-0136,
CD005139-bib-0306,"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. ",Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2014,,    ,['citation-journal']," Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD005139.pub3', 'https://scholar.google.com/scholar_lookup?title=Anti‐vascular+endothelial+growth+factor+for+neovascular+age‐related+macular+degeneration&author=SD+Solomon&author=K+Lindsley&author=SS+Vedula&author=MG+Krzystolik&author=BS+Hawkins&publication_year=2014&hl=en']",,https://doi.org/10.1002/14651858.CD005139.pub3, Solomon 2014 ,other_versions,CD005139-bbs2-0137,
CD005139-bib-0307,"Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. ",Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age‐related macular degeneration: findings from a Cochrane systematic review, Ophthalmology ,2016,123,    ,['citation-journal']," Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age‐related macular degeneration: findings from a Cochrane systematic review.  Ophthalmology 2016;123(1):70‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ophtha.2015.09.002', 'https://www.ncbi.nlm.nih.gov/pubmed/26477843', 'https://scholar.google.com/scholar_lookup?title=Intravitreal+bevacizumab+versus+ranibizumab+for+treatment+of+neovascular+age‐related+macular+degeneration:+findings+from+a+Cochrane+systematic+review+&author=SD+Solomon&author=KB+Lindsley&author=MG+Krzystolik&author=SS+Vedula&author=BS+Hawkins&publication_year=2016&hl=en']",26477843,https://doi.org/10.1016/j.ophtha.2015.09.002, Solomon 2016 ,other_versions,CD005139-bbs2-0138,
CD005139-bib-0308,"Vedula SS, Krzystolik M. ",Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration, Cochrane Database of Systematic Reviews ,2008,,    ,['citation-journal']," Vedula SS, Krzystolik M. Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration.  Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD005139.pub2', 'https://scholar.google.com/scholar_lookup?title=Antiangiogenic+therapy+with+anti‐vascular+endothelial+growth+factor+modalities+for+neovascular+age‐related+macular+degeneration+&author=SS+Vedula&author=M+Krzystolik&publication_year=2008&hl=en']",,https://doi.org/10.1002/14651858.CD005139.pub2, Vedula 2008 ,other_versions,CD005139-bbs2-0139,
